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1 Introduction  
1.1 Epilepsy, a neurodevelopmental disorder 
Epilepsy is a neurodevelopmental disorder affecting almost 1 % of the population all 
over the world (Elger 2002; Fisher et al. 2005). Neurodevelopmental disorders 
comprise diseases that develop early in brain or as a consequence of head trauma, a 
tumor or an infection in the adult brain and span throughout life. Although the 
underlying etiology of the various disorders might be different, all of them lead to 
similar brain dysfunctions (defects of the sensory and motor system) and to 
comparable cognitive deficits in learning and memory. Epilepsy represents a complex 
and multifactorial disease which is accompanied by neuropathological changes 
(particular neuronal degeneration, structural reorganization) that accumulate during 
progression of the disorder (Elger 2002). Due to the multifactorial component it is not 
defined as one disorder but as a group of diverse conditions, leading into an 
enhanced predisposition to epileptic seizures. Epilepsy is nowadays demarcated as a 
condition with (1) a history of at least one seizure, (2) a persistent brain alteration 
(measured by electroencephalography (EEG)) with the probability of upcoming 
seizures and (3) the association with neurobiologic, cognitive, psychological and 
social impairments (Fisher et al., 2005). Epilepsies develop mostly in late childhood 
or adolescence starting with an initial insult (febrile seizures, head trauma, infections 
or tumors) resulting in a process called epileptogenesis (or latency period). This 
process, starting during the initial insult and ending with the occurrence of the first 
spontaneous seizure, is highly dynamic, leading to alterations in network excitability 
and to structural reorganization (reviewed by Pitkänen & Lukasiuk 2011). 
 
1.2 Epilepsy animal models 
For an efficient treatment of epilepsy it is essential to shed light on the molecular 
pathways underlying epileptogenesis. However, human tissue samples from patients 
that underwent surgery due to intractable epilepsy are obtained from the end stage of 
a long and complex treatment period. To overcome the lack of human tissue samples 
from the stage of epileptogenesis and the absence of human control tissue samples, 
many animal models have developed over the years. The widely used animal models 
to study temporal lobe epilepsy (TLE), which is the most common type of partial 
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complex seizures in adulthood (Hauser et al., 1996; Wieser & Häne, 2004), are post-
status epilepticus (SE) models. Self-sustained SE is induced (1) by persistent 
electrical stimulation of the hippocampus or (2) by injection of epileptogenic 
compounds at convulsant doses (pilocarpine or kainic acid). The acquired changes 
lead to segmental neuronal cell loss in the hippocampus and to the occurrence of 
spontaneous recurrent seizures after a latency period of 3-4 weeks after SE 
(reviewed by Majores et al. 2007; reviewed by Löscher 2002). However, there are 
differences in the neuropathological changes observed after pilocarpine compared to 
kainic acid-induced SE: Neuronal injury seems to be different in extent and regional 
distribution within the hippocampal formation (CA1 or CA3/CA4) and appears to be 
less variable after the use of pilocarpine compared to kainic acid (KA) (reviewed by 
Majores et al. 2007). Yet, epileptogenesis occurs after both, pilocarpine and kainic 
acid-induced SE. 
 
1.3 Epileptogenesis 
Epileptogenesis describes a process in which an initial insult triggers multiple cellular 
and molecular changes finally resulting in recurrent spontaneous seizures. The 
occurrence of various acquired alterations includes structural reorganization, 
neurodegeneration, blood-brain barrier disruption, recruitment of inflammatory cells 
into brain tissue and cellular plasticity (Figure 1.1). Due to the multifactorial nature of 
the disease, many investigators try to unravel the molecular pathways underlying the 
circuitry reorganization by analyzing gene expression at the whole transcriptome 
level. Most of the studies vary among each other regarding the animal model for 
epilepsy, the time point after SE or the array platform used. Nevertheless, there are 
genes that are commonly altered, which possess rather general functions (signal 
transduction or transcription) but also specific functions associated with 
epileptogenesis (ion transport, synaptic transmission and plasticity, inflammation, 
channel/receptor function and neurotransmitter metabolism) (reviewed by Pitkänen & 
Lukasiuk 2011). 
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Figure 1.1 Pathogenetic concept of temporal lobe epilepsy (TLE). Schematic drawing of 
different stages in the pathogenesis of TLE and of the corresponding hallmarks. Modified from 
Majores et al., 2007. 
 
1.4 Mechanisms underlying epileptogenesis 
1.4.1 Transcriptional regulation 
Changes in gene expression are an important link between external stimuli and 
intracellular responses. Through binding of trans-acting transcription factors to cis-
acting DNA regions, such as enhancers and promoters, regulated gene expression 
can mediate developmental changes, cell survival and division (Figure 1.2). In 
mature neurons, altered activity levels might induce long-lasting changes in neuronal 
gene expression, forming the molecular basis for synaptic plasticity. Common 
sequence elements like a TATA box or an initiator sequence and binding sites for 
general transcription factors are found in most of the promoters and might be 
considered as characteristics for a so called core promoter. These elements are 
important for recruitment of the transcription machinery to the transcription start site 
(TSS) and lead to basal activity of a promoter (Figure 1.2 Step 1). Enhancers, which 
are usually located upstream or downstream of the TSS, also contain transcription 
factor binding sites. However, when DNA sequence specific transcription factors bind 
to cis-elements in the proximal part of the promoter, general transcription is 
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enhanced by stabilizing the binding of general factors via site-specific factors (Figure 
1.2 Step 2). Further stimulation of a promoter is achieved by binding of site-specific 
factors to an enhancer region (Figure 1.2 Step 3). Another interaction, which is 
thought to enhance promoter activity in a cell-type specific manner, is the interaction 
of cell-type specific co-activators with bound factors. A more favorable chromatin 
environment (by histone acetylation) is achieved through these factors, which leads 
either to recruitment of histone-modifying enzymes (i.e. histone acetyltransferase 
(HAT)) (Figure 1.2 Step 4) or to recruitment of a kinase and subsequent 
phosphorylation of RNA polymerase II followed by stimulation of elongation (Figure 
1.2 Step 5). Not only activating factors bind to cis-elements, there are also repressing 
factors leading to interference with activator binding or to repressive chromatin 
structures (reviewed by Farnham 2009). 
Figure 1.2 Mechanism of transcriptional regulation by promoters and enhancers. 
Diagram depicts distinct states of promoter regulation. Step 1: Basal transcription with universal 
transcription factors (green spheres) bound to the core promoter. Step 2: Increased transcription (+) 
through stabilization of the transcription machinery via bound site-specific factors (red triangle) to cis 
elements (dark blue box). Step 3: Further enhanced transcription (++) by binding of site-specific 
factors (orange box) to enhancers (light blue box). Stimulation of transcription by Step 4: Recruitment 
of histone acetyltransferase (HAT) or by Step 5: Phosphorylation of RNA polymerase II via a kinase 
and subsequent elongation. TATA: TATA box, INR: initiator, P: Phosphorylation, Ac: histone 
acetylation. Modified from Farnham 2009. 
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1.4.2 Mechanisms of activity-dependent gene transcription 
Two of the most extensively studied activity-regulated genes are Brain-derived 
neurotrophic factor (BDNF) and Activity-regulated cytoskeletal protein (Arc/Arg3.1). 
BDNF reacts to neural activity with expression of BDNF mRNA in the activated brain 
area and thereby regulates local secretion of BDNF protein and transport of the 
BDNF receptor to the plasma membrane. BDNF is essential for neuronal 
differentiation and growth, synapse formation and plasticity and higher cognitive 
functions (Park & Poo, 2013). Therefore, the function of BDNF depends strongly on 
the exact temporal and spatial control of BDNF expression. Recently, the promoter 
underlying this tight control mechanism has been characterized in numerous studies 
(reviewed by Lyons & West 2011). Transcription factors mediating the induction of 
neuronal activity regulated Exon I of the rat BDNF gene are CREB, USFs, MEF2D, 
NFkB and additionally for the human BDNF gene NPAS4 was identified (Tabuchi et 
al., 2002; Lubin et al., 2007; Flavell et al., 2008; Pruunsild et al., 2011). 
Transcription of Arc is increased by synaptic activity that is mediated by a proximal 
promoter and a distal enhancer element named synaptic activity response element 
(SARE). Some transcription factors regulating Arc transcription have already been 
identified namely Egr1/3 binding the proximal promoter and SRF binding with co-
activator a ternary complex factor (TCF) the serum response element (SRE) (Posern 
& Treisman, 2006). A possible role for MAL acting as another co-activator of SRE 
has been postulated recently (Zaromytidou et al., 2006). Besides a SRE, a cAMP 
response element (CRE) site, a myocyte enhancer factor 2 (MEF2) site and a Zeste-
like response element (ZRE) have been identified and binding of CREB and MEF2 
are confirmed (Kawashima et al., 2009; Pintchovski et al., 2009). However, besides 
the yet unknown binding factors acting through the novel ZRE, there might be other 
unknown transcription factors regulating the transcription of Arc (reviewed by Korb & 
Finkbeiner 2011). 
Altered transcription of a given gene has an impact on disease progression as it may 
lead to changes in intrinsic and synaptic plasticity. Many genes have been identified 
as differentially expressed during epilepsy. 
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1.4.3 Altered transcription during epilepsy 
Whole transcriptome studies have revealed a large number of genes that are 
differentially expressed during epileptogenesis. However, only few candidate genes 
have been studied in further detail concerning their functional significance in 
epileptogenesis. One differentially changed gene that has been studied in detail with 
regard to epileptogenesis is the GABAA receptor. Brooks-Kayal et al. analyzed in 
1998 GABAA receptor subunit expression in dentate granule cells via single cell 
mRNA amplification and found that GABAA receptor subunit expression was altered 
in pilocarpine-treated rats. This change was already observed at the latent phase 
(before the onset of spontaneous seizures) indicating that altered GABAA receptor 
subunit expression may influence epileptogenesis. Functional analyses from the 
same study suggested that these dentate granule cells reveal a higher sensitivity to 
zinc indicating that the GABA-mediated inhibition is altered during epilepsy and that 
these changes are essential for the process of epileptogenesis (Brooks-Kayal et al., 
1998). 
The T-type Ca2+ -channel Cav3.2 is another channel with a transient up-regulation on 
the mRNA and protein level in pilocarpine-treated rats leading to functional changes 
in the intrinsic burst firing and an increase in cellular T-type Ca2+ -currents (Becker et 
al. 2008). Recently, the underlying transcriptional changes mediating the induction of 
Cav3.2 after SE were uncovered (van Loo et al., 2012). The promoter driving Cav3.2 
expression was found to be regulated bi-directionally by the transcription factors early 
growth factor 1 (Egr1) (activation) and repressor element 1-silencing transcription 
factor (REST) (repression) resulting in increased Ca2+ -currents in neuroblastoma 
NG108-15 cells overexpressed with Egr1. Understanding the mechanisms regulating 
epileptogenesis represents a possibility to interfere with the phenotype that might 
have an essential role in epileptogenesis. 
 
1.4.4 Membrane trafficking 
Structural reorganization during epileptogenesis is dependent on the insertion and 
removal of membranous organelles. To accommodate the changing intracellular 
distribution of a wide range of proteins, vesicles and other membranous organelles 
move along distinct pathways and finally fuse with the plasma membrane or with 
other components in a process known as membrane trafficking. The distinct steps of 
this process include cargo selection, budding and fission of vesicles from a donor 
Introduction 
 7 
organelle, transport of cargo via microtubules and actin filaments, association of 
vesicles with the exact target membrane and finally fusion of vesicles with the target 
via requisite SNARE proteins (Hutagalung & Novick, 2011). 
In eukaryotic cells, two major pathways of membrane traffic exist: (A) the secretory 
pathway from the Endoplasmatic Reticulum (ER) to cis-Golgi membranes via the ER 
to Golgi Intermediate Compartment (ERGIC) and (B) the endocytic pathway where 
endocytosed material is transported to early sorting endosomes. From there, 
organelles are either delivered back to the plasma membrane, are sorted by slow 
transport processes to the plasma membrane via recycling endosomes or are 
degraded in lysosomes (reviewed by Blackstone et al., 2011). 
Trafficking in neurons is even more complex given that protein cargo needs to be 
sorted and transported long distances to their target, to the active zone or to 
dendrites. To achieve maintenance of dendrites by local biosynthesis of lipids and 
proteins, the ER extends into all dendrites but the Golgi Apparatus is outposted only 
to several dendrites (Hanus & Ehlers, 2008). Axon outgrowth is accomplished 
differently due to the lack of Golgi outposts in axons (reviewed by Horton & Ehlers, 
2003; Ye et al., 2007). Sorting of synaptic vesicle (SV) proteins relies on signal 
sequences for axonal transport and different proteins use distinct pathways indicating 
that the transport mechanism might be unique for its protein cargo. 
Communication of neurons occurs at highly specialized sites of the synapse. For this, 
an additional form of membrane traffic is essential, the synaptic vesicle exocytosis. 
This unique form of Ca2+ -ion triggered fast membrane fusion can be categorized into 
distinct steps, the SV loading, docking of SVs to the site of fusion, priming, which 
renders the SVs competent to fuse, and finally fusion. Two forms of exocytosis exist, 
namely synaptic exocytosis of small SVs in presynaptic nerve terminals and 
hormonal (endocrine) exocytosis of large dense core vesicles (LDCVs) in endocrine 
cells. The machinery of this complex process involves proteins specialized for distinct 
steps of the synaptic vesicle cycle. One class of proteins that is critically involved in 
the fusion of the two membranes is the Synaptotagmin (Syt) family, a class of Ca2+ -
binding proteins (reviewed by Südhof, 2002, 2012; reviewed by Chapman, 2008). 
Influx of Ca2+ -ions into the presynaptic bouton triggers the binding of e.g. Syt1 to 
membrane lipids and SNARE proteins. Consequently, full assembly of the partially 
zippered SNARE-complex leads to fusion pore opening and to complete fusion of the 
vesicle membrane with the plasma membrane. As calcium sensors, Syts are crucial 
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for the synaptic vesicle cycle and due to the complexity of the Syt family, it is thought 
that they facilitate different forms of membrane trafficking pathways (Dean, et al. 
2012). 
 
1.5 Synaptotagmin gene family 
Syts comprise a large family of membrane trafficking proteins that are evolutionary 
conserved (Craxton, 2001, 2004). First, Syt1 was described in 1981 as a vesicle-
specific membrane protein, p65, localized to SVs and LDCVs in neurons and 
neuroendocrine cells, identified by a screen for synaptic proteins with monoclonal 
antibodies (Matthew et al., 1981). Later, two C2-domains were identified in Syt1 and 
these domains were suggested to function as Ca2+ -sensors for vesicle exocytosis 
(Perin et al. 1990). Subsequently, other Syts were described in vertebrates. Whereas 
in Drosophila, seven Syt isoforms have been identified (Syt1, 4, 7, 12, 13, 16 and Syt 
alpha), only four isoforms were found in Caenorhabditis elegans (Syt1, 4, 7, and Syt 
alpha) (Craxton, 2010). According to bioinformatical analyses, mammalian Syts 
comprise 17 isoforms (Syt1-17) (Craxton, 2010). However Pang et al. included only 
16 isoforms into the mammalian Syt gene family due to the lack of a transmembrane 
domain in Syt17 (reviewed by Pang & Südhof 2010). Since many members of the Syt 
gene family were discovered in recent years, there is a constant change of 
nomenclature. For example, the latest members of the Syt family, Syt16 and 17 
(which is still debated), were formerly referred to as Strep 14 (Syt14-related protein) 
and B/K protein (brain/kidney protein), respectively (reviewed by Gustavsson & Han 
2009). 
 
1.5.1 Synaptotagmin protein domain structure 
Syts share a common protein structure including an N-terminal intraluminal domain, 
an extracellular tail, a central variable linker and two C-terminal tandem C2-domains 
(Perin et al. 1991) (Figure 1.3 A). 
 
A 
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B 
 
C     D 
 
 
 
 
 
 
 
 
Figure 1.3 Syt domains, crystal structure and the Ca2+ -activated membrane fusion 
complex. (A) Schematic drawing of structural protein domains of Syts. N: N-terminus, TMD: 
transmembrane domain, C2A: C2A domain, C2B: C2B domain, C: C-terminus. Scaling based on the 
isoform Syt10. (B) Interaction sites and binding partners of Syt1. Note that interactions vary between 
different Syt isoforms and have to be studied in detail for others. SVs: synaptic vesicles, LDCVs: Large 
dense core vesicles, PM: plasma membrane, SNAREs: Soluble NSF-attachment protein receptor, 
SV2: synaptic vesicle protein 2, PS: phosphatidylserine, PC: phosphatidlycholine, PIP2: 
phosphatidylinositol 4,5-bisphosphate, AP2: clathrin assembly (adapter) protein 2. (C) Atomic 
structure of the Syt1 C2 domains formed by an eight-stranded ß-sandwich. The C2A and the C2B 
domain contain 3 and 2 bound Ca2+ -ions, respectively (red spheres). Picture was taken from Südhof 
2012. (D) Model for the Ca2+ -activated membrane fusion complex. In response to Ca2+ the C2A and 
C2B binding loops insert into the bilayer and directly interact with the SNARE complex (Synaptobrevin, 
Syntaxin, SNAP-25). SNAP-25: synaptosome-associated protein of 25 kDa. Picture was taken from 
Bai and Chapman, 2004. 
 
The N-terminal transmembrane domain serves to anchor the Syt proteins in synaptic, 
secretory vesicles or plasma membranes whereas the C2-domains form binding 
pockets for Ca2+ (Brose et al. 1992; Davletov & Südhof 1993; Chapman & Jahn 
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1994). The central linker region varies in each Syt isoform and is the region with the 
highest sequence dissimilarity among the different isoforms. The different protein 
domains of Syts form contacts with distinct binding partners and thus exhibit diverse 
functions (Figure 1.4 B). 
The N-terminus was shown to vary among the isoforms and therefore exhibits 
interactions that are not common to all Syt isoforms. Syt1 and Syt2 possess sites for 
N-glycosylation, which was shown in rat pheochromocytoma (PC12) cells to direct 
Syt1 to secretory vesicles and to be important for the readily releasable pool of SVs 
in neurons (Han et al. 2004). In non-neuronal cells, N-terminal O-glycosylation seems 
to mediate sorting of Syt1 and 2 to secretory vesicles (Atiya-Nasagi et al. 2005; 
Kanno & Fukuda 2008). However, a contradictory report showed that neither N- nor 
O-glycosylation is important for the sorting of Syt1 to SVs (Kwon & Chapman 2012). 
Another posttranslational modification shown to be important for Syts is 
palmitoylation (Figure 1.4 B). It has been proposed that it facilitates targeting of Syts 
to SVs (Prescott et al., 2009). There is evidence that Syt1 and Syt7 are targeted by 
palmitoylation to SVs and lysosomes, respectively (Veit et al. 1996; Heindel et al. 
2003; Flannery et al. 2010). If not palmitoylated, these Syts are transported and 
anchored in the plasma membrane via their transmembrane domain. 
Some of the Syts contain a cluster of cysteine residues specifically at the N-terminus 
(Syts 3, 5, 6, 10) (Fukuda et al. 1999a) or at the transmembrane region (Fukuda et 
al. 2001a) and might thereby be palmitoylated. Disulfide-bonded homodimerization 
as well as heterodimerization has been found to depend on cysteine residues in a 
subgroup of Syts, namely comprising Syts 3, 5, 6 and 10 (Fukuda et al. 1999a). 
Furthermore, it has been shown that both the TMD (Lewis et al., 2001) and the linker 
region (Fukuda et al. 2001b) are critical for Ca2+ -independent oligomerization but 
neither of the domains is sufficient (reviewed by Tucker & Chapman 2002). The most 
conserved protein domains of Syts are the C2-domains that are composed of 
ß-sheets connected by loops (Rizo & Südhof 1998) (Figure 1.3 C). The Syt1 C2A 
domain binds three Ca2+ -ions with an evident affinity of ~60-75 µM, ~400-500 µM 
and more than 1 mM (Ubach et al., 1998) and the C2B domain of Syt1 forms two 
binding pockets for Ca2+ -binding with a similar affinity in the range of ~300-600 µM 
(Fernández-Chacón et al. 2001) (Figure 1.3 C). However, the Ca2+ -affinity of the C2-
domains is distinct in the different Syt isoforms. Both C2-domains bind to 
phospholipids in a Ca2+ -dependent manner (Davletov & Südhof 1993; Fernández-
Introduction 
 11 
Chacón et al. 2001) and to SNARE proteins (Figure 1.3 D) (Bennett et al. 1992; 
Chapman et al. 1995; Li 1995). Whereas both C2-domains bind to 
phosphatidlycholine (PC) and phosphatidylserine (PS), only the C2B domain binds to 
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) (Radhakrishnan et al., 2009). 
The exact mode of C2-domain function is still unclear. There is evidence from Doc2 
proteins, that the C2B domain blocks synchronous exocytosis whereas blocking Ca2+-
binding to the C2A-domain decreases exocytosis only by approximately 40 % thus 
indicating that the C2B-domain is more relevant for exocytosis (Pang et al., 2011). 
Oppositional results demonstrate that Syt’s C2A domain is essential for synchronous 
synaptic transmission whereas the C2B domain only serves for fine-tuning of this 
process (Striegel et al., 2012). It is thought, however, that the C2-domains function 
cooperatively (reviewed by Südhof 2012). Both C2-domains have been shown to bind 
the clathrin assembly (adapter) protein 2 (AP2) and thereby function as a dual Ca2+ -
sensor for both, exo- and endocytosis (Zhang et al. 1994; Yao et al. 2012). In a 
Ca2+ -dependent manner, C2A and C2B domains bind to SV2 (Schivell et al. 1996; 
Schivell et al. 2005; Lazzell et al. 2004) and to RIM (Coppola et al., 2001). 
 
1.5.2 Classification of Synaptotagmins 
The highly homologous family of Syt proteins can be divided in subgroups and they 
can be classified based on their ability to bind Ca2+ or by their sequence homology. 
Regarding their binding properties, Syts can be divided into Ca2+ -dependent 
isoforms, namely Syt1, 2, 3, 5, 6, 7, 9, 10. From this subgroup, only Syts 3, 5, 6 and 
10 contain evolutionary conserved disulfide-bonded cysteine residues. Syts 4, 8 and 
11-16 comprise a group of Ca2+ -independent Syts. The Ca2+ -independent Syts can 
be further divided into conserved isoforms (Syt4 and 11 and 14-16) and into a 
heterogeneous subgroup of non-conserved isoforms (Syt8, 12 and 13) (reviewed by 
Südhof 2012). In an evolutionary genomics approach, Syts were grouped by means 
of gene duplications trying to determine the phylogenetic relationships between 
vertebrate and invertebrate isoforms (Craxton, 2010). The classification described 
here, however, relies on protein structure similarities. Other multiple C2-domain 
proteins (with and without a transmembrane domain) have been described and it has 
been suggested that, due to their structural homology, they might be good 
candidates for exocytotic Ca2+ -sensors. Besides Syts, three other protein classes of 
multiple C2-domains with a transmembrane domain are encoded in the mammalian 
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genome: (1) extended Syts (E-Syt1-3), (2) Multiple C2-transmembrane proteins 
(MCTPs) and (3) ferlins. Moreover, a large group of soluble C2-domain proteins 
lacking a transmembrane domain was identified, consisting of Copines and Syt-like 
proteins (SLPs) (reviewed by Pang & Südhof 2010). 
 
1.5.3 Expression of Synaptotagmins 
Except for Syts 8, 14 and 15, that lack expression in the brain, mRNA expression of 
all Syts has been detected in the rodent brain in distinctive expression patterns 
(Fukuda 2003b, a; Mittelsteadt et al., 2009). Syts 1, 3, 4, 5, 7, 11, 12 and 13 are 
universally expressed in most brain areas, whereas the remaining isoforms Syt2, 6, 9 
and 10 are restricted to distinct regions of the brain. Syt2 is mainly expressed in the 
hindbrain and brainstem, Syt6 and 10 are specifically enriched in the olfactory bulb, 
the cerebellum and the hippocampus. However, strong Syt10 expression is found 
mainly in the olfactory bulb. Finally, Syt9 expression is detected in the cerebellum, 
the olfactory bulb, the thalamus and the putamen (Mittelstaedt et al., 2009). 
Similar to the distinct distribution of Syts throughout the brain, likewise the subcellular 
localization of the isoforms is very specific. Syts 1, 2, 9 and 12 were shown to be 
localized on SVs (Matthew et al. 1981; Poser et al. 1997; Xu et al. 2007; Maximov et 
al. 2007). Based on pHluorin experiments, Syt9 and 12 were suggested to localize on 
distinct vesicle subtypes (Dean, et al. 2012a). The above mentioned isoforms (1, 2, 
9, 12) are also present on secretory granules in neuroendocrine cells (reviewed by 
Südhof 2012). Syt1 was found additionally in LDCVs of neuroendocrine PC12 cells 
where Syts 4, 7 and 9 are expressed as well (Fukuda et al. 2004a, b; Wang et al. 
2003; Wang & Chicka 2005). Syt2, besides Syts 3, 5 and 9 (Melicoff et al. 2009; 
reviewed by Baram et al. 2001; Haberman et al. 2007; Grimberg 2002) was identified 
as the major isoform present on lysosomes of mast cells (Baram et al., 1999). In 
addition to LDCVs, Syt4 was found to localize to the Golgi complex (Ibata et al., 
2000; Matsuoka et al., 2011), to postsynaptic organelles in Drosophila (Adolfsen et 
al., 2004), to peptidergic nerve terminals and to neurotrophin-containing dense-core 
vesicles in hippocampal neurons (Zhang et al. 2009; Dean et al. 2009). Besides Syt1 
and 9, Syt7 is the predominant isoform in granules of rat adrenal chromaffin cells 
(Matsuoka et al., 2011). 
The subcellular localization of Syts 3 and 6 remains uncertain as they are thought to 
be enriched at the plasma membrane (Butz et al., 1999; Saegusa et al., 2002) but 
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were also identified on secretory granules (Brown et al., 2000; Gao et al., 2000; 
Falkowski et al., 2011), the Golgi/ER complex (Fukuda et al. 1999b) and on 
endosomal compartments. Syt5 is localized to phagosomes (Vinet et al., 2008) and 
to LDCVs in PC12 cells (Saegusa et al., 2002). Until recently, the localization of 
Syt10 was uncertain. It has been reported, that Syt10 is present on secretory 
vesicles containing insulin-like growth factor 1 (IGF-1) in olfactory bulb mitral neurons 
(Cao et al., 2011). As Syt10, also IGF-1 is intensely expressed in the olfactory bulb 
(Rotwein et al., 1988). Moreover, Syt10 mRNA expression is also detected in 
pancreas, lung and kidney (Zhao et al., 2003). The exact localization of the remaining 
Syt isoforms still remains to be clarified. 
 
1.5.4 Function of Synaptotagmins 
Syt1, the best-characterized Syt isoform, was shown to be present on SVs and 
LDCVs where it functions as a Ca2+ -sensor for fast synaptic transmission and 
endocrine exocytosis, respectively (Geppert et al. 1994; Diantonio & Schwarz 1994; 
Littleton et al. 1994; Voets et al. 2001; Sørensen et al. 2003). In addition to Syt1, 
Syt2 and 9 function as Ca2+ -sensors for fast synchronous neurotransmitter release in 
cortical neurons (Xu et al. 2007). Previous studies already observed that Syt2 plays a 
role in fast synchronous release (Stevens & Sullivan 2003; Nagy et al. 2006). 
However, in a systematic analysis regarding rescue capacity of all Syt isoforms, Syt9 
was found also to rescue the Syt1 knockout (KO) phenotype of abolished 
synchronous release in neurons (Xu et al. 2007). Interestingly, Syt2 and 9 exhibit 
distinct kinetics for synchronous release whereby Syt2 constitutes the fastest and 
Syt9 the slowest Ca2+ -sensor for fast synchronous release. Additionally, Syt2 acts as 
the major Ca2+ -sensor for exocytosis in non-neuronal and non-endocrine cells, 
namely in mast cells (Melicoff et al., 2009). 
Intriguingly, Syt7 was not sufficient to rescue the Syt1 KO phenotype even though it 
has been described to localize to the synapse and to regulate Ca2+ -dependent 
exocytosis in endocrine cells, such as PC12 cells, fibroblasts, adrenal chromaffin 
cells and pancreatic cells (Martinez et al. 2000; Sugita et al. 2001; Wang & Chicka 
2005; Li et al. 2007; Schonn et al. 2008; Gustavsson et al. 2008; Gustavsson & Han 
2009). Nevertheless, deletion of Syt1 and Syt7 in chromaffin cells impairs the fast or 
the slow component of LDCV exocytosis, respectively; deletion of both isoforms 
abolishes both phases. Thus, both isoforms are functionally overlapping but the 
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reason for the selectivity to the fast or slow component remains uncertain (Sugita et 
al. 2002). 
Syt4 is a Syt isoform whose function and localization is under debate in the literature. 
In PC12 cells and rat brain, Syt4 is induced by depolarization as an immediate early 
gene (Vician et al. 1995) and Syt4 KO mice showed impairment in memory and 
motor performance (Ferguson et al. 2000). Despite the lack of the conserved amino 
acid aspartate in the Ca2+ -binding loop of the C2A domain in mice (von Poser et al., 
1997), the C2A domain of Drosophila carrying the same substitution has the potential 
to bind Ca2+/phospholipids (Dai et al. 2004; Wang & Chapman 2010). Indeed, Syt4 is 
sufficient to rescue neurotransmitter release of the Syt1 KO in Drosophila (Robinson 
et al., 2002) suggesting a positive role for the C2A domain in Ca2+ -binding. The role 
of the C2B domain regarding its ability to function as a Ca2+ -sensor remains 
controversial due to one report indicating that the C2B domain of Syt4 is sufficient to 
promote glutamate release in astrocytes (Zhang et al. 2004) and another work 
reporting that the C2B domain does not bind Ca2+ in vitro (Dai et al., 2004). In 
contrast to the predominant localization of Syt4 in astrocytes found by Zhang et al. 
2004, Syt4 expression was found at low levels in astrocytes and at high levels in 
pyramidal neurons of the hippocampus (Mittelstaedt et al., 2009). In mouse 
hippocampal neurons Syt4 negatively regulates the release of BDNF containing 
vesicles in axons and dendrites (Dean et al. 2012b; Dean et al. 2009) and 
overexpression of Syt4 in PC12 cells showed inhibition of evoked hormone secretion 
from dense core vesicles (Wang et al. 2001; Machado et al. 2004; Zhang et al. 
2010). In posterior pituitary nerve terminals, high levels of Ca2+ lead to Syt4-mediated 
Ca2+ -dependent exocytosis, whereas at low levels Syt4 inhibits this exocytosis 
(Zhang et al. 2009). 
The function of Syts 3, 5, 6 and 8 is widely unknown, even though reports have 
described that Syt6 and 8 are involved in acrosomal exocytosis in the sperm head 
(Michaut et al., 2001; Hutt et al., 2002) and that Syt3 functions as a plasma 
membrane Ca2+ -sensor for exocytosis in PC12 cells (Sugita et al. 2002). 
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1.6 Synaptotagmin10 
1.6.1 Synaptotagmin10 native expression 
Compared to Syt1, the overall Syt10 expression throughout the brain is very low 
(Figure 1.4 A, B) (Mittelstaedt et al., 2009). The only regions where Syt10 is highly 
expressed are the olfactory bulb (OB) and the suprachiasmatic nucleus (SCN) 
(Figure 1.4 C) (Mittelstaedt et al., 2009; Husse et al., 2011). In the OB, Syt10 
expression is not restricted to a specific layer but expressed in all three layers, the 
glomerular, the mitral and the granule cell layer. In contrast, in the neocortex, overall 
Syt10 expression is low and specifically restricted to layers II, V and VI. Mittelstaedt 
et al (2009) observed that Syt10 expression in the hippocampus is restricted to single 
cells as revealed by a punctate labeling. Moreover, within the HC, Syt10 is nearly 
exclusively detected in the dentate gyrus (DG). The ventral pallidum is the only 
region of the striatum that exhibits Syt10 expression. 
Figure 1.4 Differential expression pattern of Syt1 and Syt10. (A), (B) Horizontal sections of 
P28 rat brains. Via radioactive in situ hybridization with 35S-labeled oligonucleotides specific for Syt1 
and Syt10 gene expression levels were analyzed. (A) Expression of Syt1 is distributed throughout the 
whole brain. (B) In contrast, Syt10 shows low gene expression in the brain. The OB is the only region 
with high levels of Syt10. Olfactory bulb (OB), white matter regions (WM), caudate putamen (CPu), 
cortex (Cx), thalamus (TH), hippocampus (HC), colliculus (CO), cerebellum (CB) (modified from 
Mittelstaedt et al., 2009). (C) Syt10 expression in the suprachiasmatic nucleus. Coronal section of 
mouse brains labeled with digoxigenin-tagged riboprobes specific for Syt10. In situ hybridization 
shows strong Syt10 expression in the SCN. Paraventricular nucleus of the hypothalamus (PVN), third 
ventricle (3V), suprachiasmatic nucleus (SCN), optic chiasm (OC) (modified from Husse et al., 2011). 
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No specific labeling of Syt10 could be detected in the cerebellum, the midbrain and 
diencephalon. Similar to most other Syt isoforms, Syt10 expression levels in the 
brainstem are low. 
Recently, Dean et al. (2012a) analyzed the subcellular localization and kinetics of 
Syt1 to 17 in pHluorin experiments. In this functional screen, they found Syt10 to be 
localized to the axonal plasma membrane of hippocampal neurons under resting 
conditions. Depolarization of the neuronal membrane did not lead to an alteration in 
fluorescence, indicating that no exo- or endocytosis of Syt10 containing vesicles 
occurred. The authors concluded that a weak stimulus is not sufficient to induce a 
change in Syt10 localization but conceivably strong synaptic activity may alter the 
kinetics and localization of Syt10. 
 
1.6.2 Synaptotagmin10 localization to IGF1 containing vesicles 
Until recently, the functional role of Syt10 remained undetermined. However, Cao et 
al. (2011) identified Syt10 to completely co-localize with IGF1 in somatic and 
dendritic vesicles of OB neurons via immunofluorescence of overexpressed tagged 
proteins (Cao et al., 2011). Analyzing Syt10 KO mice, Cao et al., 2011 found that 
synaptic transmission was impaired in mitral cells from Syt10 KO mice and that the 
size of Syt10 KO neurons was decreased as measured by a higher input resistance 
and a decrease in cell capacitance. IGF1 immunoassay revealed an impairment in 
the activity-dependent IGF1 secretion in Syt10 KO mice that resulted in smaller 
neurons. Strikingly, the Syt10 KO phenotype could not be rescued by the Syt10 
related Syt isoforms Syt3, 5 and 6 but by application of exogenous IGF1. These 
results indicate that the Syt10-dependent exocytosis is a distinct pathway that is 
independent of Syt1-mediated exocytosis of synaptic vesicles (Figure 1.5). 
Furthermore, it suggests the occurrence of two different vesicle exocytosis pathways 
in the same neuron. 
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1.6.3 Synaptotagmin10, a seizure-induced gene 
In 1997, Babity et al. first identified Syt10 by differential display (Babity et al., 1997). 
Syt10 mRNA expression was increased in the hippocampus 3 hours (h) after 
seizures evoked by systemic KA administration into adult rat (Figure 1.6 A). Peak 
expression of Syt10 was observed 6 h after seizure activity and declined 12 h 
following kainic acid treatment. In the piriform cortex, basal Syt10 mRNA expression 
was stronger compared to basal expression in the hippocampus. Following seizure 
activity, Syt10 expression was elevated in the piriform cortex at 3-6 h and decreased 
at 12 h after KA administration. 
The parietal cortex served as a control region since it is a tissue in which seizure-
induced neurodegeneration is not observed. In fact, no up-regulation of Syt10 
expression was observed in this region after seizure activity. Using in situ 
hybridization Babity et al. (1997) confirmed Syt10 mRNA expression to be more 
abundant 6 h after seizure activity in the granule cell layer of the dentate gyrus and 
layer II of the piriform cortex (Figure1.6 B). 
 
Figure 1.5 Schematic drawing of 
Syt10-mediated IGF1 exocytosis. The 
picture summarizes Syt1 and Syt10-
mediated exocytosis. Syt10 is located to 
IGF1 containing vesicles and acts there as 
the calcium sensor for release of IGF1 from 
non-synaptic vesicles. The parallel existing 
pathway of Syt1-mediated exocytosis is 
shown as well. Syt1 functions as a Ca2+ -
sensor for release of neurotransmitters into 
the synaptic cleft where they bind to their 
receptors. Note that the distinct types of 
exocytosis can occur in the same neuron 
(Kononenko & Haucke, 2011). 
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Figure 1.6 Induction of Syt10 gene expression following systemic administration of 
KA. (A) Northern blot analysis of Syt10 expression in KA administered rats at different time points 
following seizure activity. Induction of Syt10 expression was observed in the hippocampus and the 
piriform cortex but not in the parietal cortex. (B) In situ hybridization of rat brain coronal sections using 
olignucleotides specific for Syt10. Compared to the control, gene expression was induced in the 
hippocampus of seizure-experienced rats (Babity et al., 1997). 
As mentioned above, Syt10 is expressed at high levels in the OB where it is crucial 
for IGF1 release. During development, IGF1 is distributed ubiquitously but in the 
adult brain it is restricted to the OB as well (Rotwein et al., 1988). In the OB, IGF-1 
regulates axon guidance and neuronal migration (Scolnick et al., 2008; Hurtado-
Chong et al., 2009), which may be important for neuronal repair. 
In addition, IGF1 mRNA expression was described to be increased at 3 days (d), 7 d 
and in the chronic phase after pilocarpine-induced SE (Okamoto et al., 2010). IGF1 
protein expression levels are more abundant 2 d after SE (Choi et al., 2008). 
Furthermore, IGF1 plays a role in epileptogenesis as it is important for progenitor cell 
proliferation in the subgranular zone of the dentate gyrus 2 d following pilocarpine-
induced SE (Choi et al., 2008). Hence, expression of IGF1 and Syt10 is altered in 
response to seizure activity but Syt10 is not the only Synaptotagmin gene family 
member that is altered during neurodegeneration. To understand the different 
pathways of Syt-dependent vesicle exocytosis and their potential interactions, it is 
essential to understand the role of Syts in neurodegeneration. 
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1.7 The role of Synaptotagmins in neurodegeneration 
There is growing evidence that membrane trafficking underlies pathophysiological 
and adaptive changes in neurodegeneration, neuronal plasticity and glial activation. 
Given that Syts are membrane trafficking proteins, Syt expression may be altered 
during the process of plasticity. Neurodegenerative changes are characterized by 
malfunctions of synaptic connections and/or loss of neurons within specific regions in 
the CNS. These alterations can appear after epileptic seizures, cerebrovascular 
insults or neurodegenerative diseases, namely Alzheimer’s disease, Parkinson’s 
disease or Huntington’s disease. Even though the underlying pathophysiological 
processes between distinct neurodegenerative diseases may differ, all lead to cell 
death either by apoptosis, leakage of detrimental cytoplasmic contents (necrosis) or 
membrane disruption (reviewed by Glavan et al. 2009). 
Numerous reports show that Syts are important for plasmalemmal and axolemmal 
repair and that this resealing is mediated by Ca2+ -regulated exocytosis (Detrait et al. 
2000b; Detrait & Eddleman 2000a; Bi et al. 1995; Reddy et al. 2001; Miyake & 
McNeil 1995; Steinhardt et al. 1994). It is therefore tempting to speculate that Syts 
are involved in remodeling after neuronal cell loss and in the repair of degenerating 
neurons. 
In Parkinson’s disease, four Syts exhibited altered expression, namely Syts 2, 4, 7 
and 10. In an animal model for Parkinson’s disease Syt2 mRNA was decreased 
whereas the expression of Syt10 mRNA was increased (Glavan & Zivin, 2005). In 
response to anti-Parkinson drug treatment, Syt4 and 7 mRNA expression levels were 
increased indicating that these Syts might be involved in pathophysiological 
alterations of synaptic transmission. A role for Syt11 in Parkinson’s disease was 
suggested due to binding of Syt11 to the parkin protein (Huynh et al., 2003). 
In rat hippocampus, Syt4 mRNA expression is more abundant 24 h after transient 
global cerebral ischemia (Yokota et al., 2001) whereas using a different method, 
mRNA expression levels of Syt4 were described to be increased at a later time point 
(21 d) (Krüger et al., 2006). This discrepancy may result from different brain ischemia 
models used in the studies. 
The only Syt isoform that was reported to be less abundant in the context of 
Alzheimer’s disease is Syt1 (Masliah et al. 2001; Reddy et al. 2001; Sze et al. 2000; 
Yoo & Cairns 2001; Mufson et al. 2002). 
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Epilepsy is another disease that induces morphological plasticity, i.e. mossy fiber 
sprouting and reactive gliosis in the hippocampus. Cell death occurs in the CA1 and 
CA3 region and in hilar cells of the dentate gyrus (Nadler 2003; Tauck & Nadler 
1985; Dashtipour et al. 2002). Several Syt isoforms are differentially regulated in 
epilepsy, namely Syts 1, 3, 4 and 10. In patients with mesial temporal lobe epilepsy 
(MTLE), a decrease of Syt1 protein was detected based on two-dimensional gel 
electrophoresis (2-DE) combined with mass spectrometry (Yang et al. 2006). The 
reduction of Syt1 protein is consistent with a down-regulation of Syt1 mRNA in CA1 
and CA3 subfields of the hippocampus in adult rats with KA-induced seizures (Tocco 
et al., 1996). Recently, it has been reported that spontaneous epileptic rats (SER), 
which exhibit tonic convulsions and absence seizures after 6 weeks of age, express 
Syt1 protein at lower levels in frontal piriform and entorhinal cortices and in the inner 
molecular layer of the dentate gyrus compared to Wistar rats (Hanaya et al., 2012). 
Decreased Syt1 probably leads to impaired SV exocytosis and consequently to 
GABAergic dysfunction, thus resulting in expression and propagation of epileptic 
seizures in SERs. Moreover, Syt1 is thought to play a role in refractory epilepsy as 
protein expression of patients with refractory epilepsy is more abundant. Furthermore 
mRNA and protein expression levels of Syt1 are augmented in kindled rats with 
phenytoin-resistance (Xiao et al. 2009; Zeng et al. 2009). These results indicate that 
Syt1 might play a role in the strengthening of refractory epilepsy by increased SV 
trafficking. 
Two more Syts are altered in response to seizures, (a) Syt3 mRNA expression was 
found to be decreased in hippocampus following electroconvulsive seizures (Elfving 
et al., 2008) and (b) Syt4 expression was altered after kainate injection. In situ 
hybridization of adult rats revealed a peak increase of Syt4 mRNA 4 h after seizure 
onset in the dentate gyrus and 8 h after seizure onset in CA1, CA3 and piriform 
cortex. This transient up-regulation decreased in all regions 30 h post seizure onset. 
A similar time course of mRNA increase after KA injection was observed in rats 
analyzed for Syt10 expression. As mentioned above, both Syt10 mRNA as well as 
IGF1 mRNA expression levels are augmented in the hippocampus after SE (Babity et 
al., 1997; Choi et al., 2008; Okamoto et al., 2010). Hence, Syt10 and IGF-1 play a 
role in epileptogenesis but to date it remains to be defined whether they are 
regulated simultaneously and subsequently function together in the hippocampus. 
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2 Aims of the study 
Epileptogenesis describes a process of multiple cellular and molecular changes in 
the brain finally resulting in the occurrence of recurrent spontaneous seizures. It 
involves alterations leading to morphological changes of neuronal connections and 
circuits in the brain and to functional modifications of the cellular network. 
Understanding the mechanisms underlying these modifications is essential for new 
and efficient treatment possibilities. Analyzing changes in gene expression during 
epileptogenesis is a first step in this direction. One gene that is rapidly and transiently 
up-regulated in the rat hippocampus early after the experimental induction of SE but 
is barely detectable under native conditions is Syt10. It was therefore suggested that 
Syt10 might be involved in cerebral changes influencing the process of 
epileptogenesis or act neuroprotectively. However, to date, little is known about the 
function of Syt10 in health and disease conditions especially in the hippocampus. 
In order to gain further insight into the signaling cascades mediating Syt10 
expression and to resolve the function of Syt10 the following aims will be pursued: 
Firstly, define the mechanisms regulating the Syt10 expression in the hippocampus. 
Therefore, the Syt10 promoter and genomic regulatory regions will be 
bioinformatically and functionally characterized. Next, using Luciferase assays and 
quantitative RT-PCR the signaling cascades controlling basal and activity-induced 
transcription will be further examined. 
Secondly, resolve, in which subcellular compartment Syt10 is present. Isoform-
specific antibodies will be generated to comparatively analyze the distribution of 
Syt10 and the related Syt isoforms 3, 5 and 6 using immunocytochemistry and 
overexpression of GFP-tagged proteins in neurons. Next, different Syt10 sequences 
will be probed for their relevance in subcellular targeting. 
Thirdly, establish a procedure to identify Syt10 containing organelles and protein 
complexes. This approach will allow the isolation of the respective Syt10 complexes 
or organelles from the hippocampus after SE. 
Fourthly, examine the role of Syt10 in epileptogenesis. The time course of Syt10 
expression in response to pilocarpine-induced SE will be examined in mice. In the 
same model functional changes of Syt10 KO mice in the hippocampus will be 
studied. 
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In summary, this study will provide novel insights into key mechanisms controlling 
Syt10 gene expression in response to transient hyperexcitability as well as into the 
functional role of Syt10 in the normal and epileptic brain. 
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3 Materials 
3.1 Equipment 
 
Table 3.1: List of equipment used for this study 
 
Application Model Company
Acrylamid electrophoresis system
Mini-PROTEAN 3 Electrophoresis 
System BioRad
Agarose electrophoresis system SUB-CELL GT BioRad
Analytical balance BP210S Sartorius
Analytical balance Toledo Mettler
Autoclave Varioclav 75T H + P
Balance SBC53 SCALTEC
Capillary Sequencer 3130/xl/Genetic Analyzer Applied Biosystems
Cell-culture hood MSC-Advantage Thermo Scientific
Cell-culture hood HERA SAFE KS Thermo Scientific
Centrifugation concentrator Amicon Ultra-4 / Ultra-15 100K Millipore
Centrifuge Function line Heraeus
Centrifuge 5415C Eppendorf
Centrifuge Mikro 22R Hettich
Centrifuge Mikro 200R Hettich
Centrifuge Rotina 220R Hettich
Centrifuge Megafuge 1.0R Heraeus
Confocal laser scanning 
microscope
LSM710 Zeiss
Confocal laser scanning 
microscope
Eclipse Ti Nikon
Confocal laser scanning 
microscope
Leica TCS Leica
Controller Micro4 Controller, 4-Channel World Precision 
Instruments
Cryostat FV300 MICROM
Gel documentation system AlphaImager Alpha Innotech
Heparin column HiTrap Herparin HP GE Healthcare
Incubator TH 30 / TH 15 Edmund Bühler GmbH
Incubator Binder
Incubator (cells/cell culture) HERAcell 150 / 150i Thermo Scientific
Incubator (media/cell culture) Modell 100 Memmert
Incubator small Inkubator 1000, Unimay 1010 Heidolph
Incubator small Incubating Mini shaker VWR
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 Table 3.1 (continued) 
 
Application Model Company
Infrared imaging system Odyssey Li-cor
Inverse microscope Axio Observer 1A Zeiss
Luminometer Glomax 96 microplate 
luminometer
Promega
Micro pump UltraMicroPump III World Precision 
Instruments
PCR-Cycler UNOII Biometra
PCR-Cycler T3 Biometra
PCR-Cycler T3000 Biometra
pH-meter pHMeter 766 Calimatic Knick
Precision Syringe Nanofil Hamilton 10µl World Precision 
Instruments
Quick-seal tubes 26.3ml 25x89mm Beckman Coulter
Real time PCR (Taqman) 9700HT ABI Prism
Rotor Type 70 Ti Beckman Coulter
Shaker plate Polymax 1040 Heidolph
Spectrophotometer ND-1000 NanoDrop
Thermo shaker MKR13 HLC
Thermo shaker Thermomixer compact Eppendorf
Transfer System Mighty Small Transphor/Hoefer 
TE22
Amersham
Ultrasonic Processor UP50H Hielscher
Vibratom Microm HM 650V Thermo Scientific
Vortex Vortex-Genie 2 Scientific Industries
Vortex Reax control Heidolph
Water bath Shake Temp SW23 Julabo
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3.2 Materials and reagents 
3.2.1 Antibodies 
 
Table 3.2: Primary antibodies 
 
Name Assay Dilution Company
anti-rat biotin cross SP IHC 1:165
Jackson Immuno 
Research Laboratories 
Inc.
BrdU IHC 1:150 AbD Serotec
FLAG WB 1:5000 Sigma-Aldrich
GFAP ICC 1:2000 Dako
GM130 ICC 1:500
BD Transduction 
Laboratories
HA ICC 1:100 Covance
HA ICC 1:100 Sigma-Aldrich
MAP2 ICC 1:500 Chemicon
PSD95 ICC 1:200 Chemicon
ß-actin WB 1:10000 Abcam
Synapsin ICC 1:100 Synaptic Systems
Syt1 ICC 1:200 Synaptic Systems
Syt10 1D3 ICC 1:2-5
Helmholtz Zentrum         
Dr. Kremmer
Syt10 2A9 ICC 1:2-5
Helmholtz Zentrum         
Dr. Kremmer
Syt10 poly 150 T3 ICC/WB 1:250 Pineda
vGAT ICC 1:500 Synaptic Systems
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Table 3.3: Secondary antibodies 
 
 
3.2.2 Enzymes 
Table 3.4: Enzymes used in this study 
 
Name Assay Dilution Company
anti-mouse Cy3 ICC 1:400
Jackson Immuno 
Research Laboratories 
Inc.
anti-mouse Cy5 ICC 1:400
Jackson Immuno 
Research Laboratories 
Inc.
anti-mouse FITC ICC 1:400
Jackson Immuno 
Research Laboratories 
Inc.
anti-rabbit Cy3 ICC 1:400
Jackson Immuno 
Research Laboratories 
Inc.
anti-rabbit FITC ICC 1:400
Jackson Immuno 
Research Laboratories 
Inc.
Cy3-Streptavidin IHC 1:160
Jackson Immuno 
Research Laboratories 
Inc.
IRDye anti-mouse 
800nm WB 1:20000 Licor
IRDye anti-rabbit 
680nm WB 1:20000 Licor
Enzyme Company
GoTaq® Flexi DNA Polymerase Promega
DNase I Roche
Lipofectamine™ 2000 Transfection Reagent Life technologies
Pfu DNA Polymerase Thermo Scientific
T4 Ligase Thermo Scientific
Trypsin GIBCO BRL
Restriction Enzymes
MluI, SalI, XhoI, KpnI, HindIII, EcoRI, BamHI, MfeI, XbaI Thermo Scientific
StuI New England Biolabs
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3.2.3 Chemicals 
Table 3.5: Chemicals used in this study 
 
3.2.4 Diverse material 
Table 3.6: Diverse products used in this study 
 
Chemical Company
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) Life technologies
5-bromo-2'-deoxyuridine (BrdU) Sigma-Aldrich
Arabinofuranosyl cytidine (Ara-C) Sigma-Aldrich
Bovine serum albumin (BSA) Sigma-Aldrich
cOmplete Protease Inhibitor Cocktail Tablets Roche
Diazepam Ratiopharm
dimethyl sulfoxide (DMSO) Roth
Fetal calf serum (FCS) Life technologies
Gelatin from cold water fish skin Sigma-Aldrich
glucose solution 5 % Fresenius
Iodixanol OptiPrep Nycomed Pharma
Isofluran Forene
Kainic acid (KA) Abcam
N,N-Bis-(2-hydroxyethyl)-2-amino-ethansulfonic acid (BES) Roth
Normal goat serum (NGS) GIBCO BRL
Paraformaldehyd (PFA) Merck
Pilocarpine hydrochloride Sigma-Aldrich
Poly-L-lysine Sigma-Aldrich
Scopolamine methyl nitrate Sigma-Aldrich
Triton X-100 Sigma-Aldrich
Product Company
Nitrocellulose membrane (Protran® 0,45 µm pore size) Watman, GE Healthcare
Nylon cell strainer 100µm BD Biosciences
Tissue tek Sakura Finetek
Vectashield Hard Set Mounting Medium Axxora
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3.2.5 Cell culture media 
Table 3.7: Cell culture media used in this study 
 
3.2.6 Kits 
Table 3.8: Kits used in this study 
 
Cell culture medium Company
B27 Gibco
Basal Medium Eagle (BME) Life technologies
Dulbecco's Modified Eagle's Medium (DMEM) Gibco
Fetal calf serum (FCS) Life technologies
Glucose Sigma-Aldrich
Hank's Buffered Salt Solution (HBSS) Gibco
Iscove's Modified Dulbecco's Medium (IMDM) Gibco
L-Glutamine Gibco
minimum essential medium (MEM) Sigma-Aldrich
Opti-MEM Gibco
Papain Sigma-Aldrich
Penicillin-Streptomycin Gibco
Phospate saline buffer (PBS) Gibco
Poly-D-Lysin Sigma-Aldrich
sodium bicarbonate Invitrogen Life technologies
sodium hypoxanthine, aminopterin, thymidine (HAT) Life technologies
Kit Company
BigDye® Terminator v3.1 Cycle Sequencing Kit Applied Biosystems
Cell viability imaging kit Roche
DNA Clean and Concentration kit Zymo Research
Dual-Luciferase® Reporter Assay System Promega
DyeEx 2.0 (Purification of Sequencing) Qiagen
Dynabeads® mRNA DIRECT™ Micro Kit Life technologies
EndoFree Plasmid Maxi Kit Quiagen
GeneJET™ Plasmid Miniprep Kit Thermo Scientific
High Capacity cDNA Reverse Transcription Kit Applied Biosystems
Maxima™ SYBR Green/ROX qPCR Master Mix (2X) Thermo Scientific
PureLink™ HiPure Plasmid Filter Maxiprep Kit Life technologies
PureLink™ HiPure Plasmid Filter Midiprep Kit Life technologies
QuickChangeII XL Site Directed Mutagenesis kit Stratagene
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific
TOPO vectors Life technologies
Zymoclean Gel DNA recovery kit Zymo Research
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3.3 Oligonucleotides 
3.3.1 Cloning 
Table 3.9: Primers used for cloning of full-length Syts and IGF1. #: primer number of the 
lab internal primer list; RE: restriction enzymes that were used for cloning of fragments into the 
corresponding vectors. Fw: forward; rev: reverse 
 
 
Gen Direction # 5'-SEQUENCE-3' RE
GFP fw 1309
GCGGTCGACGGGGGCGGCGGAATGGTGAGCAAG
GGCGAG SalI
GFP rev 1310 GCGAGATCTTACTTGTACAGCTCGTCCATG BglII
mCherry fw 1309
GCGGTCGACGGGGGCGGCGGAATGGTGAGCAAG
GGCGAG SalI
mCherry rev 1310 GCGAGATCTTACTTGTACAGCTCGTCCATG BglII
mRFP fw 2152 GCGGTCGACATGGCCTCCTCCGAGGACGT SalI
mRFP rev 2153 GCGAGATCTTTAGGCGCCGGTGGAGTGGC BglII
Syt10 fw 1449 GCGGAATTCACCATGAGTTTCCGCAAGGAGG EcoRI
Syt10 rev 1798
GCGGGATCCGCCTCCAGGGCCTCCTGGTGTGGAC
GGTGGC BamHI
Syt10 fw 1449 GCGGAATTCACCATGAGTTTCCGCAAGGAGG EcoRI
Syt10 rev 1796 GGATCCTTATGGTGTGGACGGTGG BamHI
Syt10 fw 1449 GCGGAATTCACCATGAGTTTCCGCAAGGAGG EcoRI
Syt10 rev 1497 GCGGGATCCCCCTGGTGTGGACGGTGGC BamHI
Syt3 fw 1463 GCGCAATTGACCATGTCTGGGGACTACGAAGATG MfeI
Syt3 rev 1382 GCGGTCGACCTCTGAATTCTCTTTCTCTGACAATC SalI
Syt5 fw 1383 GCGGAATTCACCATGCCCGGGGCCAGGGACGC EcoRI
Syt5 rev 1384 GCGCGTCGACTCGTTTCTCCAGCAGAGAGTG SalI
Syt6 fw 1385 GCGGAATTCGGCATGAGCGGAGTTTG EcoRI
Syt6 rev 1386 GCGCGTCGACCAACCGGGGGGTTCCC SalI
IGF1 fw 1949 GAATTCACCATGACCGCACCTGCAATAA EcoRI
IGF1 rev 1951
GGATCCGCCTCCAGGGCCTCCGCCCAGTCTTTTTT
CTCTGG BamHI
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Table 3.10: Primers used for cloning of chimeric Syts. #: primer number of the lab internal 
primer list; RE: restriction enzymes that were used for cloning of fragments into the corresponding 
vectors. Fw: forward; rev: reverse 
 
 
 
Table 3.11: Primers used for cloning of promoter fragments. #: primer number of the lab 
internal primer list; RE: restriction enzymes that were used for cloning of fragments into the 
corresponding vectors. Fw: forward; rev: reverse  
 
 
Gen Domain Direction # 5'-SEQUENCE-3' RE
Syt10
TMD to C-
terminus fw 1449
GCGGAATTCACCATGAGTTTCC
GCAAGGAGG EcoRI
Syt10
TMD to C-
terminus rev 1610
GCGGAATTCAGGCCTGTTAGCG
GTTGTTGTAAGC BamHI
Syt3
N-
terminus fw 1611
GCGACCATGTCTGGGGACTACG
AAGATG blunt
Syt3
N-
terminus rev 1677 CTGTCTGCATCCGGACC blunt
Syt5
N-
terminus fw 1613 GCGACCATGCCCGGGGCCAG blunt
Syt5
N-
terminus rev 1678 CTATCTGGGTCGCGGAGC blunt
Syt6
N-
terminus fw 1615
GCGACCATGAGCGGAGTTTGG
GGG blunt
Syt6
N-
terminus rev 1679 CTGACAGAGGTGCCTGAGTC blunt
region Direction # 5'-SEQUENCE-3' RE
genomic position 
(bp) relative to the 
start ATG
pGL3-306 fw 1472
GCGACGCGTTCAGGAAGGTGT
GTGGGAA MluI -306 to 0
pGL3-306 rev 1473
GCGGTCGACCTTGGCTTCTGCT
CGCAG SalI -306 to 0
pGL3-1036 fw 1476
GCGACGCGTGGGGTAACTTTAC
CATAACCTGG MluI -1036 to 0
pGL3-1036 rev 1473
GCGGTCGACCTTGGCTTCTGCT
CGCAG SalI -1036 to 0
pGL3-4713 fw 1480
GCGACGCGTAGTGATTTGTAGA
AAAGACCACATGA MluI -4713 to 0
pGL3-4713 rev 1473
GCGGTCGACCTTGGCTTCTGCT
CGCAG SalI -4713 to 0
RR-IN fw 1541
GCGGGATCCTAAAGGGACAAGC
TTGGGCT XhoI 152 to 3034
RR-IN rev 1542
GCGGGTCGACAAAATTCTTGAT
AAATACTTGCTGAA BglII 152 to 3034
RR-5' fw 1682
GCGGGTACCTCTTCAGGCTCAA
AATTAGTGG KpnI -33755 to -32055
RR-5' rev 1683
GCGGGTACCCAAACTTCAAAAA
CATCATGCTA KpnI -33755 to -32055
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Table 3.11 (continued) 
 
region Direction # 5'-SEQUENCE-3' RE
genomic position 
(bp) relative to the 
start ATG
RR-3' fw 1884
GTCGACGTTCTTCTCGCAGAGC
CTCA SalI -63567 to- 63029
RR-3' rev 1885
GTCGACAAGTCGGGGAAAGGG
ATTATT SalI -63567 to -63029
RR-1 fw 1952
GCGGGTACCAGAAGTTTACCCA
GCTCACCA KpnI -4344 to -3675
RR-1 rev 1953
GCGGGTACCACTCACTGTGGTA
AGCATTCATT KpnI -4344 to -3675
RR-2 fw 1954
GCGGGTACCCTGCCCAGACTGT
AGATAAACG KpnI -4054 to -3675
RR-2 rev 1953
GCGGGTACCACTCACTGTGGTA
AGCATTCATT KpnI -4054 to -3675
RR-3 fw 1952
GCGGGTACCAGAAGTTTACCCA
GCTCACCA KpnI -4344 to -4054
RR-3 rev 1955
GCGGGTACCTTATCTACAGTCT
GGGCAGAACA KpnI -4344 to -4054
Exon 1 fw c64
GCGCTCGAGTACCTGTGCCACC
TCCG XhoI 0 to 149
Exon 1 rev c65
GCGAAGCTTAGTTTCCGCAAGG
AGGAC HindIII 0 to 149
Del I fw 1472
GCGACGCGTTCAGGAAGGTGT
GTGGGAA MluI -306 to -108
Del I rev c154
GCGCTCGAGGACGGACGCTGC
TGC XhoI -306 to -108
Del II fw 1472
GCGACGCGTTCAGGAAGGTGT
GTGGGAA MluI -306 to -76
Del II rev c151
GCGCTCGAGGTTGGCAAGGGC
GCA XhoI -306 to -76
Del III fw c153
GCGACGCGTTCCCAGTCACGA
GTCATGAT MluI -724 to 0
Del III rev c265
GCGCTCGAGCTTGGCTTCTGCT
CGCAG XhoI -724 to 0
Del IV fw c152
GCGACGCGTGGAATCAAGTGG
TGCCTCC MluI -740 to 0
Del IV rev c265
GCGCTCGAGCTTGGCTTCTGCT
CGCAG XhoI -740 to 0
Del V fw c264
GCGACGCGTGTAGGCAGTAGCT
TGACTTCTCCA MluI -2165 to 0
Del V rev c265 GCGCTCGAGCTTGGCTTCTGCT
CGCAG
XhoI -2165 to 0
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Table 3.12: Primers used for cloning constructs for tandem affinity purification. #: 
primer number of the lab internal primer list; RE: restriction enzymes that were used for cloning of 
fragments into the corresponding vectors. Fw: forward; rev: reverse 
 
 
Gen Direction # 5'-SEQUENCE-3' RE
SF-TAP fw 1543
GCGGGATCCCCCGGACCCTGGAGCCACCCTCAGT
TC SalI
SF-TAP rev 1437 GCGGTCGACTCATTTATCATCATCATCTTTATAATCC HindIII
SF-TAP fw 1544 GCGGAATTCACCATGGATTATAAAGATGATGATG EcoRI
SF-TAP rev 1545
GCGGGATCCTGGTCCTGGTTTCTCGAACTGCGGGT
G BamHI
Syt10 fw 1449 GCGGAATTCACCATGAGTTTCCGCAAGGAGG EcoRI
Syt10 rev 1497 GCGGGATCCCCCTGGTGTGGACGGTGGC BamHI
Syt6 fw 1385 GCGGAATTCGGCATGAGCGGAGTTTG EcoRI
Syt6 rev 1768 GCGGGATCCCCAACCGGGGGGTTCCC BamHI
Syt10 fw c24 GCGGGATCCAAGTTGTGCTGGCCATGCT BamHI
Syt10 rev c25 GCGTCTAGATTATGGTGTGGACGGTGGC XbaI
Syt6 fw c26 GCGGGATCCAAGCTGTGCTGGATGCCC BamHI
Syt6 rev c27 GCGTCTAGATTACAACCGGGGGGTTCCC XbaI
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3.3.2 Diverse oligos 
Table 3.13: Sequencing primers. #: primer number of the lab internal primer list; Fw: forward; 
rev: reverse 
 
 
3.3.3 Site directed mutagenesis 
Table 3.14: Primers used for site directed mutagenesis. #: primer number of the lab internal 
primer list; Fw: forward; rev: reverse 
 
 
Template Direction # 5'-SEQUENCE-3' Position (bp)
pCMV ß-Globin 
Intron fw 1461 GAGTCCAAGCTAGGCCCTTT 1197
pSyn fw 1379 GCGAGATAGGGGGGCACG 518
Syt10 fw 1797 CTTGGGAGAGACCATTGGAA 1426
pGL3 fw 1455 CTAGCAAAATAGGCTGTCCC 4760
pGL3 rev 1456 CTTTATGTTTTTGGCGTCTTCCA 89
mCherry rev 1462 AAGCGCATGAACTCCTTGAT 37
Template Direction # 5'-SEQUENCE-3' aa exchange
pAAV-Syn-
Syt10-GFP fw 1617 GTGTGAGCAGCCTGGCCCAGAAGGCGCTGC C13-->A
pAAV-Syn-
Syt10-GFP rev 1618 GCAGCGCCTTCTGGGCCAGGCTGCTCACAC C13-->A
pAAV-Syn-
Syt10-GFP fw 1619 TCATCACCGAGCTGGCCTTCGCGGGTCAGG C24-->A
pAAV-Syn-
Syt10-GFP rev 1620 CCTGACCCGCGAAGGCCAGCTCGGTGATGA C24-->A
pAAV-Syn-
Syt10-GFP fw 1621
GGTGGAGTGGGACAAGGCTTCGGGCATCTT
TCCA C34-->A
pAAV-Syn-
Syt10-GFP rev 1622
TGGAAAGATGCCCGAAGCCTTGTCCCACTCC
ACC C34-->A
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3.3.4 Quantitative RT-PCR 
Table 3.15: Primers used for quantitative RT-PCR. #: primer number of the lab internal primer 
list; Fw: forward; rev: reverse 
 
 
3.4 Vectors and vector construction 
3.4.1 Multiple cloning sites (MCS) 
 
Additional information about the backbone vectors that were used for cloning is given 
in the appendix (Supplementary Figures 1 - 6). 
Gene Direction # 5'-SEQUENCE-3' position (bp)
Syp fw TCAGGACTCAACACCTCAGTGG 580 to 653
Syp rev AACACGAACCATAAGTTGCCAA 580 to 653
rNPAS4 fw q97 GGTGTCTCAACATTCCCCTA 2333 to 2432
hNPAS4 rev q55 GTTCCCCTCCACTTCCATCT 2333 to 2432
IGF1 fw q111 TTGCGGGGCTGAGCTGGTG 142 to 240
IGF1 rev q112 GCCCTCCGAATGCTGGAGCC 142 to 240
rSyt10 fw 753 GTGTCGAACTGGACTTGACG 1398 to 1463
rSyt10 rev 754 TGATAGGCCAGCATTTCA 1398 to 1463
mSyt10 fw q129 TCCCTCCAGAGAATGTGGAC 1404 to 1503
mSyt10 rev q130 AGTCCAGTTCGACACACGCCT 1404 to 1503
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3.4.2 Generated constructs 
Table 3.16: List of all generated constructs 
 
Name Insert Template Vector Enzymes
pcDNA3.1 TOPO 
Syt3 Syt3 (rat) pCMV-Syt3 pcDNA3.1 TOPO -
pcDNA3.1 TOPO 
Syt5 Syt5 (rat) pCMV-Syt5 pcDNA3.1 TOPO -
pcDNA3.1 TOPO 
Syt6 Syt6 (rat) pCMV-Syt6 pcDNA3.1 TOPO -
pcDNA3.1 TOPO 
Syt10 Syt10 (mouse) cDNA pcDNA3.1 TOPO -
pSyn-GFP Cterm. GFP EGFP pSyn-MCS SalI/BglII
pSyn-mCherry 
Cterm. mCherry mCherry pSyn-MCS SalI/BglII
pAAV-Syn-mRFP mRFP mRFP pAAV-Syn-MCS SalI/BglII
pSyn-Syt3-GFP Syt3
pcDNA3.1 TOPO 
Syt3 pSyn-GFP Cterm. MfeI/SalI
pSyn-Syt5-GFP Syt5
pcDNA3.1 TOPO 
Syt5 pSyn-GFP Cterm. EcoRI/SalI
pSyn-Syt6-GFP Syt6
pcDNA3.1 TOPO 
Syt6 pSyn-GFP Cterm. EcoRI/SalI
pSyn-Syt10-GFP Syt10
pcDNA3.1 TOPO 
Syt10 pSyn-GFP Cterm. EcoRI/BamHI
pAAV-Syn-Syt10-
mRFP Syt10
pcDNA3.1 TOPO 
Syt10 pAAV-Syn-mRFP EcoRI/BamHI
pAAV-Syn-IGF1-
mRFP IGF1 pAAV-IGF1 pAAV-Syn-mRFP EcoRI/BamHI
pAAV-Syn-Syt10-
TMD to C-terminus-
GFP
Syt10-TMD to C-
terminus
pcDNA3.1 TOPO 
Syt10 pAAV-Syn-GFP EcoRI/BamHI
pAAV-Syn-Syt3/10-
GFP Syt3 N-terminus
pcDNA3.1 TOPO 
Syt3
pAAV-Syn-Syt10-
TMD to C-terminus-
GFP
StuI/blunt
pAAV-Syn-Syt5/10-
GFP Syt5 N-terminus
pcDNA3.1 TOPO 
Syt5
pAAV-Syn-Syt10-
TMD to C-terminus-
GFP
StuI/blunt
pAAV-Syn-Syt6/10-
GFP Syt6 N-terminus
pcDNA3.1 TOPO 
Syt6
pAAV-Syn-Syt10-
TMD to C-terminus-
GFP
StuI/blunt
Syt/IGF constructs
TOPO-constructs
fluorescent reporter protein constructs
chimeric constructs
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Table 3.16 (continued) 
Name Insert Template Vector Enzymes
pGL3-306 fragment -306 genomic DNA (rat) pGL3 basic MluI/SalI
pGL3-1036 fragment -1036 genomic DNA (rat) pGL3 basic MluI/SalI
pGL3-4713 fragmant -4713 genomic DNA (rat) pGL3 basic MluI/SalI
pGL3-IN fragment Intron genomic DNA (rat) pGL3 basic XhoI/BglII
pGL3-306+RR5' fragment RR5' genomic DNA (rat) pGL3-306 KpnI
pGL3-306+RR3' fragment RR3' genomic DNA (rat) pGL3-306 SalI
pGL3-306+RR-1 fragment RR-1 pGL3-4713 pGL3-306 KpnI
pGL3-306+RR-2 fragment RR-2 pGL3-4713 pGL3-306 KpnI
pGL3-306+RR-3 fragment RR-3 pGL3-4713 pGL3-306 KpnI
pGL3-306+ExonI
fragment Exon 2. 
half genomic DNA (rat) pGL3-306 XhoI/HindIII
pGL3-DelI fragment DelI pGL3-4713 pGL3 basic MluI/XhoI
pGL3-DelII fragment DelII pGL3-4713 pGL3 basic MluI/XhoI
pGL3-DelIII fragment DelIII pGL3-4713 pGL3 basic MluI/XhoI
pGL3-DelIV fragment DelIV pGL3-4713 pGL3 basic MluI/XhoI
pGL3-DelV fragment DelV pGL3-4713 pGL3 basic MluI/XhoI
pAAV-CMV-C-TAP SF-TAP Cterm. pAAV-CMV-MCS SalI/HindIII
pAAV-CMV-N-TAP SF-TAP Nterm. pAAV-CMV-MCS EcoRI/BamHI
pAAV-CMV-Syt6-
TAP Syt6
pcDNA3.1 TOPO 
Syt6 pAAV-CMV-C-TAP EcoRI/BamHI
pAAV-CMV-Syt10-
TAP
Syt10 pcDNA3.1 TOPO 
Syt10
pAAV-CMV-C-TAP EcoRI/BamHI
pAAV-CMV-Syt6-
TAP without 
Nterm.+TMD
Syt6
pcDNA3.1 TOPO 
Syt6 pAAV-CMV-N-TAP EcoRI/BamHI
pAAV-CMV-Syt10-
TAP without 
Nterm.+TMD
Syt10
pcDNA3.1 TOPO 
Syt10 pAAV-CMV-N-TAP EcoRI/BamHI
TAP constructs
promoter constructs
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Table 3.16 (continued) 
 
 
Plasmids kindly provided by other labs 
pcDNA3.1-hNPAS4, pcDNA3.1-hUSF1, pcDNA3.1-hUSF2, pcDNA3.1-Arnt2-V5: 
Prof. Tõnis Timmusk (Tallinn University of Technology, Tallinn, Estonia). 
pCMV-CREB: PD Dr. Bernd Evert (University of Bonn Medical Center). 
pcDNA cJun-FLAG: Dr. Marc Piechaczyk (Insitute of Molecular Genetics, Montpellier, 
France) 
pcDNA3-MEF2A-FLAG, pcDNA3-MEF2C: Dr. Eric N. Olson (University of Texas, 
Southwestern Medical Center) 
pcDNA3.1-Per1: Prof. Gregor Eichele / Prof. Henrik Oster (Max Planck Institute for 
Biophysical Chemistry, Göttingen) 
pAAV-IGF1: Prof. S. Ramakrishnan (University of Minnesota Medical School, 
Minneapolis, USA) 
TfR-GFP, NPY-GFP: Prof. Casper C. Hoogenraad (Cell Biology, Faculty of Science, 
Utrecht University, Utrecht, The Netherlands) 
Name Insert Template Vector Enzymes
pAAV-Syn-Syt10-
Mut1-GFP -
pAAV-Syn-Syt10-
GFP - -
pAAV-Syn-Syt10-
Mut2-GFP -
pAAV-Syn-Syt10-
GFP - -
pAAV-Syn-Syt10-
Mut3-GFP -
pAAV-Syn-Syt10-
GFP - -
pAAV-Syn-Syt10-
Mut1+2-GFP -
pAAV-Syn-Syt10-
GFP - -
pAAV-Syn-Syt10-
Mut1+3-GFP -
pAAV-Syn-Syt10-
GFP - -
pAAV-Syn-Syt10-
Mut2+3-GFP -
pAAV-Syn-Syt10-
GFP - -
pAAV-Syn-Syt10-
Mut1+2+3-GFP
- pAAV-Syn-Syt10-
GFP
- -
site-directed mutagenesis constructs
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4 Methods 
4.1 Bioinformatics 
4.1.1 Promoter analysis 
The databases UCSC (http://genome.ucsc.edu/) and the ECR browser of rvista 2.0 
(http://rvista.dcode.org/) were used for multiple alignments to search for evolutionary 
conserved regions. Searches for transcription factor binding sites were carried out 
using the Genomatix database (http://www.genomatix.de/) and multiTF of rvista 2.0 
(http://rvista.dcode.org/). Prediction of the transcription start site (TSS) was 
performed using Eponine TSS from Wellcome Trust Sanger Institute 
(http://www.sanger.ac.uk/resources/software/eponine/), whereas the CpG islands 
were predicted with the platform CpGPlot from EMBL-EBI  
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/). 
 
4.2 Molecular biology methods 
4.2.1 RNA extraction and cDNA synthesis 
mRNA from primary hippocampal neurons and from microdissected hippocampal 
subregions was isolated using Dynabeads® mRNA DIRECT Micro Kit (Life 
technologies, Karlsruhe, Germany,) and cDNA was synthesized using RevertAid™ 
First Strand cDNA Synthesis Kit (Fermentas) both carried out according to the 
manufacturer’s specifications. 
 
4.2.2 PCR 
Table 4.1: Standard PCR thermal profile 
Step Temperature Time Cycle 
    
1 95 °C 10 min  
2 95 °C 15 sec  
3 59 °C 60 sec  
4 72 °C 40 sec 40 cycles step 2-4 
5 4 °C ∞  
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General amplification protocol 
For all amplifications from plasmid DNA, Pfu polymerase was used with the standard 
PCR thermal profile. 
 
Genomic DNA amplification protocol: 
Amplifications from genomic DNA carried out for the promoter fragments were 
performed using Taq polymerase with 1/3 Pfu polymerase for proofreading activity, 
2.5 mM DMSO, 1.5-2 mM MgCl2 and the standard PCR thermal profile with 60 °C 
annealing temperature. Primers used for the amplification are listed in table 3.11. 
 
4.2.3 Real-time PCR 
For quantitative RT-PCR, the Maxima SYBR Green qPCR Master Mix/ROX 
(Fermentas) was used according to the following protocol: 
 
Table 4.2: Real-time PCR protocol 
Reaction component Volume 
  
Master Mix 3.125 µl 
cDNA 1.25 µl 
primer fw (10 pmol/ml) 0.1875 µl 
primer rev (10 pmol/ml) 0.1875 µl 
DEPC-H2O 1.5 µl 
Σ 6.25 µl 
 
Table 4.3: Real-time PCR thermal profile 
Step Temperature Time Cycle 
    
1 95 °C 10 min  
2 95 °C 15 sec  
3 59 °C 60 sec  
4 72 °C 40 sec 40 cycles step 2-4 
 
Experiments were performed in triplicates on an ABI Prism 9700HT system (PE 
Applied Biosystems, Foster City, CA, USA) and analysis was carried out according to 
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the ΔΔCt method. Expression of the housekeeping gene Synaptophysin was used to 
normalize expression. Primers used for real time PCR are listed in table 3.15. 
 
4.2.4 Vector construction 
For all cloning strategies, DNA was amplified by PCR and separated on an agarose 
gel to verify the correct size of the PCR product. Subsequently, the band of interest 
was cut out and purified (Zymoclean Gel DNA recovery kit). The PCR fragment and 
vector were cut with the respective restriction enzymes and purified (Zymoclean DNA 
clean and concentrator kit). The ligation reaction was carried out at 37 °C for 1 h. All 
generated constructs are listed in table 3.16. 
 
4.2.5 Site directed mutagenesis 
Primers (Table 3.14) were designed following the instructions of the QuickChange 
Primer Design Program (https://www.genomics.agilent.com/). Mutations were 
introduced with QuickChange II XL Site-Directed Mutagenesis Kit using the standard 
conditions as recommended by the manufacturer with the following variation: 10 ng 
Plasmid DNA and additional 2 µl Quick Solution were added to the PCR reaction and 
2 min/kb DNA was chosen as elongation time with a final elongation of 7 min. 
 
4.2.6 Sequencing 
The PCR reaction for sequencing of plasmid DNA was prepared using the BigDye 
Terminator v3.1 cycle sequencing kit with template specific primers (Table 3.13). The 
sequencing PCR reactions were purified through a gel filtration spin column (DyEx 
2.0 spin kit) or with the DNA clean and concentrator kit and run on a capillary 
sequencer. Subsequent analysis of the results was performed with the help of the 
Lasergene 8 software SeqMan. 
 
4.3 Biochemical methods 
4.3.1 Polyclonal peptide antibody generation 
An epitope-specific antibody was raised in rabbits against the following peptide: 
CKEVEENEKPAPKAIEPAIK (mSyt10). The localization of the peptide is shown in 
figure 5.15. Using the immunizing peptide, the antibody was affinity purified 
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according to standard procedures. Generation and purification of the antibody was 
performed by Pineda antibody service (http://www.pineda-abservice.de). 
 
4.3.2 Monoclonal peptide antibody generation 
Two antibodies were generated in mice against the following peptide: 
DSQGSAbuSSPRPPS. Figure 5.15 shows the localization of the peptide in the C-
terminus of Syt10. A cysteine was added to the N-terminus for coupling. Generation 
and purification of the antibody was carried out by the service platform of the 
Helmholtz Zentrum Munich (Dr. Kremmer, Institute of Molecular Immunology, 
Helmholtz Zentrum, Munich). 
 
4.3.3 Western blotting 
Preparation of protein extracts 
Tissue and cells were lysed under denaturing conditions with 1x PBS containing 1 % 
SDS and 10 mM EDTA pH 8.0 followed by sonification. HEK293T cells used for lysis 
under native conditions were prepared in the respective lysis buffer containing 1-2 % 
detergent and Complete Protease Inhibitor Cocktail. The lysis reaction was incubated 
on a rotating wheel at 4 °C for 1 h. Cell debris was separated from the lysed 
supernatant by 10 min centrifugation at 14,000 rpm and 4 °C. 
 
Electrophoresis and blotting 
Samples were loaded with 6x loading buffer (378 mM Tris/HCl (pH 6.8), 30 % 
Glycerol, 12 % SDS, 0.06 % Bromphenol blue) containing 8 % ß-Mercaptoethanol 
and were heated at 95 °C for 5 min. 50-100 µg protein was loaded on 12 % SDS-
polyacrylamide gels and transferred to a Whatman® Protran® nitrocellulose 
membrane. For immunolabeling, membranes were blocked 1 h with 2 % fish gelatin 
in 1x PBS at room temperature. Next, membranes were incubated with the 
respective primary antibody at 4 °C overnight in PBS with 0.1 % Tween. After three 
washing steps with 1x PBS, the secondary antibody was used on the subsequent 
day in PBS with 0.1 % Tween and 0.01 % SDS for 1 h at room temperature. The 
secondary antibodies were IR-labeled (Licor) and were visualized with an infrared 
Methods 
 42 
imaging System (Odyssey, Licor). Quantification of Western Blots was carried out 
using the software AIDA. 
 
4.4 Cell culture 
4.4.1 HEK293T cell culture 
HEK293T cells were maintained in Dulbecco’s Modified Eagle‘s Medium with sodium 
pyruvate (DMEM) supplemented with 10 % (v/v) heat inactivated fetal calf serum 
(FCS) (Hyclone), 100 units/ml penicillin/streptomycin (pen/strep) and 2 mM glutamine 
at 37 °C and 5 % CO2. Cells were passaged every 2-3 days in a 1:10 dilution. 
 
4.4.2 Transfection of HEK293T cells 
HEK293T cells were transfected with lipofectamine to obtain protein lysates of 
overexpressed Syts for antibody characterization using immunoblots. 
For Syt10 antibody characterization in immunocytochemistry, HEK293T cells were 
transfected based on the DNA/Ca2+-phosphate precipitation method in 48-wells. The 
same method on a larger scale (10 cm plates) was used to overexpress Syt10 and 
Syt6 in HEK293T cells to study Syt10 binding partners. 
Therefore, HEK293T cells were transfected at approximately 70 % confluency. 
Before transfection, the medium was exchanged by Iscove's Modified Dulbecco's 
Medium (IMDM) containing 5 % FCS. DNA and CaCl2 were mixed and 2x HEBS was 
added dropwise while using a vortex mixer and the precipitate was given directly to 
the cells. The cells with the mixture were incubated at 5 % CO2 and 37 °C overnight. 
On the following morning, cells were washed once with 1x PBS to remove the 
precipitate and then kept in DMEM supplemented with 10 % FCS and 
penicillin/streptomycin (pen/strep). 36-48 h after transfection, cells were harvested or 
fixed. 
 
Buffer (2x HEBS) 
50 mM HEPES 
280 mM NaCl 
1.5 mM Na2HPO4 
pH 7.05 – pH 7.10 
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Table 4.4: Components of the HEK293T transfection protocol 
24-well plate 10 cm plate 
DNA 500 ng (≈0.5 µl) DNA 6-8 µg (≈5-8 µl) 
250 mM CaCl2 30 µl 2.5 M CaCl2 145.2 µl 
- - H2O 1,056 µl 
2x HEBS 30 µl 2x HEBS 1,320 µl 
 
4.4.3 NG108-15 cell culture 
NG108-15 cells were maintained in DMEM without sodium pyruvate supplemented 
with 1.5 g/L sodium bicarbonate, 10 % (v/v) FCS, 100 units/ml pen/strep, 2 mM 
glutamine and 1x HAT (sodium hypoxanthine, aminopterin, and thymidine; Life 
technologies, Karlsruhe, Germany) at 37 °C and 5 % CO2. Cells were passaged 
every 2-3 days in a 1:3.5 dilution. 
 
4.4.4 Transfection of NG108-15 cells 
Transfection of NG108-15 cells was performed in 48-well cell culture plates in 
triplicates using lipofectamine (Life technologies, Karlsruhe, Germany) according to 
the manufacturer’s protocol. Cells were transfected at approximately 70 % 
confluency. During transfection, DMEM was replaced by reduced serum medium 
(OPTI-MEM) containing the transfection solution and cells were kept at 37 °C and 
5 % CO2. The transfection mixture contained 50 ng of the pGL-promoter construct 
expressing firefly luciferase, 12 ng pRL-TK with the Renilla gene (Promega), the 
indicated amount of overexpression plasmid for the respective transcription factor, 
and 0.5 µl lipofectamine in 25 µl OPTI-MEM. The mixture was incubated at room 
temperature for 20 min and then added to the wells. The DNA/Lipofectamine mixture 
in OPTI-MEM was replaced by serum containing medium 12 h after transfection and 
the cells were collected 48 h following transfection. 
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4.4.5 Primary neuronal cell culture 
Solutions 
• Borate buffer containing 0.1 mg/ml Poly-D-Lysin 
• DNase I (0.001 g/ml) 
• BME: 
500 ml BME containing 
10 % FCS 
2 % B-27 
1 % glucose 45 % 
1.2 ml L-glutamine (200 mM) 
 
Cover slip and well treatment 
For optimal adhesion of primary neurons, the coverslips or wells were treated as 
follows. Coverslips were baked for approximately 12 h at 200 °C. 24-wells with or 
without and 6-wells without sterile coverslips were coated overnight with poly-D-
lysine (0.1 mg/ml in borate buffer) at 37 °C. Subsequently, wells were washed with 
sterile water and after an incubation for approximately 2 h at 37 °C, two additional 
washing steps were carried out. 
 
Preparation of primary neurons 
A pregnant rat or mouse was sacrificed, and the uterus containing the embryos (E16-
E19) was removed. The embryo heads were dissected in HBSS and placed in a Petri 
dish with ice-cold HBSS. Then, the hippocampus and cortex of every pup were 
isolated and collected separately in a 3.5 cm Petri dish. The cortices were cut into 
approximately 1 mm thick pieces and all collected tissue was transferred into a 15 ml 
falcon tube. The tissue was washed 3-5 times with HBSS and trypsin solution 
(0.025 g/ml trypsin) was added. The incubation was performed for 20 min at 37 °C 
followed by 3-5 washing steps with HBSS. Afterwards, the tissue was transferred into 
2 ml tubes and the remaining DNA was digested with DNase I (0.001 g/ml) in 
approximately 1 ml HBSS. Next, the tissue was dissociated using cannulas (three 
times 0.9 mm x 40 mm; three times 0.45 mm x 23 mm). The solution from rat tissue 
was given through a Nylon cell strainer (100 µm) and the mesh was rinsed with 4-
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10 ml Basal Medium Eagle (BME) supplemented with 1 % glucose, 10 % FCS, 2 % 
B-27, and 0.5 mM L-glutamine to collect all cells. Tissue from mice was resuspended 
by pipetting up and down repeatedly with a 1 ml pipette. After counting in a Neubauer 
chamber, the cells were plated on a 24-well cell culture plate at densities listed in 
table 4.5. One to 24 h after seeding, the medium was replaced by fresh BME. 
Neurons were cultured in a humidified incubator at 37 °C and 5 % CO2. Olfactory 
bulbs from newborn mouse pups (P0-3) or from embryos were isolated according to 
the same protocol with the following modifications. Dissociation was performed by 
papain digestion (10 U/ml, with 1 µM Ca2+ and 0.5 µM EDTA). Neurons that were 
analyzed regarding their survival following KA stimulation were supplemented with 
5 µM Arabinofuranosyl cytidine (Ara-C) from DIV3 to the time point of analysis to limit 
glial cell division. 
 
Table 4.5: Cell numbers plated 
Well Cell number 
24-well (low density) 40,000 
24-well (high density) 70,000 
6-well 300,000 
 
4.4.6 Transfection of neurons for promoter studies 
Rat hippocampal neurons were transfected in 24-well cell culture plates in triplicates 
at DIV5 (OB neurons at 7 DIV) using lipofectamine (Life technologies, Karlsruhe, 
Germany) according to the manufacturer’s protocol. During transfection, BME 
medium was replaced by OPTI-MEM containing the transfection solution and cells 
were kept at 37 °C and 5 % CO2. After 2 h, OPTI-MEM was substituted for the 
original BME-Medium. The transfection mixture contained 0.1 µg of the pGL-
promoter construct expressing firefly luciferase, 0.025 µg pRL-TK with the Renilla 
gene (Promega), the indicated amount of overexpression plasmid for the respective 
transcription factor, and 1 µl lipofectamine in 50 µl OPTI-MEM. The mixture was 
incubated at room temperature for 20 min and then added to the wells. 
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4.4.7 Transfection of neurons for localization studies 
For localization studies, transfection of mouse cortical and hippocampal neurons was 
carried out using a protocol based on DNA/Ca2+ -phosphate co-precipitation 
(Köhrmann et al., 1999). Neurons were transiently transfected on DIV5-7. The 
original medium of the neurons was exchanged for minimum essential medium 
(MEM) and was kept in the incubator for the transfection procedure. Per 24-well, 2 µg 
endotoxin-free plasmid DNA was used. A mixture of DNA, 60 µl CaCl2 and 60 µ l 2x 
BES buffered saline (2x BBS) was prepared for two wells. After using a vortex mixer 
for 20 s the precipitate was directly added to the wells and the plate was incubated at 
2.5 % CO2 at 37 °C for 30-40 min. Formation of the amount of precipitate was 
monitored under the microscope. Subsequently, neurons were washed twice with 1x 
HBS and twice with BME and then the original medium was added back to the cells. 
 
Buffers 
• 2x BBS 
280 mM NaCl 
1.5 mM Na2HPO4 
50 mM BES 
pH 7.1 
• HEPES buffered saline (1x HBS) 
135 mM NaCl 
4 mM KCl 
1 mM Na2HPO4 
2 mM CaCl2 
1 mM MgCl2 
10 mM glucose 
20 mM HEPES 
pH 7.35 
 
4.4.8 Stimulation of neurons 
For stimulation of primary neurons with potassium chloride (KCl) or kainic acid (KA), 
half of the original medium was removed and mixed with the respective concentration 
of the stimulant. Then, the other half of the medium was removed well by well and 
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the mixture containing the stimulant was added directly to the well, to ensure that the 
neurons were always covered by medium. After stimulation, the cells were washed 
2-3 times with 1x PBS and subsequently, the second half of the medium was added 
back to the neurons. The medium of the control cells was exchanged as often as the 
one of stimulated neurons followed by the same washing steps. All stimulations were 
carried out in 24-well cell culture plates in triplicates. 
 
4.5 rAAV virus production 
Transfection of HEK293T cells 
For high titer purified rAAV preparations (Serotype 1/2 or 8), HEK293T cells were 
plated on 10 x 15 cm culture dishes per rAAV construct and transfected at 
approximately 70 % confluency. Three hours before transfection, the medium was 
exchanged by IMDM containing 5 % FCS. The transfection procedure was carried 
out as described in chapter 4.4.2. Cells were harvested approximately 72 h following 
transfection. 
 
Table 4.6: Components of the rAAV transfection protocol (Mix for 5 x 15cm dishes) 
 
AAV-Serotype 1/2 AAV-Serotype 8 
62.5 µg rAAV construct of interest 25 µg rAAV construct of interest 
125 µg pFdelta6 50 µg pFdelta6 
31.25 µg pRV1 25 µg pNLrep 
31.25 µg pH21 - 
1650 µl 2.5 M CaCl2 1650 µl 2.5 M CaCl2 
10500 µl H2O 10500 µl H2O 
+ 12000 µl 2xHEBS + 12000 µl 2xHEBS 
 
Harvesting cell lysates 
Cells were scraped off in the culture medium and centrifuged 20 min at 2000 rpm and 
4 °C. The pellet was resuspended in 45 ml 150 mM NaCl, 20 mM Tris-HCl, pH 8.0 
and stored over night at -20 °C. On the following day, cell pellets were incubated with 
Benzonase endonuclease (50 U/ml) and sodium deoxycholate (0.5 %) for 1-2 h. After 
30 min, 1M NaCl was added only to cell lysates for serotype 8 purification and 
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incubated another 30 min at 56 °C. After centrifugation at 4500 rpm for 20 min at 
4 °C, the supernatant was stored at -20 °C over night. 
 
Purification of Serotype 1/2 
The cell lysate was thawed at room temperature and centrifuged at 4500 rpm for 
20 min at 10 °C. Meanwhile the HiTrap Heparin column for purification was calibrated 
as follows: 10 ml 150 mM NaCl, 20 mM Tris-HCl, pH 8.0 was run through the column 
by an automatic pump at 60 ml/h. Sample loading was carried out with an Omnifix 
LuerLock 50 ml syringe at a rate of 60 ml/h. Afterwards, the following washing and 
elution steps were performed. Only the first washing step was carried out using the 
pump, the other ones were performed manually. 
 
Washing 
• 20 ml 100 mM NaCl, 20 mM Tris-HCl. pH 8.0 
• 1 ml 200 mM NaCl, 20 mM Tris-HCl, pH8.0 
• 1 ml 300 mM NaCl, 20 mM Tris-HCl, pH8.0 
Elution 
(fractions were collected in a sterile 15 ml tube) 
• 1.5 ml 400 mM NaCl, 20 mM Tris-HCl, pH 8.0 
• 3 ml 450 mM NaCl, 20 mM Tris-HCl, pH 8.0 
• 1.5 ml 500 mM NaCl, 20 mM Tris-HCl, pH 8.0 
 
The virus was concentrated using an Amicon Ultra-4 100K column at 4 °C and a 
maximum speed of 3200 rpm. The sample was concentrated to a volume as small as 
possible. Then, the column was washed two times with 1x PBS and finally 
concentrated to approximately 500 µl. The purified virus was stored at 4 °C. 
Purification of the virus was examined by loading 15 and 7.5 µl of purified virus on a 
10 % SDS-PAGE and subsequent Coomassie staining. Highly purified virus should 
reveal only viral protein bands at 60, 70 and 80 kDa. 
Methods 
 49 
Purification of Serotype 8 
After thawing, centrifugation was carried out using an ultracentrifuge with a JA-20 
rotor (Beckman) at 7000 rpm for 30 min at 4 °C. Then, 2 cycles of freezing (with an 
isopropanol/dry ice bath) and thawing with the same centrifugation step in between 
as before. Discontinuous iodixanol step gradients were formed in quick-seal tubes 
(25 x 89 mm, Beckman) by underlaying and displacing the less dense cell lysate 
(15 ml) with iodixanol. The solution was prepared using a 60 % sterile solution of 
iodixanol OptiPrep (Nycomed) and 1x PBS supplied with 1 mM MgCl2 and 2.5 mM 
KCl (PBS-MK). The gradient consists of (from the bottom) 3 ml 54 %, 3 ml 40 %, 4 ml 
25 % and 7 ml 15 %; the 15 % density step also contained 1 M NaCl. On the top, 
7.5 ml of the virus was added, tubes were sealed and centrifuged in a JA-20 rotor at 
60.000 g for 90 min at 18 °C (without setting the brake). The 40 % phase was 
aspirated with a syringe and the virus was concentrated using an Amicon Ultra-15 
100K. For this, the sample was adjusted with PBS-MK to 15 ml and centrifuged at 
2000 g for 2 min at 4 °C. The refilling to 15 ml and centrifugation was repeated four 
times. Afterwards, the virus was concentrated to approximately 500 µl and stored at 
4 °C. Purification of the virus was examined by loading 15 and 7.5 µl of purified virus 
on a 10 % SDS-PAGE and subsequent Coomassie staining. Highly purified virus 
should reveal viral protein bands at 60, 70 and 80 kDa. 
 
4.6 P0-3 virus injection 
Newborn C57/Bl6 mice (P0) were anesthetized 45 s on ice and intracerebral injection 
of viral particles in the ventricles and in the OB was performed using a 10 µl Hamilton 
syringe at a rate of 451 nl/sec. The injection was performed on both hemispheres on 
three consecutive days (P0-3). Six to eight weeks after injection, mice were deeply 
anesthetized with Isofluran and subsequently sacrificed via perfusion with 4 % PFA. 
After this, the mice were decapitated and the brain was removed. Using a vibratome, 
20 µ m thick slices were prepared and viral injection was examined using an 
epifluorescence microscope. All experiments were performed in accordance with the 
guidelines of the University of Bonn Medical Center Animal Care Committee. 
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4.7 Promoter analysis methods 
4.7.1 Luciferase assay 
For luciferase measurements, cells were washed with 1x PBS and subsequently 
lysed with passive lysis buffer (PLB). Lysis of 24-well plates (primary neurons) was 
performed in 100 µl/well PLB and of 48-well plates (NG108-15 cells) in 50 µl/well 
PLB. During lysis, cells were incubated 20 min at room temperature on a shaking 
plate. Before lysis incubation, neurons were carefully scraped off the wells with a 
scraper. Meanwhile, luciferase assay reagent, which provides the substrate for the 
luciferase measurement and Stop and Glo, which quenches the luciferase 
luminescence and contains the Renilla substrate, were freshly prepared. The 
measurement was carried out with 50 µl of each substrate using a Glomax 
Luminometer (Promega). Duration of luciferase measurement was 10 s with a 2 s 
delay between luciferase and Renilla luminescence measurement. 
 
4.8 Immunochemical methods 
4.8.1 Immunocytochemistry 
Primary hippocampal and cortical neurons at DIV14-16 were fixed for 10 min with 
4 % paraformaldehyde (PFA), washed three times in 1x PBS and permeabilized with 
0.3 % TritonX-100 in 1x PBS for 10 min. Then, neurons were incubated over night 
with primary antibodies at 4 °C in blocking solution (1 % BSA, 10 % NGS, 0.1 % 
Triton X-100 in 1x PBS). On the following morning, cells were washed three times 
with 1x PBS and incubation with the secondary antibody was performed in blocking 
solution for 45 min at room temperature in the dark. Cover glasses were mounted in 
Mowiol. 
 
4.8.2 Immunohistochemistry 
Mouse brains were perfused with 4 % paraformaldehyde (PFA) and incubated on a 
shaker plate at 4 °C overnight in PFA. On the following day, the right hemisphere 
was embedded in freezing medium (Tissue-Tek). 50 µm thick cryosections were cut 
on a cryostat and every second of 10 sections were stained against BrdU. Sections 
sections were kept in sterile 1x PBS and incubated in 24-wells in 2 N HCl for 30 min 
at 35 °C in a waterbath. After four washing steps in TBS, sections were incubated 
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overnight at 4 °C with primary antibody (BrdU) in 1x TBS containing 0.6 % Triton X-
100 (1x TBST). On the following day, sections were washed four times with 1x TBS 
and the incubation with the anti-rat biotin antibody was performed in 1x TBST for 
three hours at 35 °C in the waterbath. Following four washing steps, the secondary 
antibody (Cy3-Streptavidin) was added to the wells in 1x TBST and was incubated 
3 h at 35 °C in the dark. After extensive washing with 1x TBS, sections were 
mounted in Vectashield hard set mounting medium. 
 
4.9 Pilocarpine injection 
Male C57/BL6 mice, ordered from Charles River, as well as male Syt10 wildtype 
(WT) and Syt10 knockout (KO) mice (all ≥ 60 d old; weight ≥ 20 g) were housed 
under a 12 light/dark cycle with food and water ad libitum. Administration of 
pilocarpine, a muscarinic agonist, was used to induce sustained seizures in these 
experimental animals. First, animals received a low dose of 1 mg/kg scopolamine 
methyl nitrate subcutaneously (s.c.). After 20 min, mice were injected with 335 mg/kg 
pilocarpine hydrochloride (s.c.) to induce SE. Series of continuous generalized tonic-
clonic seizures were defined as SE and represent the seizure description stage V. 
Treatment of sham-injected control animals was identical except for the injection of 
an isotonic NaCl solution instead of pilocarpine. To terminate seizures, 4 mg/kg (s.c.) 
diazepam was administered to the mice 40 min after onset of SE. After SE, animals 
were fed with soaked rodent food and with a 5 % glucose solution. For subsequent 
analysis, only those of the pilocarpine-injected animals were used that developed SE. 
All experiments were performed in accordance with the guidelines of the University of 
Bonn Medical Center Animal Care Committee. 
 
4.10 BrdU injection 
Syt10 WT and Syt10 KO control and SE-experienced mice received a single dose of 
300 mg/kg Bromodeoxyuridine (BrdU) intraperitoneally 2 d after SE. Two hours 
following BrdU-injection mice were deeply anesthetized with Isofluran and 
subsequently sacrificed via perfusion with 4 % PFA. 
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4.11 Imaging 
Labeled sections were imaged with an epifluorescence microscope (Zeiss Axiovert 
Observer 1A). For high magnification of cells, imaging was performed with a confocal 
microscope (Leica TCS, Zeiss LSM710 and Nikon Eclipse Ti). 
 
4.12 Statistical analysis 
Results were tested for statistical significance using Student’s t-test or One-Way 
Analysis of Variance followed by Tukey’s Posthoc Test. Values were considered 
significantly at p < 0.05. All results were plotted as mean ± SEM. 
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5 Results 
Syts comprise a large family of membrane trafficking proteins that are evolutionary 
conserved (Craxton, 2001, 2004). However, the function of many Syt family members 
remains enigmatic, especially in disease conditions. To gain first insights into the role 
of this gene family in epilepsy, Syts were screened for differential expression in the 
hippocampal formation following status epilepticus (SE) induced in rats (unpublished 
data by T. Mittelstaedt). One Syt isoform was less abundant (Syt3) in response to SE 
but two family members, namely Syt6 and Syt10 showed a rapid and transient up-
regulation of their mRNA in all hippocampal subregions (data not shown). The strong 
increase of Syt10 mRNA 6 h after SE (5-fold in the dentate gyrus and the CA3 
region, 4-fold in the CA1 region) returned near to basal levels 5 d following SE. This 
was an intriguing finding as Syt10 was only barely expressed in the native brain. 
However, as the function and localization of Syt10 in the hippocampus are unknown, 
its role in epileptogenesis remains enigmatic. 
 
5.1 Analysis of signaling pathways regulating Syt10 gene 
expression 
5.1.1 Identification of the Syt10 core promoter 
Syt10 mRNA levels are rapidly and transiently augmented in response to kainic acid-
induced SE in rat (Babity et al., 1997). Intriguingly, this transcriptional up-regulation is 
limited to the hippocampus and the piriform cortex. The restricted expression of 
Syt10 to the olfactory bulb (OB) under native conditions indicates the presence of an 
intricate control mechanism that hasn’t been resolved yet. In order to delineate the 
transcriptional mechanisms mediating the transcriptional response of the Syt10 gene 
to SE the Syt10 promoter region was bioinformatically analyzed. For this purpose, 
the sequence 355 bp upstream and 320 bp downstream of the translation start site of 
the Syt10 rat gene was examined for characteristics typically associated with core 
promoter regions: a) the presence of CpG-islands, b) a high level of conservation 
between species, and c) transcription start sites (TSS) (Figure 4.1 A). In the Syt10 
gene a CpG island of 423 bp was found around the first exon, with 286 bp upstream 
and 137 bp downstream of the start ATG. Six transcription start sites were detected 
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at 63 bp, 100 bp, 125 bp, 138 bp, 198 bp and 232 bp upstream of the start ATG 
(Figure 5.1 A). 
 
Figure 5.1 Identification of the Syt10 core promoter. (A) Graphic representation of the rat 
Syt10 gene (Chromosome 7: 355 bp up- and 320 bp downstream of the start ATG). The identified 
CpG island (423 bp around the start ATG), the level of conservation and six transcription start sites 
(TSS) are indicated. The lower grey bars represent pairwise alignments between the indicated 
species. (B) Basal luciferase activity of the predicted Syt10 core promoter in NG108-15 cells, rat 
hippocampal neurons, mouse olfactory bulb neurons and rat cortical neurons. A construct containing 
Renilla luciferase under control of a standard promoter was used for standardization and the results 
are presented as Firefly/Renilla relative luciferase units (RLUs). The core promoter fragment -306 was 
active in all four cell types compared to the pGL3 basic vector. All values were normalized to the pGL3 
basic vector and statistical analysis was carried out using Student's t-test (*** p ≤ 0.001). Results are 
presented as mean +/- SEM. 
 
To examine whether the bioinformatically identified core promoter indeed showed 
promoter activity the corresponding genomic fragment (-1 to -306, relative to the start 
ATG) was cloned into a luciferase reporter vector (pGL3 basic) and the luciferase 
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activity was measured in NG108-15 cells, primary rat hippocampal (RH) and cortical 
(RC) neurons and in mouse olfactory bulb (MOB) neurons. The presence of the core 
promoter fragment -306 increased the luciferase activity relative to the promoterless 
control pGL3 basic 2-fold in NG108-15 cells, 4-fold in rat hippocampal neurons,  
3-fold in mouse olfactory bulb neurons and 7-fold in rat cortical neurons (each 
p ≤ 0.001) (Figure 5.1 B). These results indicate that the bioinformatically identified 
core promoter contains promoter characteristics leading to functional promoter 
activity. 
 
5.1.2 Bioinformatic analysis of potential regulatory elements 
Activity of a promoter is often regulated by enhancers and repressors. These 
regulatory elements are frequently located distally from a gene as shown for the 
Arc/Arg3.1 promoter, which is regulated by the synaptic activity-responsive element 
(SARE) (Kawashima et al., 2009). To search for putative regulatory regions the 
analysis was extended to 40 kb upstream and 70 kb downstream of the start ATG. 
Comparative sequence analysis between the rat reference sequence and human, 
mouse and dog orthologs revealed five regions conserved among all four species 
and one region that was conserved between rat, mouse and human orthologs. The 
promoter region analyzed in the subsequent experiments is depicted in figure 5.2 as 
black box and regulatory regions as grey boxes. 
 
 
Figure 5.2 Bioinformatic analysis of the Syt10 gene. (A) Graphic representation of the rat 
Syt10 gene (Chromosome 7). Using UCSC, 50 kb up- und 70 kb downstream of the start ATG were 
analyzed. The conservation track was based on PhastCons (black bars). The lower grey bars 
represent pairwise alignments between the indicated species. Regions with high homology were 
identified and according to their position, they were named regulatory region-5‘ (RR-5‘), regulatory 
region-Intron (RR-IN), regulatory region-3‘ (RR-3‘) and regulatory region-1, -2 and -3 (RR-1, -2, -3). 
Grey boxes and black box with positions (-306, -1036, -4713) indicate the fragments that were 
subcloned in the pGL3 basic vector carrying a luciferase reporter gene. 
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5.1.3 Functional characterization of activating and repressing regions within 
the Syt10 promoter 
To determine whether the promoter fragments of varying length and the regulatory 
regions contain activating or/and repressing elements, the corresponding sequences 
were cloned into a luciferase reporter vector and their transcriptional activity was 
tested in NG108-15 cells and in primary hippocampal, olfactory bulb and cortical 
neurons. Compared to the core promoter an increase in activity was only observed 
for fragment -1036 in hippocampal neurons indicating the presence of a cell-type 
specific enhancer or the absence of a repressor (Figure 5.3, right diagram). 
Furthermore, compared to the other cell types promoter activity in NG108-15 cells 
was lower for most fragments, but roughly the same for the other cell types (Figure 
5.3, left diagram). As plasmid -306/RR-IN exhibited a promoter activity even lower 
than the one of the promoterless control plasmid pGL3 basic, it was not further 
examined. 
 
 
Figure 5.3 Functional analysis of regulatory regions of the Syt10 gene. Basal luciferase 
activity of different Syt10 promoter constructs in NG108-15 cells (white bars), rat cortical neurons (RC; 
dark grey bars), rat hippocampal neurons (RH; light grey bars) and mouse olfactory bulb neurons 
(MOB; black bars). RH and RC neurons were transfected on DIV5, MOB neurons on DIV7 and 
NG108-15 cells 24 h after seeding. 48 h later, cells were lysed for luciferase measurements. 
Firefly/Renilla relative units are normalized to pGL3 basic (left diagram) and to the Syt10 core 
promoter fragment -306 (right diagram). Analysis of basal luciferase activity revealed a specifically 
higher activity of Syt10 promoter fragment -1036. This result indicates the presence of a potential 
hippocampus specific activating region or a repressing region that is not functional in the 
hippocampus. Results are presented as mean +/- SEM and statistical analysis was performed using a 
One-way ANOVA followed by Tukey posthoc test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; ### p ≤ 0.001). 
 
The region identified as the core promoter (chapter 5.1.1), -306, increased the 
promoter activity relative to the promoterless control pGL3 basic in all tested cell 
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types (Figure 5.1). Furthermore, even though the fragment -4713 comprises a longer 
region upstream of the first exon, its promoter activity was not higher compared to 
the core promoter (Figure 5.4, right diagram). Intriguingly, the fragment -4713 
contains a region that is highly conserved among species (RR-1; genomic position  
-4344 to -3675 relative to the start ATG, Figure 5.2). This region can be further sub-
divided into two smaller regions, one that has a higher degree of conservation (RR-2; 
-4054 to -3675 upstream of the start ATG) than the other one (RR-3; -4344 to -4054 
relative to the start ATG) (Figure 5.2). To test these fragments for their activating or 
repressing properties, their luciferase activity was analyzed in the four cell types used 
before and the results were normalized to pGL3 basic (Figure 5.4, left diagram) or to 
the core promoter, -306 (Figure 5.4, right diagram). The fragment -306/RR-1 resulted 
in a higher promoter activity compared to the core promoter and compared to -4713. 
Furthermore, in hippocampal neurons luciferase assays revealed the presence of an 
activating element in the fragment -306/RR-2 whereas the presence of the fragment  
-306/RR-3 decreased the promoter activity to levels of -306/RR-1 (Figure 5.4, right 
diagram). These results indicate that the region RR-2 is a hippocampus specific 
regulatory element, which is, similar to -1036, suppressed in the genomic context. 
 
 
Figure 5.4 Active regulatory regions within the Syt10 promoter. Basal luciferase activity of 
different Syt10 promoter constructs in NG108-15 cells (white bars), rat cortical neurons (RC; dark grey 
bars), rat hippocampal neurons (RH; light grey bars) and mouse olfactory bulb neurons (MOB; black 
bars). RH and RC neurons were transfected on DIV5, MOB neurons on DIV7 and NG108-15 cells 
24 h after seeding. 48 h later, cells were lysed for luciferase measurements. Firefly/Renilla relative 
units are normalized to pGL3 basic (left diagram) and to the Syt10 core promoter fragment -306 (right 
diagram). Combined fragments consisting of -306 and the complete first exon (without ATG) or RR1, 2 
and -3 show stronger luciferase activity in NG108-15 cells and in rat hippocampal neurons. Results 
are presented as mean +/- SEM and statistical analysis was performed using a One-way ANOVA 
followed by Tukey posthoc test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; ### p ≤ 0.001). 
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Due to the presence of a CpG island and putative binding sites for transcription 
factors, the first exon might be an important element of the Syt10 promoter. To test 
this hypothesis, a luciferase plasmid was generated containing the genomic 
sequence -306 to +149 that however did not contain the start ATG (-306/149). With 
the exception of cortical neurons fragment -306/149 showed a stronger luciferase 
activity compared to the core promoter in all cell types indicating that this region 
contains positive regulatory elements. The higher activity of the complete exon I 
compared to the core promoter indicates that the first exon is important for the basal 
activity of the Syt10 promoter. 
 
5.1.4 The Syt10 promoter harbors functional binding sites for activity-
regulated transcription factors 
To assess which transcription factors might contribute to the up-regulation of Syt10 
following SE, first a bioinformatic analysis using different algorithms (Genomatix, 
rVISTA) was performed. The focus was on transcription factors, which are known to 
be differentially expressed after synaptic activity, namely cAMP responsive element 
binding protein (CREB), activator protein 1 (AP1), myocyte enhancer factor 2A 
(MEF2A), neuronal PAS domain protein 4 (NPAS4) and upstream stimulatory factor 
1 and 2 (USF1 and 2). 
DNA-binding sites were predicted in the Syt10 promoter for all of these factors. Most 
of the binding sites were observed within the region -4713 bp upstream of the ATG 
(Figure 5.5 A). However, none of these factors were overrepresented in the Syt10 
promoter sequence as assessed by the RegionMiner (Genomatix) algorithm for the 
search of overrepresented transcription factors binding sites in the Syt10 promoter 
(Appendix, supplementary table 1). To determine the functionality of the putative 
transcription factor binding sites on the Syt10 promoter fragments, NG108-15 cells, 
which are often used to assess the activating potential of transcription factors, were 
used. These cells were co-transfected with expression plasmids coding for the 
predicted transcription factors (MEF2A, MEF2C, NPAS4, cJun, USF1 and USF2) and 
with the promoter fragments -306, -1036, -4713, -306/RR3’ and -306/RR5’. Analyzing 
luciferase activity in NG108-15 cells clearly revealed no alteration of the promoter 
fragments with the transcription factors MEF2A and MEF2C compared to mock 
transfected cells (Figure 5.5 B). 
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Figure 5.5 The Syt10 gene harbors functional binding sites for activity-regulated 
transcription factors. (A) Graphic representation of the rat Syt10 gene with predicted transcription 
factor binding sites of factors known to be involved in differential expression after synaptic activity 
(CREB1, NPAS4, AP1, MEF2, USF1/2). (B) Luciferase activity in NG108-15 cells of the promoter 
fragments with overexpressed transcription factors (MEF2A/C, NPAS4, cJun, USF1/2). A construct 
containing Renilla luciferase under control of a standard promoter was used for standardization and 
the results are presented as Firefly/Renilla relative luciferase units (RLUs). All values were normalized 
to the respective control condition (not shown) and statistical analysis was performed using One-way 
ANOVA followed by Tukey posthoc test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). Results are presented 
as mean +/- SEM. 
 
In NPAS4-transfected samples, measurement of luciferase activity showed a clear 
activation of the promoter fragment -1036 (3.6-fold, p ≤ 0.001) and -4713 (3.4-fold, 
p ≤ 0.001) (Figure 5.5 B). The transcription factor cJun induced the promoter 
fragments -1036 (1.9-fold, p ≤ 0.05), -4713 (3.3-fold, p ≤ 0.001) and -306/RR5’ 
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(3.5-fold, p ≤ 0.001) (Figure 5.5 B). The other AP1 transcription factors tested, JunB 
and JunD, also strongly activated the Syt10 promoter in NG108-15 cells (Data not 
shown). USF1 and USF2 transfected cells showed a similar activation of the 
promoter fragments with the difference that USF1 induction of the promoter was 
stronger compared to USF2. Whereas USF1 increased the promoter fragment -306 
(3.4-fold, p ≤ 0.05) (and not USF2) -306/RR5’ was only induced by USF2 (2.5-fold, 
p ≤ 0.05) (and not by USF1). Taken together, these results indicate that not all of the 
predicted transcription factor binding sites lead to a functional activation of the Syt10 
promoter in NG108-15 cells (MEF2A, MEF2C), whereas some factors strongly alter 
the promoter activity (NPAS4, cJun, USF1, USF2). 
 
5.1.5 Activity-regulated transcription factors induce endogenous Syt10 gene 
expression in primary neurons 
Using quantitative real-time RT-PCR, the ability of the transcription factors that 
increase the Syt10 promoter activity in NG108-15 cells was examined to effect 
endogenous Syt10 expression in primary neurons. Rat hippocampal neurons were 
therefore transfected on DIV5 with NPAS4, USF2 and cFos and the cells were lysed 
for extraction of mRNA at DIV6-7 (indicated as 24 or 48 h after transfection). Even 
though only less than 30 % of neurons were transfected, overexpression of NPAS4, 
USF2 and cFos resulted in a robust increase of endogenous Syt10 expression in 
hippocampal neurons (each p ≤ 0.05) (Figure 5.6). Neurons transfected with cJun did 
not show an augmented Syt10 mRNA expression (0.8-fold, p > 0.05, Figure 5.6), 
which indicates that either the transfection efficiency was to low or that cJun does not 
affect the Syt10 promoter in neurons. 
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Figure 5.6 Activity-regulated transcription factors activate endogenous Syt10 gene 
expression. Quantitative RT-PCR on mRNA from rat hippocampal neurons transfected with an 
empty vector or with the indicated transcription factors on DIV5. Cells were lysed 24 or 48 h after 
transfection and Synaptophysin was used as housekeeping gene. Overexpression of NAPS4, USF2 
and cFos but not of cJun led to augmented Syt10 mRNA expression levels. All values were 
normalized to the respective control condition (black line) and statistical analysis was performed using 
Student's t-test (* p ≤ 0.05). Results are presented as mean +/- SEM. 
 
5.1.6 NPAS4 activates the Syt10 promoter 
NPAS4 is an interesting candidate transcription factor to be involved in the regulation 
of Syt10 gene expression as it is up-regulated in the hippocampus in response to 
seizure activity (Flood et al., 2004). Since NPAS4 markedly augmented the promoter 
activity of Syt10 in NG108-15 cells and was sufficient to robustly increase 
endogenous Syt10 expression, it was next examined if NPAS4 also activates the 
Syt10 promoter in neurons. Therefore, primary hippocampal neurons were co-
transfected at DIV5 with the Syt10 promoter fragment -4713 and with or without 
NPAS4 and the cells were lysed 48 h later for analyzing luciferase activity. NPAS4 
showed a markedly increase of luciferase activity of the promoter fragment -4713 
(2.5-fold, p ≤ 0.001) (Figure 5.7). 
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Figure 5.7 Transcription factor NPAS4 activates the Syt10 promoter. The transcription 
factor NPAS4 increased the luciferase activity of the Syt10 promoter fragment -4713. RH neurons 
were transfected on DIV5 with either an empty vector or 25 ng NPAS4 and 48 h later, cells were lysed 
for luciferase measurements. Firefly relative units are normalized to the basal values (mock 
transfected cells). Statistical analysis was performed using the Student’s t-Test (*** p ≤ 0.001). Results 
are presented as mean +/- SEM. 
 
5.1.7 Analysis of NPAS4 binding sites mediating activation of the Syt10 
promoter 
NPAS4 strongly activated the Syt10 promoter in NG108-15 cells and in rat 
hippocampal neurons (Figure 5.5 and 5.7). To delineate the exact NPAS4 binding 
sites in the Syt10 promoter that increase the activity of the promoter, deletion 
constructs covering the distinct predicted binding sites were designed (Figure 5.8 A). 
Fragments of different lengths were cloned into the pGL3 basic vector and were 
transfected on DIV5 into rat hippocampal neurons. To assess all predicted binding 
sites for NPAS4, the deletion constructs were compared to the promoter fragments  
-306, -1036 and -4713. Lysis of transfected neurons was carried out 48 h later for 
subsequent luciferase assays. Figure 5.8 B depicts the luciferase activity of these 
fragments in rat hippocampal neurons that were co-transfected with an empty vector 
(basal values) or 50 ng NPAS4 and were normalized to basal values (not shown). 
Due to the finding that the Syt10 promoter was saturated with NPAS4 at a 
concentration of 50 ng (Appendix, supplementary Figure 7), this concentration was 
used in further experiments. NPAS4 increased the promoter activity of the deletion 
constructs I, II and fragment -306, which cover the first two predicted binding sites 
(Figure 5.8 B). 
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Figure 5.8 Analysis of the key NPAS4 binding sites mediating the activation of the 
Syt10 promoter via deletion constructs. (A) Schematic drawing of deletion constructs covering 
the distinct bioinformatically predicted NPAS4 binding sites that are indicated by the black lines. 
NPAS4 binding sites are numbered from 1-7 starting with the one closest to the start ATG. (B) Rat 
hippocampal neurons were transfected on DIV5 with either an empty vector or 50 ng NPAS4 and 48 h 
later, cells were lysed for luciferase assays. The Luciferase/Renilla values were normalized to the 
respective basal values (not shown) and plotted into the diagram. The deletion constructs covering 
NPAS4 binding sites 1, 2 and 5-7 showed a strong increase in the luciferase activity compared to 
basal values. Statistical analysis was performed using a One-way ANOVA followed by Tukey posthoc 
test (** p ≤ 0.01, *** p ≤ 0.001). Results are presented as mean +/- SEM. 
 
Deletion constructs III, IV and fragment -1036 did not show induced promoter activity 
indicating that there might be a repressing region that overrules the activity of the first 
two NPAS4 binding sites in the Syt10 promoter. This repressing activity was not 
found in the luciferase activity of deletion constructs V and fragment -4713, which 
were activated by NPAS4 (Figure 5.8 B). This indicates that NPAS4 binding sites 5-7 
might reverse the repressing activity in the middle part (genomic position -306 to  
-1036 relative to the start ATG) of the Syt10 promoter. 
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5.1.8 NPAS4 and Per1 double the activity of the NPAS4 induced Syt10 
promoter 
NPAS4 forms heterodimers with other basic helix-loop-helix Per-Arnt-Sim (bHLH-
PAS) transcription factors, for example members of the Arnt family (Ooe et al., 
2009b; Pruunsild et al., 2011). Arnt2 has recently been found to activate the BDNF 
promoter as an Arnt2:NPAS4 heterodimer (Pruunsild et al., 2011). Therefore, it was 
next tested, if heterodimer formation would affect the stimulatory ability of NPAS4. 
The promoter fragments -306, -1036 and -4713 were co-transfected into primary 
hippocampal neurons with either 25 ng of an empty vector, 25 ng NPAS4, 25 ng 
Arnt2 or a combination of both, NPAS4 and Arnt2 (25 ng each). The amount of 
transfected DNA was adjusted in each sample with the empty vector to a total 
amount of 50 ng. Transfection of NPAS4 increased the activity of the core promoter 
(3-fold, p ≤ 0.001) and fragment -4713 (4-fold, p ≤ 0.001) as seen above in figure 5.8. 
Overexpression of Arnt2 alone did not affect the Syt10 promoter activity. Co-
transfection of NPAS4 and Arnt2 increased the luciferase activity of -4713 2-fold 
compared to the basal values (p ≤ 0.05). These results indicate that instead of 
exhibiting a synergistic function together with NPAS4 Arnt2 presumably represses 
NPAS4 (Figure 5.9). 
 
Figure 5.9 Arnt2 represses the stimulatory ability of NPAS4. The promoter fragments -306, 
-1036 and -4713 were transfected into rat primary hippocampal neurons together with an empty 
vector, 25 ng NPAS4, 25 ng Arnt2 or both transcription factors together (25 ng each). Neurons were 
lysed for luciferase assays 48 h later and the Luciferase/Renilla values were normalized to the basal 
values. When transfected alone, NPAS4 increased the luciferase activity of fragments -306 and -4713. 
Arnt2 alone did not affect the Syt10 promoter activity. When transfected with NPAS4 Arnt2 seemed to 
repress the activity of NPAS4. Statistical analysis was performed using a One-way ANOVA followed 
by Tukey posthoc test (* p ≤ 0.05, *** p ≤ 0.001). Results are presented as mean +/- SEM. 
 
Nevertheless, bHLH-PAS transcription factors can form heterodimers via their bHLH-
domain and homodimers through PAS-PAS interactions (Hirose et al., 1996; Huang 
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et al., 1995; Ooe et al., 2004; Pongratz et al., 1998). Recently, Husse et al. observed 
Syt10 expression in the SCN (Husse et al., 2011), the brain region, in which clock 
genes are expressed in an oscillatory manner. One of the clock genes is a bHLH-
PAS transcription factor named Period1 (Per1). Moreover, Per1 expression was 
found to be more abundant in the hippocampus in response to kainic acid-induced 
SE and to electroconvulsive seizures (Eun et al., 2011). 
Luciferase measurement of transfected rat hippocampal neurons revealed that this 
transcription factor induced the activity of the longest promoter fragment, -4713 
(Appendix, supplementary Figure 7). To elucidate whether Per1 could heterodimerize 
with NPAS4 and thereby could further increase the Syt10 promoter activity the 
longest promoter fragment -4713 was co-transfected into rat hippocampal neurons 
on DIV5 with either an empty vector (100 ng), NPAS4 (50 ng), Per1 (50 ng) or a 
combination of both, NPAS4 and Per1 (50 ng each). The amount of transfected DNA 
in each sample was adjusted with the empty vector to a total amount of 100 ng. 
Transfection of both, NPAS4 and Per1 alone, led to a 2.5-fold increased luciferase 
activity (p ≤ 0.01) compared to basal values. Co-transfection of NPAS4 and Per1 
nearly doubled the luciferase activity to 5-fold compared to basal values (p ≤ 0.001) 
(Figure 5.10). Hence, NPAS4 and Per1 might act as heterodimers on the Syt10 
promoter. 
 
Figure 5.10 NPAS4 and Per1 increase Syt10 promoter activity as putative 
heterodimers. Rat hippocampal neurons were transfected with the longest promoter fragment, 
-4713, and an empty vector, 50 ng NPAS4, 50 ng Per1 or both transcription factors together (50 ng 
each). Neurons were lysed for luciferase measurements 48 h later and the Luciferase/Renilla values 
were normalized to the basal values. When transfected alone, both NPAS4 and Per1, lead to a 2.5-
fold increase of the luciferase activity. Transfection of both factors together revealed a doubled 
increase (nearly 5-fold) compared to the factors alone. Statistical analysis was performed using a 
One-way ANOVA followed by Tukey posthoc test (** p ≤ 0.01, *** p ≤ 0.001). Results are presented as 
mean +/- SEM. 
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5.2 Stimulation protocols to mimic epilepsy-mediated up-
regulation of Syt10 
5.2.1 Membrane depolarization induces Syt10 expression 
One hallmark of epileptogenesis is the occurrence of a hyperexcitable network 
(reviewed by Pitkänen & Lukasiuk, 2011). To mimic this strong synaptic activity in 
vitro, rat primary hippocampal neurons were depolarized on DIV7 for 8 h with 25 mM 
KCl and first Syt10 gene expression was analyzed using quantitative RT-PCR. 
Relative Syt10 mRNA expression levels were 2.1-fold increased after stimulation of 
rat hippocampal neurons compared to the control condition (p ≤ 0.001) (Figure 5.11 
A). Rat cortical neurons were stimulated following the same protocol. Here, Syt10 
mRNA expression was not elevated compared to basal values (Figure 5.11 A).  
 
 
Figure 5.11 Membrane depolarization with potassium chloride induces Syt10 
expression. (A) Relative mRNA expression levels of rat hippocampal (RH) and rat cortical (RC) 
neurons on DIV7. Neurons were stimulated with 25 mM KCl for 8 h and subsequently lysed for 
quantitative RT-PCR. Up-regulation of Syt10 gene expression was restricted to RH neurons (2-fold 
increase) and was not observed in RC neurons. For quantitative RT-PCR experiments expression of 
the house keeping gene Synaptophysin was used to normalize gene expression. (B) Representative 
immunoblot of RH neurons that were stimulated at DIV14 with 55 mM KCl for 15 min. Cells were 
harvested 24 h later for Western Blot analysis. Here, beta-actin was used to normalize protein 
expression. (C) Western Blot analysis of stimulated RH neurons as shown in (B). Quantification of 
Western Blots was carried out using the software AIDA. Strong depolarization revealed a 1.7-fold 
increase in Syt10 protein expression. All values were normalized to the respective control condition 
and statistical analysis was performed using Student's t-test (** p ≤ 0.01, *** p ≤ 0.001). 
 
To evaluate whether the increase obtained on the mRNA expression level translates 
into higher levels of Syt10 protein following membrane depolarization, rat 
hippocampal neurons were stimulated on DIV13 for 15 min with 55 mM KCl and were 
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harvested 24 h after washing for Western blot analysis. The immunoblots were 
probed with a Syt10 specific antibody (described in chapter 5.3.1) and an antibody 
for the internal standard ß-actin (Figure 5.11 B). Quantification of the immunoblots 
revealed that Syt10 protein expression was increased significantly after treatment of 
cultured hippocampal neurons with 55 mM KCl (1.7-fold up-regulation, p ≤ 0.01; 
Figure 5.11 B and C). Taken together, both Syt10 mRNA and protein levels of rat 
hippocampal neurons were elevated in response to membrane depolarization by KCl. 
 
5.2.2 Analysis of Syt10 promoter activity following membrane depolarization 
Next, to examine if the transcriptional regulatory elements mediating the response to 
membrane depolarization are located in the above characterized Syt10 promoter, 
transfection of primary neurons was carried out on DIV5 with the promoter fragments 
-306, -1036 and -4713. Following established protocols (Flavell and Greenberg, 
2008; Kim et al., 2010; Eun et al., 2011; Pruunsild et al., 2011; Ramamoorthi et al., 
2011), the neurons were depolarized at 7 DIV with 25 mM KCl for 8 h (controls were 
treated equally) and were directly lysed for analyzing luciferase activity. Membrane 
depolarization only increased the relative luciferase activity of the promoter fragment 
-4713 (2.8-fold, p ≤ 0.001; Figure 5.12 A). 
One transcription factor, NPAS4, is known to function as an activity-regulated 
transcription factor (Lin et al., 2008; Zhang et al., 2009a; Pruunsild et al., 2011; 
Ramamoorthi et al., 2011) and results showed that NPAS4 markedly increased both, 
the Syt10 promoter and endogenous Syt10 expression (chapter 5.1). Due to the 
finding that membrane depolarization activates the Syt10 promoter as well, it was 
tested whether NPAS4 acts activity-dependent on the Syt10 promoter. 
Therefore, primary neurons were transfected at 5 DIV with the indicated promoter 
fragments and with/without NPAS4 and depolarization was carried out at 7 DIV with 
25 mM KCl for 8 h (controls were treated equally). Subsequently, neurons were lysed 
for measuring luciferase activity and the results were compared with the basal activity 
of these fragments. Depolarization with KCl alone induced only fragment -4713 
(Figure 5.12 A). A synergistic effect was observed when neurons contained both, 
transfected NPAS4 and 25 mM KCl. Under this condition, all Syt10 promoter 
fragments were augmented 4-5-fold but their activity was stronger than with NPAS4 
alone (p ≤ 0.001). Taken together these findings indicate that NPAS4 increases the 
Syt10 promoter in an activity-dependent manner. 
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Figure 5.12 Syt10 promoter fragments are stimulated by membrane depolarization and 
by the activity-regulated transcription factor NPAS4. (A) Rat hippocampal (RH) neurons 
were transfected with the indicated promoter fragments on DIV5. 40 h later cells were stimulated with 
25 mM KCl for 8 h and lysis was performed directly after stimulation revealing an induction of promoter 
fragment -4713 following KCl stimulation (2.8-fold). (B) Luciferase activity of RH neurons that had 
been transfected with the indicated promoter fragments and with 25 ng NPAS4 followed by KCl 
stimulation. Note that luciferase activity of all promoter fragments carrying a binding site for NPAS4 
was up-regulated when NPAS4 and KCl were present, indicating that NPAS4 acts as an activity 
dependent transcription factor on the Syt10 promoter. RH neurons were transfected on DIV5 with 
either an empty vector or 25 ng NPAS4 and 40 h later, cells were stimulated with 25 mM KCl for 8 h or 
were treated as controls. Following stimulation, cells were lysed for luciferase measurements and 
Firefly units were normalized to the basal values (mock transfected cells). Statistical analysis was 
performed using a One-way ANOVA followed by Tukey posthoc test (*** p ≤ 0.001). 
 
5.2.3 Syt10 gene expression is induced by kainic acid stimulation 
Expression of Syt10 seems to be tightly controlled and in vivo has only in the 
hippocampus been observed after SE, induced either by kainate or pilocarpine 
injection. Thus, it was investigated whether kainic acid (KA) can induce the Syt10 
expression in primary neurons. Therefore, rat hippocampal neurons were stimulated 
with KA using different stimulation durations and the time between stimulation and 
lysis of the cells was varied as indicated in the diagram in figure 5.13 A-C. 
Subsequently, Syt10-, IGF1-, Synaptophysin to control for cell death, and NPAS4- 
gene expression levels were determined using quantitative RT-PCR. Relative Syt10 
gene expression was strongly augmented by two different stimulation conditions. 
Constant stimulation of neurons with 50 µm KA for 24 h increased relative Syt10 
gene expression 9.3-fold (p ≤ 0.001) compared to basal values and a stronger 
stimulation with 150 µm KA (1/2 h, harvested 24 h later) led to an even slightly higher 
augmentation (11-fold, p ≤ 0.001) compared to values of non-stimulated samples 
(Figure 5.13 A). 
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IGF1 mRNA expression paralleled the one observed for Syt10 but with a stronger 
increase (19-fold and 40-fold, p ≤ 0.001; figure 5.13 B). As NPAS4 regulated Syt10 
expression, NPAS4 gene expression levels after KA stimulation were analyzed as 
well. Significant increases in NPAS4 expression were observed with a constant 
stimulation (24 h) of neurons with 25 µM (4-fold, p ≤ 0.001) or 50 µM KA (5.5-fold, 
p ≤ 0.001) (Figure 5.13 C). 
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Figure 5.13 Altered gene expression of rat hippocampal neurons following KA 
stimulation. Quantitative RT-PCR on mRNA extracted from non-stimulated rat hippocampal neurons 
on DIV14 (white bar) and from rat hippocampal neurons stimulated with KA. The amount of KA, the 
incubation duration and the harvesting time after incubation are indicated under each diagram. (A) 
Syt10 gene expression after continuous (24 h) KA stimulation with 50 µM KA revealed a significant 
increase as well as 1/2 h stimulation with 150 µM KA and a time period until harvesting of 24 h 
compared to non-stimulated controls. (B) The same conditions as observed for Syt10 increased IGF1 
gene expression levels compared to non-stimulated controls. (C) NPAS4 mRNA expression was up-
regulated compared to controls after continuous (24 h) KA stimulation with 25 µM or 50 µM KA. For all 
measurements Synaptophysin was used for standardization, all values were normalized to the control 
condition (white bar) and statistical analysis was performed using a One-way ANOVA followed by 
Tukey posthoc test (*** p ≤ 0.001). Results are presented as mean +/- SEM. 
 
5.2.4 Survival of neurons after KA stimulation is affected by Syt10 loss 
Due to the finding that Syt10, IGF1 and NPAS4 gene expression was up-regulated in 
response to KA stimulation, the functional role of this induction was investigated. 
Since the IGF1 signaling pathway is known to be important for neuroprotection 
(Sansone et al., 2013) it was investigated if knockout of Syt10 that controls the Ca2+ -
dependent release of IGF1-containing vesicles, alters survival of neurons after 
stimulation with KA. Therefore, primary hippocampal neurons from Syt10 knockout 
(KO) and wildtype (WT) mice littermates were stimulated on DIV13 with KA using two 
stimulation conditions that augmented IGF1 (7.4-fold and 6.5-fold, p > 0.05) and 
Syt10 (3.8-fold and 3.7-fold, p > 0.05) mRNA expression levels (see figure 5.13 A, 
B), 25 µM KA for 24 h and 150 µM KA for 1/2 h fixed 8 h later. Although the mRNA 
expression levels were more abundant under these conditions they were only 
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detected as significantly altered using Student’s t-test (not shown) but not using One-
Way ANOVA followed by Tukey posthoc test. 
Subsequently, these neurons were labeled with microtubule-associated protein 2 
(MAP2), a marker for dendrites, astrocytes with glial fibrillary acidic protein (GFAP) 
and cell nuclei were labeled with DAPI. Figure 5.14 A shows representative images 
of neurons from Syt10 WT and KO animals under basal condition (Figure 5.14 A, 
upper panel) and stimulated with 25 µM KA for 24 h that were processed directly 
after stimulation (Figure 5.14 A, lower panel). The images showed that the number of 
neurons were not different in unstimulated cultures between Syt10 WT and KO 
(Figure 5.14 A, upper panel). However, the images revealed that the loss of Syt10 
led to a decrease in neuronal cell survival when cultures were stimulated with 25 µM 
KA for 24 h (Figure 5.14 A, lower panel). 
Quantification using the ImageJ software was carried out and results were analyzed 
as a ratio of GFAP or MAP2 positive cells versus the total cell number (DAPI) of the 
respective image. For the two genotypes, the values were normalized to the 
respective basal values (100 %, not shown) and the means are shown in the diagram 
(Figure 5.14 B). It was observed that stimulation for 24 h with 25 µM KA decreased 
the number of MAP2 positive Syt10 KO neurons compared with Syt10 WT neurons 
(52 % versus 38 %, p ≤ 0.05) whereas the number of GFAP positive astrocytes was 
not different in both genotypes (90 % versus 96 %, p > 0.05). Following the second 
stimulation protocol tested (150 µM KA for 30’ harvested 8 h later) the number of 
surviving neurons was lower. The number of MAP2 positive neurons decreased to 
4 % and 2 % in Syt10 WT and KO cultures, respectively. But neither the rate of 
MAP2 positive nor of GFAP positive cells (WT: 94 % versus KO: 119 %) was 
significantly different between both genotypes (p > 0.05). 
Taken together, these results indicate that the loss of Syt10 significantly decreased 
the number of surviving neurons but not of astrocytes after a 24 h stimulation with 
25 µM KA. When stimulated with 150 µM KA for 1/2 h and processed 8 h later, no 
significant difference between the two genotypes was observed in either cell types. 
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Figure 5.14 Loss of Syt10 decreases the survival rate of neurons after KA stimulation. 
Dissociated hippocampal Syt10 KO or WT neurons were stimulated following two protocols that 
elevated IGF1 and Syt10 gene expression (shown in figure 5.13), 25 µM KA for 24 h and 150 µM KA 
for 1/2 h fixed 8 h later. Cells were stained for the neuronal marker MAP2, the astrocytic marker GFAP 
and for cell nuclei (DAPI). (A) Representative images of control Syt10 WT and KO neurons under 
basal conditions and following stimulation for 24 h with 25 µM KA. Following this stimulation condition 
less MAP2 positive neurons were visible in cultures from Syt10 KO animals (lower panel, right image) 
compared with cultures from WT animals (lower panel, left image), whereas the number of neurons 
under basal conditions were equal (upper panel). Scale bar: 500 µm. (B) Quantification of the two 
stimulation conditions shown below the diagram. Cells that were positive for MAP2 or GFAP were 
counted with ImageJ and were normalized to the total cell number (DAPI). Then, all values were 
normalized to the basal values for each genotype (WT or KO). Statistical analysis was performed 
using Student's t-test (* p ≤ 0.05). Results are presented as mean +/- SEM. 
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5.3 Analysis of cellular and subcellular expression patterns of 
Syt10 
5.3.1 Generation and characterization of isoform-specific antibodies 
To date, nothing is known about the cellular and subcellular localization of Syt10 
protein in the hippocampus, mainly due to the lack of a Syt10-specific antibody. To 
study the cellular distribution of Syt10, isoform-specific antibodies were raised. A 
polyclonal antibody was generated using a peptide residing in the Syt10 linker region 
and the monoclonal antibodies were raised with a peptide located in the Syt10  
C-terminus (Figure 5.15 A, B). All peptides were coupled to a carrier protein in order 
to increase their immunogenicity. Due to the strong sequence homology of Syt10 
with Syts 3, 5, and 6, it was essential to verify the specificity of the Syt10 antibodies. 
By immunoblotting, it could be shown that the polyclonal antibody specifically 
recognized Syt10 as seen in the OB sample from WT mice and in the overexpressed 
Syt10 HEK293T cell lysate. The calculated molecular weight of Syt10 was about 
62 kDa and the band that appeared at around 125 kDa corresponds to the Syt10 
homodimers. The Syt10 specific bands neither appeared in the lysate from Syt10 KO 
olfactory bulbs nor in the untransfected HEK293T cell lysate sample. In addition, 
cross reactivity could not be detected as HEK293T cell lysates transfected with the 
evolutionary conserved isoforms Syt3, 5 and 6 were lacking a corresponding band 
(Figure 5.15 C). Monoclonal antibody clones from rats (23 clones) and mice (15 
clones) were examined by immunoblotting as well. In contrast to the polyclonal 
antibody, no specific signal could be observed using the monoclonal antibodies (data 
not shown). Immunoblotting of homogenates from various brain regions revealed that 
Syt10 had the strongest expression in olfactory bulb, pons and cerebellum. In the 
other brain regions examined, including the striatum, hippocampus, cortex and 
pituitary gland, Syt10 was only very weakly expressed (Figure 5.15 D). 
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Figure 5.15 Characterization of Syt10 isoform specific antibodies. (A) Protein domain 
structure of Syt10. The black box depicts the epitope region of the polyclonal antibody; the grey box 
illustrates the epitope region of the monoclonal antibody. (B) Multiple alignment of the mouse Syt 
isoforms Syt3, 5, 6 and 10. Sites with two or three identical amino acids are highlighted in grey, amino 
acid positions with complete sequence similarities are highlighted in black. The transmembrane 
domain (TMD) is marked with a dotted line, the epitope region of the polyclonal antibody is marked in 
black and the grey line assigns the epitope region of the monoclonal antibodies. (C) Protein lysates of 
OB from Syt10 WT and KO mice as well as from HEK293T cells transfected with Syts 3, 5, 6 and 10 
or untransfected () were analyzed by immunoblotting with the polyclonal Syt10 antibody (Syt10 
150 T3) at a dilution of 1:250. Syt10 molecular weight: 62 kDa. (D) Immunoblot showing the distinct 
distribution of Syt10 in several brain subregions. Syt10 was labeled with the polyclonal Syt10 antibody 
and the housekeeper ß-actin was used as a loading control. 
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Figure 5.15 (continued) Arrowheads indicate the Syt10 specific protein band. Syt10 OE: Syt10 
overexpression in HEK293T cells; OB: olfactory bulb; ST: striatum; HC: hippocampus; CTX: cortex; 
PG: pituitary gland; P: pons; CB: Cerebellum. 
 
To test if the antibodies were suitable for immunocytochemistry, first the newly 
generated antibodies (Figure 5.15) were characterized in HEK293T cells. Therefore, 
HEK293T cells were transfected with constructs carrying the CMV promoter and 
coding for Syt10-GFP, GFP alone or an empty vector (Figure 5.16 A). Next, cells 
were labeled with the polyclonal and the two monoclonal antibodies and analyzed by 
microscopy. All three antibodies (antibody 2A9 not shown) exhibited a strong 
fluorescent signal that was co-localized with overexpressed Syt10-GFP (Figure 5.16 
A and B a, d, g). This signal was absent in either GFP transfected cells (Figure 5.16 
A and B b, e, h) or cells transfected with an empty vector (Figure 5.16 A and B c, f, i). 
Taken together, the newly generated antibodies specifically recognized 
overexpressed Syt10 in HEK293T cells. 
 
 A            B 
 
Figure 5.16 The polyclonal and monoclonal antibodies specifically recognize 
overexpressed Syt10. HEK293T cells were transfected with Syt10-GFP, GFP and an empty vector 
(mock) under the control of the CMV promoter. Two days after transfection, the cells were fixed and 
stained with the polyclonal antibody 150 T3 (A) or the monoclonal antibody 1D3 (B). Both antibodies 
label overexpressed Syt10-GFP, whereas no unspecific staining of GFP alone or the empty vector 
could be detected. 
 
Some members of the Syt family, e.g. Syt1, 2 and 9, are known to function as 
regulators for vesicle release in neurons. To investigate the distribution of Syt10 in 
primary neurons, the newly generated Syt10 antibodies were characterized in mouse 
hippocampal neurons (Figure 5.17). Neurons were transfected with Syt10-GFP, 
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untagged Syt10 or GFP alone, all under control of the synapsin promoter, or with an 
empty vector under control of the CMV promoter. The polyclonal Syt10 antibody 
150 T3 specifically labeled overexpressed Syt10-GFP, shown by overlap of the two 
fluorescent signals (Figure 5.17 A a, e, i). The labeling of untagged Syt10 showed a 
staining pattern similar to overexpressed Syt10-GFP indicating that the GFP-tag 
does not lead to a change of the subcellular Syt10 localization (Figure 5.17 A b, f, j). 
No signal was detected in neurons overexpressing GFP (Figure 5.17 A c, g, k) or in 
mock transfected neurons (Figure 5.17 A d, h, l). The specificity of the monoclonal 
antibodies 1D3 (Figure 5.17 B) and 2A9 (Figure 5.17 C) was similar to the polyclonal 
antibody 150 T3. In summary, the newly generated antibodies could be used to 
specifically label Syt10 in protein lysates or in Syt10 overexpressing neurons. 
 
 A 
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Figure 5.17 In neurons, the polyclonal antibody and the monoclonal antibodies 
specifically detect overexpressed Syt10. Mouse hippocampal neurons were transfected with 
constructs coding for Syt10-GFP, Syt10 without a tag, GFP alone, all under the control of the synapsin 
promoter, or an empty vector under the control of the CMV promoter. (A) The polyclonal antibody led 
to a strong fluorescence signal in neurons overexpressing Syt10-GFP (a, e, i) and Syt10 (b, f, j). This 
signal was absent in GFP-overexpressing neurons (c, g, k) or mock transfected neurons (d, h, l). An 
identical labeling pattern was observed with the monoclonal antibodies 1D3 and 2A9. Note that the 
overall fluorescence intensity was weaker in B. Scale bar: 10 µm. 
 
5.4 Syt10 subcellular localization in PC12 cells and in neurons 
using overexpression 
Neuroendocrine rat pheochromocytoma PC12 cells possess two types of vesicles, 
synaptic vesicles (SVs) and large dense core vesicles (LDCVs) (Greene and 
Tischler, 1976). Therefore, the use of this cell line to study the subcellular localization 
of proteins that are involved in vesicular exocytosis is well established. Indeed, the 
localization of some Syts has been described in PC12 cells. Syt1 has been identified 
to be present on synaptic vesicles whereas there are confounding reports about the 
localization of Syt7. Sugita et al. 2001 reported that Syt7 was located at the plasma 
membrane (Han et al., 2004; Sugita et al., 2001), while other studies show a 
localization of Syt7 at LDCVs (Fukuda et al., 2004a; Wang & Chicka, 2005). 
However, to date, the subcellular localization of Syt10 in PC12 cells has not been 
investigated. Analysis of the subcellular localization of Syt10 in PC12 cells could 
reveal whether the protein is localized to any of the two vesicles types, to the plasma 
membrane or to other subcellular compartments. 
 
5.4.1 Distinct localization of Syt isoforms in PC12 cells 
To gain insights into the subcellular localization of Syt10, overexpression plasmids 
were generated containing full-length Syt10 fused to a C-terminal fluorescent reporter 
(mCherry or GFP) under the control of the synapsin promoter. As tags can affect the 
protein localization, first the distribution of Syt10-GFP was compared to the one of 
the untagged Syt10 protein (Figure 5.17 A, B, C). From Syt1 and Syt7 it is known that 
Syt1 localizes to synaptic vesicles in neurons/small vesicles in PC12 cells and that 
Syt7 is present at the plasma membrane (Han et al., 2004). Overexpression of Syt1-
GFP and Syt7-GFP confirmed these subcellular localizations in PC12 cells. Due to 
the strong sequence similarity of Syts 3, 5, 6 and 10, it was hypothesized that their 
proteins might be present at similar subcellular compartments. To test this, the 
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subcellular localization of these evolutionary conserved Syts was examined in PC12 
cells as well. Consistent with Sugita et al. 2002, overexpressed Syt3-GFP was clearly 
localized at the plasma membrane in PC12 cells (Figure 5.18) (Sugita et al., 2002). 
Overexpression of Syt6-GFP showed a punctate expression pattern distributed 
throughout the cytoplasm (Figure 5.18). An enrichment of Syt6-GFP at the plasma 
membrane could not be observed. Similar to Syt6-GFP, the Syt5-GFP expression 
pattern in PC12 cells was punctate (Figure 5.18). Overexpressed Syt10-GFP in 
PC12 cells was localized distinct to the plasma membrane expression of Syt3- and 
Syt7-GFP. Expression of Syt10-GFP was distributed throughout the cytoplasm with a 
punctate expression pattern similar to Syt5- and Syt6-GFP. 
 
 
Figure 5.18 Subcellular localization of overexpressed Syts in PC12 cells. Syts are 
localized differentially in PC12 cells as shown by overexpression of Syt proteins fused to a C-terminal 
GFP. Whereas Syts 3 and 7 are located at the plasma membrane, Syts 1, 5, 6 and 10, exhibited a 
punctate expression pattern in the cytoplasm. PC12 cells were analyzed by confocal microscopy 48 h 
after transfection. Scale bar: 5 µm. 
 
5.4.2 Syt10 does not co-localize to closely related isoforms in PC12 cells 
Phylogenic analysis revealed a close relationship between Syts 3, 5, 6 and 10 
(Marquèze et al., 2000). It has been postulated that Syts form heterodimers via their 
unique cysteine binding sites and thereby increase their functional repertoire (Fukuda 
et al., 1999a). To test whether those Syts change their subcellular localizations upon 
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putative heterodimerization, co-transfection of Syt10 with Syts 3, 5 and 6 tagged with 
a fluorescent reporter was carried out in PC12 cells. As a comparison, single 
transfections of the constructs are given in the appendix (Supplementary figure 8). 
When co-expressed with Syt10, Syt3 was localized at the plasma membrane. Syts 5, 
6 and 10 were distributed throughout the cytoplasm showing punctate expression but 
only Syt5-mCherry expression partially overlapped with Syt10-GFP. No change of 
the distribution pattern upon co-expression was observed in those cells (Figure 5.19). 
 
 
Figure 5.19 Co-transfection of Syt10 with Syts 3, 5 and 6 in PC12 cells. PC12 cells were 
co-transfected with Syt10 and the closely related Syt isoforms Syt3, 5 and 6, and fixed for imaging 
48 h after transfection. While Syt3-GFP was localized to the plasma membrane, Syt10-mCherry did 
not co-localize with Syt3-GFP. Partial overlap of co-expressed Syt10-GFP and Syt5-mCherry was 
observed with a punctate expression pattern near the nucleus. Syt10-GFP and Syt6-mCherry did not 
show an overlap in the punctate expression pattern. Scale bar: 5 µm. 
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5.4.3 Syt10 expression in neurons 
The subcellular localization of Syt10 remains unresolved in cortical or hippocampal 
neurons to date. Therefore, primary neurons were transfected with a construct coding 
for Syt10 tagged with a fluorescent reporter on DIV5-6 and fixed for subsequent 
immunostainings on DIV13-14. Confocal imaging of these neurons revealed an 
expression of Syt10-GFP that was mainly concentrated to the soma, showing a 
punctate pattern. Syt10-GFP distribution along neurites was weaker and bit more 
diffuse compared to the soma (Figure 5.20 A). But even in neurites, Syt10-GFP 
overexpression still appeared punctate. To further identify this subcellular expression 
pattern, several markers were used to label synapses and dendrites. Co-labeling of 
Syt10-GFP overexpressed neurons with microtubule-associated protein 2 (MAP2), a 
marker for dendrites, showed that Syt10-GFP was distributed along the dendrites. 
Even though Syt10-GFP expression was punctate, a subcellular localization to 
synapses as examined by co-labelings with Syt1 and synapsin, was not observed. 
Furthermore, Syt10-GFP was not co-localized with the vesicular GABA transporter 
(vGAT) indicating that Syt10 is not present on SVs containing GABA (Figure 5.20 B). 
Figure 5.20 Subcellular localization of Syt10-GFP in 
primary neurons DIV13-14. (A) Confocal images showing that 
overexpression in mouse cortical neurons Syt10-GFP was 
distributed along the soma and neurites. Localization of Syt10-
GFP in the branches was less pronounced compared to the 
strong punctate expression in the soma. In the two lower panels, 
higher magnifications of the soma and a neurite are shown from 
the same neuron presented in the upper panel. Scale bars: 20 µm 
(whole neuron), 10 µm (soma), 5 µm (neurite). (B) Subcellular 
localization of Syt10 in primary neurons. Inhibitory neurons were 
labeled by vGAT, dendrites by MAP2 and synapses by Syt1 and 
Synapsin. Scale bar: 5 µm 
 A 
B 
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5.4.4 Examination of Syt10 localization in the ER-Golgi trafficking pathway 
Since other Syts were described to be localized to the Golgi (Fukuda et al., 2004b; 
Fukuda et al., 2003c; Matsuoka et al., 2011) and due to the expression pattern of 
Syt10-GFP observed in PC12 cells (Figure 5.19) and in neurons (Figure 5.20), it was 
next analyzed whether Syt10 is present on intracellular compartments. To unravel, 
whether Syt10 could be localized on intracellular compartments, PC12 cells were 
transfected with Syt10-mCherry and a plasmid coding for the Transferrin Receptor 
(TfR) fused to a fluorescent reporter (TfR-GFP). Transferrin binds to the TfR and both 
the ligand and receptor are internalized into the cell via clathrin-mediated endocytosis 
and are sorted via early and recycling endosomes to the plasma membrane 
(reviewed by Mayle et al., 2012). Overexpressed Syt10-mCherry did not show a high 
degree of co-localization to TfR-GFP indicating that Syt10 does not localize to 
endosomal compartments in PC12 cells (Figure 5.21 A). For comparison with the co-
transfections, the distribution pattern of all single transfections in PC12 cells is shown 
in the appendix (Supplementary figure 8). 
To analyze whether Syt10 is present on other compartments of the Golgi ER 
trafficking pathway, vesicle trafficking in the Golgi was inhibited via treatment with 
2 µM Brefeldin A (BFA) and the localization of Syt10-GFP transfected PC12 cells 
was analyzed with a counterstain against the Golgi matrix protein 130 (GM130), a 
marker for the Golgi apparatus. BFA interrupts the anterograde transport of vesicles 
from the Endoplasmatic Reticulum (ER) to the Golgi Apparatus leading to an 
accumulation of proteins in the ER and a collapse of the typical Golgi stacks 
(Klausner et al., 1992; Pelham, 1991). Under control conditions, Syt10-GFP showed 
a slight accumulation near the nucleus where the Golgi Apparatus could be identified 
by a staining with GM130 revealing the characteristic organization of the Golgi 
stacks. Overnight treatment with BFA exhibited the collapse of the Golgi as seen by 
disorganization of the Golgi stacks. However, no change in the Syt10-GFP 
expression was observed indicating that Syt10-GFP is neither trapped in the ER nor 
in the ER to Golgi Intermediate Compartment (ERGIC) following BFA treatment 
(Figure 5.21 B). 
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Figure 5.21 Syt10 is not concentrated in Golgi-compartments and endosomes in PC12 
cells. PC12 cells were transfected and fixed for imaging 48 h after transfection. (A) Co-expression of 
Syt10-mCherry and a GFP-tagged TfR-GFP, which is a marker for early endosomes, showed that 
Syt10-mCherry was not expressed at the same endosomal compartments. (B) Overexpression of 
Syt10-GFP and counterstaining against GM130, a Golgi matrix protein, showed that Syt10-GFP was a 
resident Golgi protein. Treatment with BFA did not change Syt10-GFP localization indicating that the 
disassembly of the Golgi does not influence Syt10-GFP localization. Scale bar: 5 µm. 
 
As analyzed in PC12 cells, a putative localization of Syt10-mCherry in the ER/Golgi 
complex was examined by co-expression with TfR-GFP in primary neurons. Similar 
to Syt10-GFP, Syt10-mCherry expression was weak throughout the branches but 
stronger in the soma. Higher magnification of the soma shows that Syt10-mCherry 
was co-localized to a certain degree with TfR-GFP. This co-localization was 
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restricted to the soma and not found in the branches (Figure 5.22 A). A similar 
overlap but to a lesser extend was observed for Syt10-GFP when co-labeled with 
chromogranin A, a neuroendocrine secretory protein which was located at secretory 
vesicles in neurons and neuroendocrine cells (Data not shown). For comparison with 
the co-transfections, the distribution pattern of all single transfections in neurons is 
shown in the appendix (Supplementary figure 9). 
 
 A 
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Figure 5.22 Syt10 is not concentrated in the ER-Golgi pathway. Mouse hippocampal 
neurons transfected at DIV5-6 and fixed with PFA for immunolabeling at DIV14. (A) Neurons 
overexpressing Syt10-mCherry and TfR-GFP co-localized in the soma. (B) Golgi Apparatus labeled 
with GM130 of control neurons as well as BFA-treated neurons. Syt10-GFP expressing neurons 
exhibited a partially overlapping localization with GM130 under control conditions. Disrupted vesicle 
traffic led to a collapse of the Golgi cisternae as demonstrated by GM130 labeling. 
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Figure 5.22 (continued) However, the localization of Syt10-GFP did not change following the 
stimulation. Scale bar upper rows: 10 µm; lower rows: 5 µm. 
 
To unravel, whether Syt10 is part of the ER/Golgi traffic in neurons, a putative 
localization of Syt10-GFP to the Golgi Apparatus was examined by counterstaining of 
Syt10-GFP transfected neurons with GM130. Overlap of Syt10-GFP was observed 
with the localization of the Golgi matrix protein (Figure 5.22 B upper row). In addition, 
treatment with BFA induced the collapse of Golgi cisternae, as monitored by the 
change of GM130 staining pattern, but did not lead to a change of Syt10-GFP 
localization in primary hippocampal neurons. The results obtained from PC12 cells 
and from primary neurons indicate that in both cell types Syt10 is not a resident Golgi 
protein. 
 
5.4.5 Syt10 is partially localized to neuropeptide Y containing vesicles 
To study the punctate localization of Syt10 in more detail, it was first examined if 
Syt10-mRFP is localized to NPY, a marker for peptide vesicles. Primary neurons 
were co-transfected on DIV5-6 with a construct coding for Syt10-mRFP and a vector 
containing NPY-GFP and cells were prepared for confocal imaging on DIV16. 
Overlap of Syt10-mRFP and NPY-GFP was mainly observed in the soma of these 
neurons, which could not be detected in the branches of overexpressed neurons 
(Figure 5.23 A-C). To exclude that the overexpressed mRFP-tag changes the correct 
localization of Syt10, primary neurons were overexpressed on DIV5-6 with NPY-GFP 
and untagged Syt10 and staining against Syt10 with the polyclonal Syt10 antibody 
150 T3 was carried out on DIV14. Similar to the results obtained with Syt10-mRFP, a 
stronger overlap of the proteins was found in the soma and less co-localization could 
be detected in the neurites (Figure 5.23 C-E). These results indicate that the two 
proteins might be present on the same vesicles. 
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Figure 5.23 Co-transfection of Syt10-mRFP or untagged Syt10 with NPY-GFP. Confocal 
images of mouse cortical neurons transfected on DIV5-6 and fixed for confocal imaging on DIV14-16. 
(A-C) Neurons overexpressing Syt10-mRFP and NPY-GFP. Overlapping expression of the two 
proteins could only be detected in the soma (white arrows). (D-F) Neurons that were transfected with 
NPY-GFP and untagged Syt10 were stained with the polyclonal Syt10 antibody 150 T3. Similar to the 
mRFP-tagged fusion protein, untagged Syt10 and NPY-GFP exhibited only a low degree of co-
expression in the neurites (white arrowheads) but showed a stronger overlap in the soma of 
hippocampal primary neurons (white arrows). Scale bar: 20 µm; magnification: 5 µm. 
 
5.4.6 Distribution of Syt10 and IGF1 in hippocampal neurons 
Olfactory bulb neurons overexpressing pHluorin-tagged Syt10 and FLAG-tagged 
IGF1 analyzed by immunocytochemistry were found to exhibit almost 100 % co-
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localization (Cao et al., 2011). It was therefore speculated whether in primary cortical 
or hippocampal neurons, Syt10 is also localized to IGF1 containing vesicles and 
could thereby function in these cell types as Ca2+ -sensor for IGF1 release as well. To 
address this hypothesis, mouse cortical neurons were transfected on DIV5 with 
Syt10-GFP and IGF1-mRFP and on DIV14 the neurons were fixed for confocal 
imaging. Figure 5.24 shows a neuron overexpressing both constructs. In the soma as 
well as in the branches, there were overlapping expression punctae although the 
degree of overlap was not 100 % (Figure 5.24 A). 
Due to its size GFP might interfere with the correct localization of a fusion protein. 
Hence, a putative co-expression of Syt10 and IGF1 was analyzed in neurons by 
transfection of constructs coding for proteins with a smaller tag or without a tag. 
Consequently, Syt10 and IGF1-HA were co-transfected into mouse hippocampal 
neurons on DIV5 and the cells were immunolabeled following fixation on DIV14 with 
the monoclonal antibody 2A9 and an antibody specific for the HA-tag. The 
fluorescent signal of the HA and Syt10 staining was more diffusely and weaker 
distributed along the soma and branches compared to fluorescently tagged fusion 
proteins (compare Figure 5.24 A and B). Analysis of Syt10 and IGF1 distribution in 
the dendrites revealed a rather low degree of co-localization although Syt10 was 
localized to a few IGF1-HA positive punctae (Figure 5.24 B, 2). An identical pattern 
was observed using different Syt10 antibodies (Appendix, supplementary figure 10). 
 
 A 
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Figure 5.24 Partial overlap of overexpressed Syt10 and IGF1 in mouse primary 
neurons. (A) Co-transfection of mouse cortical neurons on DIV5 with constructs coding for Syt10-
GFP and IGF1-mRFP. Neurons were fixed for subsequent confocal imaging on DIV14. Overlapping 
expression of the two proteins could only be detected near the nucleus (black arrows) and at the 
branches (white arrowheads) although the degree of overlap was not 100 %. (B) Co-transfection of 
untagged Syt10 and IGF1 fused to a C-terminal HA-tag. Mouse hippocampal neurons were fixed on 
DIV14 for subsequent immunolabeling with the monoclonal Syt10 antibody 2A9 and an antibody 
specific for HA. Similar to the GFP-tagged fusion proteins, Syt10 and IGF1-HA did not exhibit a high 
degree of co-expression in the neurites (white arrowheads) but in the soma of hippocampal primary 
neurons. Numbers in the upper right image indicate the boxes with higher magnifications of the soma 
(1) and of one neurite (2). Scale bar: 20 µm, magnifications: 5 µm. 
 
5.4.7 Subcellular distribution of closely related Synaptotagmins in neurons 
Syts 3, 5, 6 and 10 exhibit a high degree of sequence similarity and only differ in their 
TMD, the linker region and the very end of the C-terminus. Nevertheless, these 
isoforms vary in their subcellular localization as shown in PC12 cells and in neurons 
(Saegusa et al., 2002). To study the subcellular localization of the different isoforms 
with regard to Syt10, primary neurons were transfected with constructs coding for 
Syts 3, 5 and 6 fused to GFP on DIV5 and fixed for subsequent confocal microscopy 
on DIV14. Syt3-GFP, Syt5-GFP and, to a higher degree, Syt6-GFP were widely 
distributed in the soma and the neurites with a punctate expression along the 
branches and the soma (Figure 5.25). 
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Figure 5.25 Localization of overexpressed Syt3, 5 and 6 fusion proteins in primary 
neurons. Confocal images of hippocampal neurons transfected with constructs coding for Syts 3, 5 
and 6 fused to GFP. Syt6 was strongly distributed throughout the soma and along neurites showing a 
punctate expression. Overexpression of Syt3 and 5 revealed a similar pattern but with a lesser degree 
of punctae. White boxes indicate magnification of branches below the respective image. Scale bar: 
20 µm; magnification: 5 µm. 
 
5.4.8 Co-expression of Syt10 with closely related isoforms 
Syts 3, 5, 6 and 10 are known to form homo- and heterodimers via evolutionary 
conserved cysteine residues indicating a potential co-localization of those isoforms 
(Fukuda et al., 1999a). To examine, whether Syt10 is co-localized with one of these 
isoforms in primary neurons, co-transfections of Syt10-mCherry with Syt3, 5 and 6-
GFP were carried out on DIV5-6. Neurons were fixed for confocal imaging on DIV13-
14. For comparison with the co-transfections, the distribution pattern following single 
transfection of individual Syt isoforms is shown in figure 5.25 and supplementary 
figure 9 (Appendix). 
Overlap of Syt3-GFP and Syt10-mCherry (Figure 5.26 left row) as well as of Syt5-
GFP and Syt10-mCherry (Figure 5.26 middle row) was mostly restricted to the soma 
and not present in neurites. In contrast, Syt6-GFP co-transfected with Syt10-mCherry 
showed a strong overlap in the soma that was also found in the branches (Figure 
5.26 right row). Moreover, co-transfection of Syt10-mCherry with Syt6-GFP seemed 
to have an effect on the overall localization of Syt10-mCherry in primary neurons 
since its co-transfection with Syt6-GFP exhibited a more punctate expression pattern 
(Figure 5.26 right row). 
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Figure 5.26 Confocal images of mouse primary neurons showing Syt10-mCherry co-
transfected with Syt3, 5 and 6-GFP. Neurons transfected on DIV5-6 and fixed for microscopy on 
DIV13-14. Left row: Overexpressed Syt3-GFP was co-localized with Syt10-mCherry in the soma but 
less in the neurites. Middle row: Overlap of Syt10-mCherry expression with Syt5-GFP was restricted to 
a small part near the nucleus. Right row: Overexpressed Syt10-mCherry overlapped with expression 
of Syt6-GFP in the soma and partially in the neurites. Scale bar: 20 µm, magnification: 5 µm. 
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5.4.9 Distribution of co-expressed Syt6-mCherry and Syt10-GFP 
Confocal analysis of the distribution patterns of co-expressed Syt10-GFP and Syt6-
mCherry indicated that the expression pattern of Syt10-GFP in the branches was 
altered in the presence of Syt6-mCherry. Due to this finding the subcellular 
distribution of Syt6 was further investigated using several markers to label synapses 
and dendrites. As observed for Syt10, Syt6 was distributed along dendrites but no 
overlap with a pre- or postsynaptic marker could be detected (Appendix, 
supplementary figure 11). 
To further analyze the phenomenon mentioned above, primary neurons were co-
transfected with Syt10-GFP and Syt6-mCherry with different DNA ratios on DIV5 and 
the cells were fixed on DIV14 for subsequent analysis via confocal microscopy. The 
results revealed a change of Syt10-GFP localization following co-transfection with  
4-fold excess of Syt6-mCherry. As described in chapter 5.4.3, single transfection of 
Syt10-GFP revealed punctate expression in the soma but a weaker and more diffuse 
distribution in the neurites. In contrast, neurons transfected with Syt6-mCherry and 
Syt10-GFP at a ratio of 4:1, showed more punctae in the branches where Syt6-
mCherry and Syt10-GFP exhibited a strong overlap (Figure 5.27). If Syt10-GFP and 
Syt6-mCherry were transfected at a ratio of 4:1, this phenomenon was not observed. 
This result might indicate that both isoforms form heterodimers in neurons in the 
presence of higher amounts of Syt6 protein and that the heterodimer might be 
targeted to the Syt6 subcellular localization. 
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Figure 5.27 Co-expression of Syt10-GFP with Syt6-mCherry changes the subcellular 
distribution of Syt10. Confocal images of cortical neurons transfected on DIV5 with different 
concentrations of Syt10-GFP and Syt6-mCherry. (A)-(C) DNA was transfected at a ratio of 1:4 (Syt10-
GFP:Syt6-mCherry). (D)-(F) Ratio of transfected DNA was 4:1 (Syt10-GFP:Syt6-mCherry). (G), (H) 
single transfections of Syt10-GFP and Syt6-mCherry (both 2 µg DNA). Scale bar: 20 µm, higher 
magnification: 5 µm. 
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5.4.10 Characterization of Syt10 N-terminal targeting sequences 
Targeting signal sequences in the N-terminus or posttranslational modifications, i.e. 
N- and O-glycosylation or palmitoylation mostly determine the localization of a given 
protein (Han et al., 2004; Flannery et al., 2010; Kwon and Chapman, 2012). Han et 
al., 2004, identified that the N-terminus of Syt1 is important for Syt1 localization to 
synaptic vesicles. Furthermore, Syts 3, 5, 6 and 10 possess evolutionary conserved 
cysteine residues in their N-terminus that are known to be important for homo- and 
heterodimerization of those isoforms (Fukuda et al., 1999a) or that might be 
palmitoylation target sites. As a first step to identify the Syt10 targeting sequences, it 
was probed if the N-terminus of those isoforms or the cysteine residues of Syt10 are 
needed for the correct targeting of the respective proteins in neurons. 
For this, the respective cysteine residues in the Syt10 full-length sequence were 
mutated into alanine (Mutation 1: C13A, Mutation2: C24A, Mutation3: C34A) and 
chimeras were constructed that are composed of either a Syt3, 5 or 6 N-terminus 
combined with the TMD, linker and C2-domains of Syt10 (Figure 5.29 A and B). 
 
 
Figure 5.28 Schematic drawing and immunoblot of mutated cysteine residues and 
Syt10 chimeras. (A) Cartoon of full-length Syt10 with cysteine residues indicated by red numbers. 
Cysteine residues are located at amino acid positions 13, 24 and 34, and are mutated by site-directed 
mutagenesis into alanine. (B) Picture of the chimera design showing the Syt10 full-length domain 
structure as a reference and the chimeras Syt3/10 (red N-terminus), Syt5/10 (violet N-terminus) and 
Syt6/10 (yellow N-terminus). The Syt10 N-terminus is exchanged by the N-terminus of the respective 
closely related isoforms. (C) Immunoblot of HEK293T cell lysates with overexpressed chimera and 
mutation proteins. Labeling with the polyclonal Syt10 antibody 150 T3 revealed the expected size of 
100 kDa in all protein lysates. 
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First, it was tested whether the DNA sequence of the chimeric and mutated GFP-
tagged proteins were translated into proteins of the correct size. HEK293T cells were 
transfected with constructs coding for the chimeric and mutated proteins and 
subsequent immunoblotting of the protein lysates was carried out using the 
polyclonal antibody against Syt10. All chimeric and mutated proteins showed the 
expected size of 100 kDa (Figure 5.28 C). 
To probe if the N-terminal cysteines are required for proper targeting, these residues 
in the Syt10-GFP construct were mutated into alanine as schematically shown in 
figure 5.28 A and were transfected into primary neurons. 
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Figure 5.29 Mutated cysteine residues in the Syt10 N-terminus changes the subcellular 
localization in neurons. Confocal images of cortical neurons transfected on DIV5 with constructs 
carrying mutated cysteine to alanine residues at the amino acid positions indicated by red numbers 
(Mutation 1: C13A, Mutation 2: C24A, Mutation 3: C34A) in the Syt10 full-length sequence fused to 
GFP. WT: full-length Syt10 without mutations. Insertion of one mutation increased the number of large 
dendritic punctate structures (white arrowheads). As two or more cysteines were mutated 
simultaneously larger aggregates were observed in the soma (white arrows). Scale bar: 10 µm. 
Confocal imaging of cortical neurons revealed that neurons transfected with either 
Syt10 Mut1, 2 or 3 exhibited more and larger punctae in the branches compared to 
WT Syt10 (Figure 5.29 upper row). Simultaneous mutation of two cysteines resulted 
in large fluorescence intense aggregates in the soma of transfected neurons (Figure 
5.29 middle row). Mutation of all three cysteine residues led to complete retention of 
Syt10 into the soma (Figure 5.29 lower row). These results indicate that mutation of 
cysteine residues leads to an accumulation of Syt10 protein in both, branches and 
the soma of cortical neurons. The more sites were changed to alanine 
simultaneously, the higher the observed degree of Syt10 protein contained in 
aggregates in the soma.  
To test if, as for Syt1, targeting signals located in the N-terminus are relevant for the 
correct targeting of Syt10 and the isoforms of the same subclass, chimeric constructs 
were made consisting of the Syt3, 5 or 6 N-terminus fused to the remaining Syt10 
full-length protein domains as depicted in figure 5.28 B. Primary neurons were 
transfected with chimeric proteins on DIV5 and fixed for confocal imaging on DIV14. 
Different from the respective Syt3, 5 and 6 full-length proteins (Figure 5.30 F-H), the 
fluorescent signal from all chimeric proteins (Figure 5.30 C-E) was more diffuse and 
widely distributed along the branches and less punctate in the soma. 
The expression pattern of the chimeric proteins was more similar to the Syt10 full-
length protein than to the corresponding Syt3, 5 and 6 full-length proteins. This 
indicates that besides the Syt10 N-terminus another protein domain appears to be 
important for the correct targeting of the Syt10 full-length protein. 
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Figure 5.30 Localization of chimeric Syt10 constructs compared to full-length Syts 3, 
5, 6 and 10 in neurons at DIV14. (A) Schematic drawing of full-length Syt10 and the chimeric 
constructs. Note that all proteins shown in (A) and the corresponding full-length Syt3, 5, and 6 are 
fused to GFP. (B)-(H) Mouse cortical neurons were transfected on DIV5 with full-length Syt10 or 
chimeric proteins (Syt3/10, Syt5/10, Syt6/10) or the corresponding full-length Syts 3, 5 and 6 and were 
fixed for confocal imaging on DIV14. Scale bar: 20 µm; higher magnification (white box): 5 µm. 
Results 
 98 
5.5 Establishment of a technical approach to characterize Syt10 
containing organelles and protein complexes 
5.5.1 Extraction of the Syt10 protein under native conditions 
Although it has been reported that Syt10 is localized on IGF1 containing vesicles in 
OB neurons (Cao et al., 2011), the nature of Syt10 containing organelles in the 
hippocampus is still unresolved. As in the hippocampus Syt10 is only highly 
expressed after seizures, an in vivo approach (e.g. purification of synaptosomes from 
SE-experienced mice) might be suitable for the characterization of Syt10 containing 
organelles. To this end, interaction partners of Syt10 could be identified via 
streptavidin/FLAG-tandem affinity purification (SF-TAP) and subsequent analysis 
using mass spectrometry. To preserve in vivo interactions, the 3-D structure of the 
proteins has to be maintained, meaning that the protein folding may not be disrupted 
by the use of denaturing conditions. 
To control for the correct size of the proteins, first all plasmids were transfected 
coding for either Syt10 or Syt6 fused to a SF-TAP tag using the Ca2+ -phosphate 
method in HEK293T cells. Lysis of the samples under denaturing conditions was 
carried out 48 h later and the immunoblot was stained with the polyclonal Syt10 
antibody 150 T3 and with a FLAG antibody. The signals from both antibodies 
completely overlapped and the expected size of the TAP fusion proteins was 
observed (Syt10: 69 kDa, Syt6: 66 kDa; Appendix, supplementary figure 12). 
Next, different approaches were tried to solubilize Syt10 under native conditions. For 
this purpose, HEK293T cells were transfected with either Syt10- or Syt6- TAP 
plasmids. To visualize the transfection efficiency before lysis, cells were transfected 
in parallel with a Syt10-GFP construct. Lysis was performed 48 h following 
transfection with lysis buffer 1 containing 30 mM Tris-HCl, 150 mM NaCl and 1 % of 
detergent. Non-denaturing detergents known not to interfere with the following 
tandem affinity purification were chosen (Triton X-100, DTT, CHAPS, DDM, NP40, 
Cholat). Subsequent immunoblotting was performed using an antibody that 
specifically recognized the FLAG-tag. Figure 5.32 A shows the immunoblot of 
samples treated with SDS as a positive control as well as two samples for each of 
the non-denaturing detergents: (1) ‘pellet after lysis’ represents the cell debris that 
could contain unsolubilized Syt10 protein, (2) ‘supernatant’ means the sample after 
lysis possibly containing solubilized Syt10 protein. By comparison of the two 
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samples, the amount of non-solubilized versus solubilized protein was determined for 
each detergent tested. As shown in figure 5.31 A, none of the detergents was able to 
completely solubilize Syt10. Bands were only visible in the cell debris sample (pellet 
after lysis) (Figure 5.31 A). A similar result was observed for Syt6-TAP protein. In 
contrast, a Syt10-GFP fusion protein was to some degree extracted with all tested 
detergents (Figure 5.31 A). However, a TAP tag is indispensable for the analysis of 
binding partners given that the GFP protein might raise the probability for unspecific 
binding. Therefore, only TAP fusion constructs were used for further analysis. Due to 
the observed insufficient solubilization, the investigation was extended to other 
detergents and the ionic strength of the lysis buffer 2 was increased (30 mM Tris-
HCl, 300 mM NaCl, 2.5 mM EGTA and 1 % detergent if not otherwise indicated). Two 
detergents (n-Octyl-ß-D-glucopyranoside and Zwittergent 3-14) showed the potential 
to get Syt10 into solution (Figure 5.31 B). Nevertheless, the corresponding Syt10 
protein band was still very faint. 
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Figure 5.31 Extraction of Syt10 from HEK293T cells under native conditions. HEK293T 
cells were either transfected with a SF-TAP-tagged Syt10 or Syt6 construct or with a Syt10-GFP 
plasmid and were collected after 48 h later. The sample containing SDS served as a positive control, 
and both, the pellet and supernatant were obtained after 1 h of lysis and subsequent centrifugation. 
The amount of Syt10 protein in the lysate was determined by immunoblotting with a FLAG antibody. 
(A) Here, lysis buffer 1 was used. In the supernatants of cells transfected with Syt10-GFP a weak 
band was visible, whereas no Syt10-TAP protein was detected in other supernatants. (B) Using lysis 
buffer 2 a faint band in the supernatant lysed with Zwittergent 3-14 and n-octyl-ß-D-glucopyranoside 
was detected. 
 
5.5.2 Syt10 and Syt6 without a TMD exhibit an altered solubility 
It could be hypothesized that the difficulties regarding the extraction of Syt10 might 
be due to the presence of the TMD. To examine whether deletion of the Syt10 or 
Syt6 N-terminus and TMD might alter the solubility of the protein, TAP fusion 
constructs lacking these domains were designed. Here, lysis buffer was composed of 
30 mM Tris-HCl, 300 mM NaCl and 10 mM EGTA at pH 7.4 and one percent of 
detergent. Surprisingly, deleting the TMD decreased the amount of solubilized Syt10 
protein in the supernatant (Figure 5.32). In contrast, the missing TMD of Syt6 led to 
an increase of the Syt6 protein solubility (Figure 5.32). As Syt10 is not endogenously 
expressed in HEK293T cells, the results might suggest that Syt10 overexpressed in 
this cell line formed aggregates that could not be solubilized. 
To probe if solubility could be increased in neuronal cells, the Syt10-TAP plasmid 
was transfected into the neuroblastoma/glioma NG108-15 cell line, and it was 
examined whether the Syt10 protein concentration on the immunoblot was higher 
compared to samples obtained from HEK293T cells. Even though NG108-15 cells 
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are neuron-like, Syt10 extraction from this cell line was not more efficient than 
compared to HEK293T cells (Data not shown). 
 
Figure 5.32 Deletion of the transmembrane domain (TMD) alters the Syt10 and Syt6 
protein solubility. HEK293T cells were either transfected with a SF-TAP-tagged Syt10 or Syt6 
construct containing (+TMD) or lacking (-TMD) a transmembrane domain. 48 h later, samples were 
lysed for 1 h with differentially composed lysis buffers. One percent of two detergents, n-octy-ß-D-
glucopyranoside (n-octyl-ß) and Zwittergent 3-14 (Zw 3-14), were tested separately in lysis buffer (see 
text above). Both, the pellet containing unsolubilized protein and the supernatant were obtained after 
1 h of lysis and subsequent centrifugation. The amount of Syt10 protein in the lysate was determined 
by immunoblots using a FLAG antibody. The Syt10 protein solubility was decreased when the TMD 
was lacking. Conversely, no Syt6 protein was detected when the TMD was present but was enriched 
in the samples lacking the TMD. 
 
5.5.3 In vivo expression of GFP in the olfactory bulb and hippocampus after 
rAAV transduction 
As mentioned above, formation of aggregates might cause the difficulties extracting 
Syt10 from HEK293T and NG108-15 cells. To overcome this problem, a different 
approach extracting native Syt10 protein was initiated. The olfactory bulb is the brain 
region in which Syt10 is expressed under native conditions. In this region, putative 
binding partners of Syt10 and the vesicle type that Syt10 is present on, are existent. 
Hence, overexpression of Syt10 in the OB might not result in the formation of 
aggregates. To test if the injection of rAAV particles results in a strong and broad 
infection of the OB, rAAV particles (serotypes 1/2 and 8) encoding the GFP protein 
were delivered into the OB and HC of newborn C57/Bl6 mice at three consecutive 
days (P0-3). Three weeks after injection, PFA perfused brains were cut horizontally 
into 30 µm thick vibratome slices. High numbers of infected neurons were found in all 
layers of the OB except for the external plexiform layer (EPL) that only contains a 
small number of tufted cells (Figure 5.33 A). Targeting the hippocampus resulted in 
Results 
 102 
an efficient viral infection of all hippocampal subregions, dentate gyrus (DG), Cornu 
Ammonis 3 (CA3) and Cornu Ammonis 1 (CA1) (Figure 5.33 B). Taken together, 
these results show, that the viral injection into P0-3 day old mice was suitable for 
stable infection of neurons in the OB and the hippocampus. This method raises the 
possibility to study Syt10 binding partners in vivo after delivery of rAAV particles 
encoding the Syt10-TAP fusion protein. With this tool, it could be questioned if a 
change in the set of Syt10 binding partners would occur in response to seizure 
activity in the hippocampus. 
 
 
Figure 5.33 Sufficient targeting of neurons in the mouse brain by P0-3 injection of 
rAAV particles into the OB and HC. C57/Bl6 mice were injected P0-3 with serotype 1/2 and 8 
viral particles purified from HEK293T cells transfected with an rAAV construct coding for GFP under 
the control of the human synapsin promoter. Three weeks after injection, mice were sacrificed by PFA 
perfusion and 30 µm thick brain vibratom slices were prepared. (A) Broad viral infection in the OB 
layers. EPL: external plexiform layer; GCL: granule cell layer; GLM: glomerular layer; MCL: mitral cell 
layer. (B) GFP positive neurons are distributed along all subregions of the hippocampus. DG: dentate 
gyrus; CA3: Cornu Ammonis 3; CA1: Cornu Ammonis 1. 
 
5.6 Functional role of Syt10 during epileptogenesis 
5.6.1 Pilocarpine-induced SE increases expression of Syt10-, IGF1- and NPAS4 
mRNA 
As mentioned above, Babity et al., 1997, found in rats that kainate injection leads to a 
rapid and transient up-regulation of Syt10 in the piriform cortex and in the 
hippocampus, with a peak expression 6 h after SE (Babity et al., 1997). Due to the 
fact that not all processes can be mimicked by stimulations in vitro, Syt10 gene 
expression was further characterized in mice that experienced SE. 
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To elucidate whether in mice, Syt10 induction after SE is observed with a similar time 
course as seen in Babity et al., 1997 mice were subjected to pilocarpine-induced SE 
and the hippocampal subregions DG, CA3 and CA1 were microdissected 2 h, 6 h, 
12 h, 24 h, 36 h, 72 h and 28 d after SE (total hippocampus was prepared at 2 h 
following SE). The different time points reflect distinct stages of epileptogenesis: The 
acute phase (2 h, 6 h, 12 h), the latency stage (24 h, 36 h, 72 h) and the chronic 
epileptic phase (28 d). By quantitative real-time RT-PCR, mRNA levels of Syt10, 
IGF1 and NPAS4 were assessed using Synaptophysin as a reference gene to 
account for neuronal cell loss (n = 5 for all groups; 2 h SE, n = 8; chronic control, 
n = 4). 
Surprisingly, the time course of Syt10 induction following SE differed from the one in 
rats. Whereas a significant down-regulation of Syt10 in DG was observed at five time 
points (2 h, 6 h, 36 h, 72 h and 28 d), an up-regulation in the CA3 region was 
detected at 12 h (2.4-fold, p ≤ 0.01), 24 h (1.9-fold, p ≤ 0.01) and 36 h (2.3-fold, 
p ≤ 0.01) following SE (Figure 5.34 A). After SE, Syt10 mRNA expression in the CA1 
region was significantly more abundant at 12 h (1.8-fold, p ≤ 0.05) and 24 h (1.7-fold, 
p ≤ 0.05) and peaked to a strong increase at 36 h (5-fold, p ≤ 0.01). In contrast to 
Syt10 mRNA levels in the DG, IGF1 mRNA expression in the DG were constantly 
augmented beginning 6 h after SE (1.7-fold, p ≤ 0.05), showing a peak expression 
72 h (3.8-fold, p ≤ 0.01) following SE and declining near to control values in the 
chronic phase (1.8-fold, p ≤ 0.05) (Figure 5.34 B). IGF1 was more abundant in the 
CA3 and the CA1 region at all time points examined, however with an overall 
stronger IGF1 increase in the CA3 region 72 h after SE (12-fold, p ≤ 0.001) and a 
strong augmentation in the CA1 region 72 h following SE (6.3-fold, p ≤ 0.01). The 
immediate early gene NPAS4 showed an early response to SE with a very strong up-
regulation 2 h following SE (128-fold, p ≤ 0.001) which was transient and decreased 
to near control values between 36 h and 72 h after SE (Figure 5.34 C). 
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Figure 5.34 Pilocarpine-induced SE increases functional expression of Syt10-, IGF1- 
and NPAS4 mRNA. (A)-(C) Syt10-, IGF1 and NPAS4-mRNA expression levels in hippocampal 
subregions of mice (C57/Bl6) microdissected 2 h, 6 h, 12 h, 24 h, 36 h, 72 h and 28 d following 
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Figure 5.34 (continued) pilocarpine-induced SE compared to control littermates (black line) as 
assessed by quantitative RT-PCR. (A) Syt10 mRNA expression levels of the hippocampal subregions 
dentate gyrus (DG), CA3 and CA1 of SE-experienced mice shown relative to control littermates. Note 
that there is a peak up-regulation of Syt10 at 36 h after SE in the CA1 region (5.14 +/- 0.73). (B) 
Relative IGF1 mRNA expression of SE-experienced mice compared to control littermates exhibited an 
increase in all subregions of the hippocampus reaching its peak expression at 72 h following SE (DG 
72 h: 3.81 +/- 0.78; CA3: 12.31 +/- 1.96; CA1: 6.25 +/- 1.10). (C) NPAS4 mRNA expression presented 
as fold change of SE-experienced mice compared to control littermates showing a peak up-regulation 
2 h after SE (128.05 +/- 3.71) that declined in all subregions to baseline at 72 h after SE. The 
housekeeping gene Synaptophysin was used to normalize gene expression and statistical analysis 
was carried out using Student’s t-test (*p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) (n = 5 for all groups; 2 h 
SE, n = 8; chronic control, n = 4). Results are presented as mean +/- SEM. 
 
5.6.2 Progenitor cell proliferation in the subgranular zone following SE is 
dependent on Syt10 
Adult neurogenesis occurs in the subgranular zone (SGZ) of the hippocampus and 
the subventricular zone (reviewed by Curtis et al., 2012; Eriksson et al., 1998; Ming & 
Song, 2005). One hallmark of epilepsy is the aberrant network reorganization that is 
caused apart from other factors by increased neurogenesis (Parent et al., 1997; 
Parent et al., 2006; Parent et al., 2006). Recently, it was found that progenitor cell 
proliferation after SE is coupled to IGF1 and that Syt10 is localized to IGF-containing 
vesicles in the olfactory bulb (Cao et al., 2011; Choi et al., 2008). 
As a first step to elucidate if Syt10 is also involved in mediating IGF1 release in the 
hippocampus after SE, pilocarpinized Syt10 WT and Syt10 KO animals were injected 
with a single dose of BrdU (300mg/kg of bodyweight) two days after SE to label 
newly proliferating cells (Figure 5.35 A). Two hours later, mice were perfused with 
4 % PFA and processed for cryosections on the following day. Slices of 50 µm 
thickness were immunostained against BrdU for subsequent fluorescence imaging of 
the hippcampus. Figure 5.35 B shows representative images of the subregion 
dentate gyrus of one animal per experimental group. The granule cell layer (GCL) 
can be distinguished by the light grey background from the hilus (H). The subgranular 
zone is located between the GCL and the hilus. The representative images showed 
that SE led to a strongly augmented number of BrdU-positive cells (Figure 5.35 B). 
The quantification of the overall number of BrdU-positive cells counted in the GCL 
and the hilus verified the increase in total BrdU-positive cells after SE in WT animals 
(Figure 5.35 C). To study specifically the neurogenic niche of the hippocampus, 
BrdU-positive cells were counted in the subgranular zone. To correct for differs in the 
variable hippocampus sizes, the cell number was normalized to the length of the 
corresponding subgranular zone. This quantification revealed a significant up-
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regulation in the rate of cell proliferation (2.5-fold, p ≤ 0.001) in WT mice but not in 
KO mice (1.5-fold, p ≤ 0.05) after SE relative to control animals (Figure 5.35 C). No 
significant difference in BrdU-positive cells was obtained in WT versus KO mice in 
the control situation. Interestingly, after SE the loss of Syt10 led to a 1.7-fold  
(p ≤ 0.01) decreased rate of cell proliferation (5.5 cells/mm) compared to WT mice 
(9.7 cells/mm) (Figure 5.35 C). Hence, Syt10 is crucial for an SE-mediated increase 
in the rate of cell proliferation. 
 
 
 
 
Results 
 107 
 
Figure 5.35 Decreased progenitor cell proliferation in Syt10 KO animals following SE. 
(A) Schematic drawing of the experimental design. Syt10 KO and WT mice experienced pilocarpine-
induced SE or were treated as controls (ctrl). Two days after SE, mice were injected with BrdU and 
were sacrificed 2 h after the injection. Subsequent immunolabeling against BrdU labels newly 
proliferating cells. (B) Representative images of the dentate gyrus (DG) from SE and ctrl Syt10 KO 
and WT mice. The granule cell layer (GCL), the hilus (H) and the subgranular zone (SGZ) of the 
dentate gyrus are indicated. The SGZ was defined as two cell layers between the GCL and the hilus. 
Per animal, five sections of the right hippocampus were labeled against BrdU. Scale bar: 100 µm. (C) 
Quantification of total BrdU positive cells counted in the GCL and in the hilus. The same samples were 
used for the quantification of BrdU-positive cells in the SGZ. Here, BrdU-positive cells were counted 
specifically in the SGZ and were normalized to the length of the SGZ. In all regions, an increase in the 
BrdU-positive cell number was observed in mice experienced SE compared to controls. Interestingly, 
Syt10 KO mice exhibit significantly less BrdU positive cells in the SGZ following SE compared to WT 
mice. Ctrl WT (n = 5), ctrl KO (n = 4), SE WT (n = 5), SE KO (n = 6). For quantification ImageJ was 
used, statistical analysis was carried out using One-way ANOVA followed by Tukey posthoc test  
(* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001) and results are presented as mean +/- SEM. 
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6 Discussion 
Epileptogenesis describes a process of multiple cellular and molecular changes in 
the brain resulting in the occurrence of recurrent spontaneous seizures. One member 
of the synaptotagmin family, Syt10, is rapidly and transiently increased in the 
hippocampus after kainic acid-induction of status epilepticus (SE) (Babity et al., 
1997). 
The aim of this thesis was to gain novel insights into the signaling mechanisms 
controlling Syt10 gene expression in response to transient hyperexcitability as well as 
to resolve the function of Syt10 in the normal and epileptic brain. 
Consequently, this study provided the first fundamental bioinformatic and functional 
characterization of the Syt10 promoter and genomic regulatory regions in different 
cell lines. 
An insight into the putative function of Syt10 in hippocampal neurons was given by 
the analysis of the subcellular distribution of Syt10 in hippocampal neurons and in a 
neuronal cell line and was compared with Syt members belonging to the same Syt 
protein subclass. 
Furthermore, the time course of Syt10 mRNA expression in mice as a response to 
SE was analyzed, which was different compared to rats. Functional changes of Syt10 
KO mice in the hippocampus were studied. Thereby, alterations in the progenitor cell 
proliferation following SE in Syt10 KO mice were demonstrated. 
 
6.1 Functional characterization of the activity-regulated Syt10 
promoter 
Under basal conditions, high levels of Syt10 mRNA expression were only detected in 
the olfactory bulb (OB) and in the suprachiasmatic nucleus (SCN) (Husse et al., 
2011; Mittelstaedt et al., 2009). A transient and local increase of Syt10 was reported 
upon SE (Babity et al., 1997), indicating that Syt10 is under tight spatial and temporal 
control. In recent years, studies have identified the transcriptional machinery that 
promotes control of activity-dependent genes (reviewed by Lyons & West, 2011; van 
Loo et al., 2012). To gain insights into upstream regulatory mechanisms mediating 
the activity-induced expression of Syt10, potential transcriptional regulatory elements 
in the Syt10 gene were examined. 
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6.1.1 Identification and functional characterization of the Syt10 promoter 
The bioinformatic analysis of the Syt10 gene carried out in the present study 
revealed characteristics commonly associated with a core promoter as well as 
evolutionary conserved potential regulatory elements. By using Luciferase assays 
these regions were examined in different primary neurons and a neuronal cell line 
(NG108-15) regarding their promoter activity. Thereby, activating and inhibitory 
elements within the Syt10 gene were identified, which are summarized in figure 6.1. 
 
 
Figure 6.1 Graphic summary of activating and repressing regions of the Syt10 
promoter. Measurements of basal luciferase activity revealed putative activating (+) or repressing (-) 
regulatory elements in the Syt10 gene. 
Two interesting regulatory regions were uncovered. Firstly, the evolutionary 
conserved part of the first Syt10 intron (RR-IN) exhibited a lower basal promoter 
activity than the core promoter. Therefore, this region represents a strongly inhibiting 
promoter control motif. Intriguingly, the corresponding human intron region was 
predicted as a heterochromatin-withstanding region (UCSC), referring to a part of the 
Syt10 gene that has low transcriptional activity. The second region comprising 
1036 bp to 306 bp upstream of the start codon strongly enhanced the activity of the 
core promoter only in hippocampal neurons. This part of the Syt10 gene might 
represent a region that could mediate the hippocampus-specific induction of Syt10 
following SE (Babity et al., 1997; this thesis). Cell-type specific promoters are well 
established and are used as tools to generate transgenic animals and for gene 
therapy (reviewed by Boulaire et al., 2009 and Walther & Stein, 1996). The 
identification of a Syt10 promoter fragment that exhibits hippocampus specific activity 
could be used to express target cDNAs only in this brain region e.g. by viral gene 
transfer. 
 
As reported for the well characterized promoter of the Arc/Arg3.1 gene, regulatory 
elements can reside far away from the core promoter (Kawashima et al., 2009; 
Pintchovski et al., 2009). Therefore, the bioinformatic analysis was extended to 
regions that were 50 kb up- und 70 kb downstream of the start ATG and conserved 
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putative regulatory regions (RR-5’ and RR-3’) were identified. However, these 
regions did not display a significant increase in promoter activity compared to the 
core promoter indicating that they do not contain elements that positively affect the 
basal Syt10 promoter activity. In addition, highly conserved regions (RR1-3) were 
subcloned and analyzed residing in the fragment 4713 bp upstream of the start ATG 
and were combined with the core promoter. Interestingly, together with the core 
promoter, these regions revealed a higher promoter activity than the full -4713 bp 
fragment. This finding suggests that there might be a repressing region located 
between 1036 bp and 3675 bp upstream of the start ATG. However, only RR-2 
exhibited a higher promoter activity specifically in hippocampal neurons. 
Taken together, these results indicate that in accordance with low basal expression 
levels of Syt10 large negative regulatory regions could be identified. Furthermore, 
these findings suggest that the identified positive regulatory elements can be 
activated by relevant stimuli. 
 
6.1.2 Activity-regulated transcription factors mediating Syt10 gene expression 
The promoters of the activity-regulated genes BDNF and Arc/Arg3.1 have been 
extensively studied and transcription factors regulating their activity have been 
identified (Kawashima et al., 2009; Kim et al., 2010; Lyons et al., 2012; Pintchovski et 
al., 2009; Pruunsild et al., 2011). However, to date the promoter of Syt10 and its 
regulatory mechanisms have not been resolved yet. 
Using different algorithms, several binding sites for transcription factors were 
predicted in the Syt10 promoter region that were also important for the activity-
dependent regulation of the BDNF and/or the Arc promoter. Luciferase assays in 
NG108 cells showed that some of these transcription factors did not induce the Syt10 
promoter (MEF2A, 2C) whereas others (AP1-factors, USF1/2 and NPAS4) strongly 
increased the promoter activity of Syt10. Functionally relevant transcription factors 
should also affect endogenous Syt10 expression levels. To test, which of the 
transcription factors that have putative binding sites, also impact Syt10 expression in 
vivo, rat hippocampal neurons were transfected with transcription factors and Syt10 
expression levels were analyzed using quantitative real-time PCR. NPAS4, USF2 
and cFos augmented endogenous Syt10 expression levels. Further analysis revealed 
that USF2 and cFos were not sufficient to activate the characterized Syt10 promoter 
fragments in luciferase measurements of primary hippocampal neurons. This 
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discrepancy suggests that the promoter fragments might not contain the respective 
functional binding sites for USF2 and cFos. Whereas in contrast, NPAS4 was the 
only transcription factor that increased both, Syt10 endogenous expression and 
Syt10 promoter activity as examined by luciferase assays in NG108-15 cells and 
neurons. Although the observed level of up-regulation of Syt10 mRNA expression 
after NPAS4 transfection in neurons is relatively weak (approx. 2-fold), it has to be 
taken into account that the transfection efficiency of primary neurons is not very high 
(less than 30 %). Therefore, the actual increase in transfected neurons is higher. As 
NPAS4 was up-regulated in the hippocampus following PTZ-induced seizure activity 
(Flood et al., 2004), after kainate (Ooe et al., 2009a) and pilocarpine injection (this 
thesis), it is a putative factor to induce Syt10 expression in response to SE.  
As NPAS4 is upstream of multiple transcription factors (Lin et al., 2008) it remained 
unclear if the observed effect on the Syt10 promoter is direct or indirect. Therefore, 
as a first step, the responsive NPAS4 binding sites were identified. Due to the finding 
that the Syt10 promoter contains several potential sites in the longest fragment, 
deletion reporter plasmids were generated. Deletion constructs carrying binding sites 
1, 2 and 3 (constructs I, II, -306) led to a strong increase of the Syt10 promoter that 
was not found in the region between the conserved elements (constructs III, IV and -
1036), whereas the two longest fragments (constructs V and -4713) were strongly 
activated by NPAS4. Thus, unknown factors in the region between the conserved 
elements repress the activation by NPAS4 binding to the core promoter. However, if 
the binding sites in construct V and -4713 are also present, the repression is 
overruled resulting in a stronger activation. 
Taken together, these results indicate that for the activity of the Syt10 promoter, 
NPAS4 binding sites 1, 2 and 5 and/or 6, 7 are most important. To test, whether this 
effect was due to direct binding of NPAS4 to the Syt10 promoter, an in vitro binding 
assay could be carried out. 
 
6.1.3 The Syt10 promoter is controlled by heterodimerization of bHLH-
transcription factors 
As a bHLH-PAS transcription factor, NPAS4 might form homo- as well as 
heterodimers with other members belonging to this transcription factor family (Hirose 
et al., 1996; Huang et al., 1993; Huang et al., 1995; Ooe et al., 2009a, b; Ooe et al., 
Discussion 
 112 
2004; Pongratz et al., 1998). An interesting candidate for the formation of a functional 
heterodimer with NPAS4 is the transcription factor Arnt2. 
Luciferase assays of rat hippocampal neurons transfected with Arnt2 alone did not 
result in a stimulation of the Syt10 promoter. Moreover, co-transfection of Arnt2 with 
NPAS4 rather caused a decrease than a positive synergistic effect on Syt10 
promoter activity. It could be further investigated if Arnt2 acts as a heterodimer with 
NPAS4 to reverse the activating function of NPAS4. Thereby, this heterodimer could 
be involved in the regulation of Syt10 gene expression. 
The mammalian homologue of the Drosophila clock gene and bHLH-PAS 
transcription factor Period1 (Per1) is expressed in the SCN, where Syt10 is 
expressed as well at high levels (Tei et al., 1997; Husse et al., 2011). Given that 
epileptic seizures induce Per1 and Syt10 expression levels, respectively, (Babity et 
al., 1997; Eun et al., 2011), it was hypothesized that this transcription factor has an 
influence on Syt10 promoter activity alone or as a heterodimer with NPAS4. 
Luciferase assays of rat hippocampal neurons transfected with Per1 revealed that 
the Syt10 promoter was indeed activated by Per1. Furthermore, co-transfection of 
NPAS4 and Per1 resulted in a synergistic effect. 
Besides in the SCN, Per1 is also expressed in the hippocampus. In addition, multiple 
reports about Per1 rhythmicity in the hippocampus stated that it is expressed in an 
oscillatory manner (Balsalobre et al., 2000; Gilhooley et al., 2011; Golini et al., 2012; 
Jilg et al., 2010; Reick et al., 2001). Taken together, these results suggest a role for 
NPAS4 and Per1 in regulating Syt10 transcription in the hippocampus. Given that 
both transcription factors were altered in response to seizures and that Per1 is 
expressed in a circadian rhythm in both, hippocampus and SCN, there is evidence 
that these transcription factors play a role in induced Syt10 expression, conceivably 
in an oscillatory manner. 
 
6.2 Stimulus-induced activation of Syt10 
Injection of kainic acid (KA) into rats as well as of pilocarpine into mice revealed an 
increase of Syt10 mRNA in vivo (Babity et al., 1997; present study). However, SE 
activates multiple downstream signaling cascades leading to altered neuronal activity 
and to an induction of multiple immune cascades. To study the consequences of 
synaptic activity on transcription, it is well established to induce membrane 
depolarization in vitro (Kim et al., 2010; Pruunsild et al., 2011). Furthermore, 
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treatment of organotypic slice cultures with KA was widely used to examine 
epileptiform activity in the hippocampus (Bausch & McNamara, 2004; Reid et al., 
2008; Routbort et al., 1999; Tinnes et al., 2011). Hence, different stimulation 
protocols were applied in vitro to study the effect of altered activity in neurons on 
Syt10 expression. 
 
6.2.1 Membrane depolarization increases Syt10 promoter activity 
Development of a hyperexcitable network is one of the hallmarks of epilepsy and 
recent studies examined changes in gene expression following SE in genome-wide 
analyses (Hendriksen et al., 2001; Becker et al., 2003; Gorter et al., 2006; Aronica 
and Gorter, 2007; Laurén et al., 2010; Okamoto et al., 2010). To screen for factors 
that might be important for the regulation of the Syt10 gene and its protein function, 
this hyperexcitable state was mimicked with strong membrane depolarization. 
Indeed, both Syt10 mRNA and protein expression were induced by stimulation with 
potassium chloride (KCl). Furthermore, the identical stimulation protocol also 
increased the activity of the promoter fragment -4713 indicating that this region may 
be centrally relevant for the endogenous Syt10 up-regulation following KCl treatment. 
NPAS4, which activated the Syt10 promoter under basal conditions, has been 
reported to be induced by synaptic activity (Lin et al., 2008; Kawashima et al., 2009; 
Pruunsild et al., 2011; Ramamoorthi et al., 2011). Luciferase experiments showed 
that stimulation of neurons co-transfected with promoter fragments -306, -1036, 
-4713 and NPAS4 led to a strong increase in promoter activation compared to both, 
NPAS4 and KCl treatment alone. Interestingly, following membrane depolarization, 
an increase of mRNA levels of NPAS4 and Per1 could be observed as well (Data not 
shown). 
Taken together, these experiments suggest that the transcription factors NPAS4 and 
Per1 are involved in mediating the up-regulation of Syt10 expression levels following 
synaptic activity. Previous studies reported that Per1 and NPAS4 mRNA expression 
is increased following strong synaptic activity further supporting this hypothesis (Eun 
et al., 2011; Rodríguez-Tornos et al., 2013). Figure 6.2 summarizes the Syt10 
promoter regulation by NPAS4, Per1 and by membrane depolarization. 
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Figure 6.2 Model of Syt10 promoter regulation by depolarization, NPAS4 and Per1. (A) 
Membrane depolarization results in the activation of the Syt10 promoter. (B) Increases in NPAS4 or 
Per1 levels alone activate the Syt10 promoter as well. NPAS4 activation of the Syt10 promoter can be 
further influenced by membrane depolarization or subsequent addition of Per1, both resulting in a 
stronger activity of the Syt10 promoter. 
 
6.2.2 Activation of kainate receptors increases endogenous Syt10 expression 
Membrane depolarization is a more general stimulation to mimic synaptic activity 
(Kawashima et al., 2009; Kim et al., 2010; Pruunsild et al., 2011) but does not match 
all characteristics of changes following epileptic seizures. KA is a neurotoxic stimulus 
used to generate epileptic seizures leading to epilepsy-specific changes, like mossy-
fiber sprouting in vivo and in vitro (Bausch & McNamara, 2004; Ben-Ari et al., 1979; 
Routbort et al., 1999; Simantov et al., 1999). Administration of KA to hippocampal 
neurons and subsequent analysis of mRNA expression revealed that endogenous 
Syt10 and IGF1 levels were significantly increased by identical conditions (chapter 
5.2.3). The similarity in the time course of augmented mRNA expression argues in 
favor of a correlation of the two proteins as described previously (Cao et al., 2011, 
2013). In contrast, NPAS4 expression was only increased by a 24 h stimulation at 
25 µM and 50 µM KA but not by the 15 min stimulation at 150 µM KA that increased 
IGF1 and Syt10 expression. This result was in line with the finding that NPAS4 is an 
immediate early gene, which is up-regulated rapidly, already 5 minutes after synaptic 
activity, and transiently, returning to basal levels one hour after synaptic activity 
(Ramamoorthi et al., 2011). Following pentylenetetrazol (PTZ) injection an 
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augmented NPAS4 expression was reported as early as one hour after generalized 
seizures (Flood et al., 2004). 
IGF1 is known for its role in neuroprotection in health and disease (Cheng et al., 
2001; Guan et al., 1996; Miltiadous et al., 2010; Selvamani et al., 2012; Wine et al., 
2009) and was up-regulated in response to KA, in parallel to Syt10 (this thesis). 
To probe if there was a correlation between IGF1 and Syt10, it was examined 
whether Syt10 knockout (KO) neurons are more vulnerable to KA-induced neurotoxic 
effects. To address this question, Syt10 KO and WT neurons were subjected to two 
kainate stimulation protocols that induced Syt10 and IGF1 mRNA expression levels. 
Loss of Syt10 significantly decreased the number of surviving neurons but not of 
astrocytes after a 24 h stimulation with 25 µM KA. 
This result indicates that Syt10 in vitro might play a role in neuroprotection. 
Interestingly, the survival rate of WT neurons was only higher compared to KO 
neurons following the KA stimulation protocol that up-regulated both, IGF1 and 
NPAS4 in parallel to Syt10. Hence, following KA stimulation NPAS4 might induce 
Syt10 expression and together with IGF1 these proteins might account for neuronal 
cell survival. 
In line with this hypothesis, a neuroprotective function for NPAS4 has been reported. 
Overexpression of NPAS4 was described to inhibit cell death in vitro induced by 
different apoptosis protocols. RNAi-mediated knock-down of NPAS4 reversed the 
neuroprotective effect in hippocampal neurons. Intriguingly, overexpression of 
NPAS4 in vivo via viral gene transfer provides neuroprotection in response to KA-
induced cell death assessed three days following SE (Zhang et al., 2009a). 
Furthermore, IGF1 was reported to be essential for hippocampal cell survival, as 
IGF1 null mice exhibit a higher rate of dentate granule cell death (Cheng et al., 
2001). Moreover, the damage caused by administration of intrahippocampal injection 
of KA such as astrogliosis, microgliosis and increased hippocampal neurogenesis as 
well as seizure severity can be decreased by simultaneous injection of IGF1 into 
mice and rats (Miltiadous et al., 2010, 2011). 
Taken together, a neuroprotective role for Syt10 and IGF1 mediated by NPAS4 
induction appeared to be plausible. However, the fact that stimulation with 150 µM 
KA for 30 min and fixation 8 h later did not exhibit significant changes between the 
genotypes might be due to the high KA concentration. This may lead to a dramatic 
cell death that could not be attenuated by endogenous Syt10 or IGF1 levels. 
Discussion 
 116 
By using Enzyme-linked immunosorbent assay (ELISA) it could be clarified whether 
the IGF1-release is different between Syt10 KO and WT hippocampal neurons after 
KA stimulation. So far, this difference has only been reported for native OB neurons 
(Cao et al., 2011, 2013). 
 
6.3 Characterization of the subcellular localization of Syt10 
Members of the Syt protein family are key players in the regulation of different fusion 
processes. Some members have been identified to function as calcium sensors for 
synaptic vesicle and dense core vesicle release (Geppert et al., 1994; Nagy et al., 
2006; Stevens & Sullivan, 2003; Sørensen et al., 2003; Voets et al., 2001; Xu et al., 
2007). Nevertheless, the subcellular distribution of Syt isoforms is highly diverse and 
has not been identified for all isoforms to date (Cao et al., 2011; Dean et al., 2012a; 
Saegusa et al., 2002; reviewed by Südhof, 2002). Recently, Syt10 was reported to be 
localized to IGF1-containing vesicles in OB neurons. However, the subcellular 
localization of Syt10 in other neuronal subtypes remained unknown. Moreover, to 
understand its function it is essential to know whether Syt10 is localized on specific 
organelles. To shed further light on this matter, a detailed analysis of the subcellular 
distribution of Syt10 was carried in PC12 cells and hippocampal and cortical neurons. 
 
6.3.1 Subcellular localization of Syt10 in PC12 cells and neurons 
PC12 cells are often used to study components of the release machinery due to their 
vesicular content, comprising synaptic-like microvesicles (SLMVs) and large dense 
core vesicles (LDCVs). In the present study, to examine the localization of Syt10, this 
cell line and primary hippocampal and cortical neurons were used. 
A punctate expression pattern of overexpressed Syt10-GFP was detected in PC12 
cells as well as in primary hippocampal and cortical neurons. Immunolabeling of 
primary neurons overexpressed with Syt10-GFP revealed that Syt10 was present on 
dendrites as analyzed with an antibody against MAP2, a microtubule associated 
protein. However, a localization of Syt10 to synaptic vesicles, as examined by Syt1 
and synapsin co-labeling and by a staining against the vesicular GABA-transporter 
(vGAT), could not be observed. 
The distribution pattern of Syt10 argues for a vesicular localization, which was 
postulated in PC12 cells stably expressing Syt10-GFP (Saegusa et al., 2002). The 
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authors proposed that Syt10 is localized to small vesicles and not to LDCVs. 
Interestingly, analysis of Syt10 dynamics upon depolarization using Syt10-pHluorin 
revealed that Syt10 is not located on synaptic vesicles (SVs) (Dean et al., 2012a) 
and overexpression of Syt10 in OB neurons suggested Syt10 to be localized on 
extremely large IGF1 containing vesicles (Cao et al., 2011; Cao et al., 2013). Taken 
together, these results suggest that Syt10 is not present on SVs in primary neurons 
but found on other vesicle types. To exclude that the punctate expression pattern 
was not due to an overexpression artifact, time lapse imaging experiments with Syt10 
fused to a photoconvertable fluorescent tag changing its fluorescence upon 
photoactivation should be performed. Thereby, immobile aggregates could be 
distinguished from vesicular structures carrying Syt10. 
 
6.3.2 Syt10 is not a resident Golgi protein 
Syt10 was present mainly in the soma and to a lesser extend in neurites. Moreover, 
Syt10 exhibited a punctate distribution (this thesis) and other Syt isoforms, Syt4, 7 
and 9, are located to lysosomes or different endosomal compartments, the Golgi 
Apparatus and secretory granules (Ahras et al., 2006; Flannery et al., 2010; 
Haberman et al., 2007; Ibata et al., 2000; Monterrat et al., 2007). Therefore, the aim 
was to further identify the subcellular localization of Syt10 and thereby potential 
trafficking steps that require Syt10. 
In the present study Syt10-mCherry was observed to be co-localized with a 
fluorescently tagged Transferrin Receptor (TfR) protein, a well established marker for 
early endosomes (reviewed by Mayle et al., 2012), mainly in the soma of neurons 
and not in PC12 cells. Furthermore, Brefeldin A (BFA) was used to study the 
trafficking of proteins from the Endoplasmatic Reticulum (ER) to the Golgi Apparatus. 
This drug was described to result in disassembly of the Golgi and to the formation of 
two intermixing compartments (merged ER-Golgi and fused TGN-early endosomes) 
(Doms et al., 1989; Fujiwara et al., 1988; Lippincott-Schwartz et al., 1989; Hunziker 
et al., 1991; Lippincott-Schwartz et al., 1991; Wood et al., 1991), thereby inhibiting 
transport between the two combined compartments (Lippincott-Schwartz et al., 
1991). Following treatment of both cell types with BFA, labeling of the Golgi marker 
protein 130 (GM130) indeed showed a collapse of the Golgi stacks but not a 
redistribution of Syt10 protein (chapter 5.4.4). This result indicates that Syt10 is not a 
resident Golgi protein. 
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Interpretation of these results becomes even more complicated by the fact that 
neurons are polarized cells with complex transport pathways, which are distinct in 
dendrites (TfR-positive endosomes, positive for the early endosome marker (EEA1) 
and BFA-sensitive) and in axons (TfR-negative endosomes, EEA1-negative and 
BFA-insensitive) (Mundigl et al., 1993). 
Taken together, the observed results may indicate that even though Syt10 was not 
identified to be a local Golgi protein, it may still be localized to other parts of the ER-
Golgi trafficking pathway, i.e. internal transport vesicles. If Syt10 were not 
glycosylated it would not pass through the Golgi Apparatus on its way to these 
endosomal structures. To further analyze Syt10 and its putative localization on 
endosomes, a detailed analysis of all compartments without the use of 
overexpressed proteins e.g. labeling of early endosomes with Rab5 or EEA1, of 
recycling endosomes with Rab8 or 11 or of late endosomes with Rab7 or Syt7 will be 
necessary. 
 
6.3.3 Syt10 partially co-localizes with NPY- or IGF1-containing vesicles in 
hippocampal or cortical neurons 
Recently, it was reported that in OB neurons overexpressed Syt10 and IGF1 co-
localize on very large vesicular structures (Cao et al., 2011). Here, it was examined 
on which types of vesicles Syt10 was localized in cortical or hippocampal neurons. 
Since Syt10-GFP was expressed in a punctate manner but was not localized on SVs, 
it was analyzed whether Syt10 is localized to secretory peptide-containing vesicles 
as marked by overexpression of NPY-GFP. In dendrites and the soma of neurons, 
only partial overlap of either Syt10-mRFP with NPY-GFP or of untagged Syt10 with 
NPY-GFP could be detected. This result suggests that Syt10 is present in a subset of 
secretory peptide vesicles. 
Furthermore, in cortical neurons Syt10-GFP and IGF1-mRFP did not exhibit a high 
degree of co-localization as it was reported for OB neurons (Cao et al., 2011, 2013). 
To exclude, that a large tag did not affect the correct localization of overexpressed 
proteins, untagged Syt10 co-transfected with IGF1-HA was analyzed. However, 
labeling with either of the Syt10 antibodies also revealed little overlap of the Syt10 
and IGF1 signals in hippocampal neurons. 
In OB neurons, Syt10 serves as a calcium sensor for Ca2+ -dependent exocytosis of 
IGF1. However, it remains still uncertain whether Syt10, after activity-dependent up-
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regulation, mediates release of IGF1 in hippocampal or cortical neurons as well. 
There is evidence that Syt10 function might differ between hippocampal neurons and 
olfactory bulb neurons as pHluorin-tagged Syt10 was found to mediate activity-
dependent exocytosis in olfactory bulb neurons (Cao et al., 2011, 2013) but not in 
hippocampal neurons (Dean et al., 2012a). Hence, maybe all components of Syt10 
vesicles are only present after SE, e.g. following up-regulation of IGF1. Figure 6.3 
summarizes the subcellular localization of Syt10 in hippocampal neurons examined 
so far in the present study. 
 
 
Figure 6.3 Cartoon depicting the subcellular localization of Syt10 in hippocampal 
neurons. The present study showed Syt10 to be absent from SVs (small, blue vesicles) or LDCVs 
(large, blue vesicles) in the presynapse. Syt10 was furthermore not identified to be a resident Golgi or 
ERGIC protein (indicated by grey color). Whether Syt10 can be enriched on endosomes or on 
neuropeptide containing vesicles (e.g. IGF1) in the soma or in dendrites remains an open question 
(blue vesicles or red depicted Syt10). Therefore, to unravel the subcellular localization of Syt10 the 
identification of its binding partners (indicated by X, Y, Z) would be crucial. EE: Early endosome; ER: 
Endoplasmatic Reticulum; LE: Late Endosome; Lys: Lysosome; RE: Recycling Endosome. 
 
6.3.4 Syt3, 5, 6 and 10 display overlapping and diverging localizations 
Due to the high sequence similarity of the Syt subgroup comprising Syts 3, 5, 6 and 
10 and their ability to form heterodimers it was hypothesized that they might be 
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limited to the same subcellular compartments. Therefore, their localization was 
analyzed after overexpression alone and after co-expression with Syt10 to examine 
whether they co-localize with Syt10 or if a change of their distribution following co-
transfection can be observed. In the present study, Syt3-GFP was observed to be 
enriched at the plasma membrane of PC12 cells. However, the results of co-
expressed Syt3-GFP and Syt10-GFP differed between PC12 cells and neurons. An 
overlapping Syt3-GFP localization with Syt10-GFP was only found in neurons but not 
in PC12 cells. Similar to the results observed in the present study, a plasma 
membrane localization of overexpressed Syt3 in PC12 cells and of endogenous Syt3 
in ß-pancreatic cells by immunocytochemistry has been described (Gut et al., 2001; 
Saegusa et al., 2002). 
In line with this thesis it was reported in an earlier study that the localization of Syt3 
differs between cell types. It was described to be localized to the plasma membrane 
in pancreatic ß-cells and neurons but exhibits a granular expression in another 
insulin-secreting cell line and in somatostatin-secreting cells (Gut et al., 2001). For 
the results obtained in this thesis it may indicate that even though Syt3 and Syt10 do 
not co-localize in PC12 cells, they may be found on the same subcellular 
compartment in neurons. 
In the present study, Syt5-GFP fusion protein was found both in the cytosol of PC12 
cells and in the soma and dendrites of neurons, with a punctate expression pattern. 
Whereas high degree of overlapping Syt5-GFP with Syt10-mCherry was observed in 
the cytosol of PC12 cells co-localization was restricted to only a small area of the 
soma of neurons. In an earlier study Syt5 was reported to be localized to LDCVs in 
PC12 cells (Saegusa et al., 2002). Syt10-mCherry was found to be co-localized with 
NPY-GFP in the soma of neurons (present study) and Syt10 was identified in OB 
neurons on IGF1 containing vesicles (Cao et al., 2011). Hence, even though 
Saegusa suggested that Syt10 is present on SLMVs in PC12 cells (Saegusa et al., 
2002), it is more likely that in neurons Syt10 might be distributed with Syt5 to LDCVs. 
Syt6-GFP was observed in the cytosol of PC12 cells and was strongly distributed 
throughout the soma and dendrites of neurons in a punctate expression pattern. 
Interestingly, following co-expression with Syt6-mCherry at a ratio of 4:1, the 
distribution of Syt10-GFP was changed to a more punctate expression pattern 
observed not only in the soma but also in the branches of neurons. The co-
localization of Syt10-GFP and Syt6-mCherry is most likely mediated by 
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heterodimerization through the conserved cysteine residues and interestingly, Syt10 
and Syt6 are both more abundant in response to SE (personal communication T. 
Mittelstaedt). Consequences of the presence of two Syt isoforms on the same 
vesicular structure could be an alteration of their functional properties, as has been 
controversially discussed for Syt1 and Syt9 (Fukuda et al., 2002; Lynch & Martin, 
2007). Though in OB neurons, a redundant function of Syt10 with Syts 3, 5 and 6 
was not found (Cao et al., 2011). Given that a change in the functional properties of 
these Syts also depends on the quantity of each variant in the cell, a functional 
redundancy as a consequence of heterodimerization appears to be plausible. 
 
6.3.5 Characterization of Syt10 N-terminal targeting signals 
Localization of a given protein is mostly defined by targeting signal sequences 
spanning up to 30 amino acids in the N-terminus or by posttranslational 
modifications, i.e. N- and O-glycosylation or palmitoylation (Han et al., 2004; 
Flannery et al., 2010; Kwon and Chapman, 2012). To unravel, which targeting signal 
determines the subcellular localization of Syt10, two approaches were pursued to 
address this question. Firstly, chimeric proteins were overexpressed in neurons to 
unravel whether a targeting signal in the N-terminus determines the localization of 
Syt10. Secondly, as cysteine-containing motifs are the main targets for palmitoylation 
(Jang et al., 2009; Prescott et al., 2009) and for dimerization (Han et al., 2004) N-
terminal cysteines of Syt10 were mutated into alanines to examine if one of these 
processes is indispensable for the targeting of Syt10. 
Chimeric proteins overexpressed in neurons contained the Syt3, 5 or 6 N-terminus 
and the TMD, the linker, the C2A and C2B domains and the C-terminus of Syt10 
fused to a GFP-tag. All chimeric proteins were more diffusely distributed in the soma 
and along the branches than the respective WT variant. Consequently, the 
localization of none of the chimeric proteins was similar to its full-length variant 
indicating that the N-termini of the other Syts were not sufficient to switch the Syt-
TMD-C2A-C2B targeting. However, also the distribution compared to the Syt10 full-
length was altered demonstrating that the C-terminus (linker, C2A, C2B) was not 
sufficient for the localization of Syt10. 
N-terminal cysteines were mutated into alanines and the distribution of the mutated 
Syt10-GFP protein was examined by overexpression in neurons. The results suggest 
that cysteine residues were crucial for the correct trafficking and stability of Syt10-
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GFP, since in neurons transfected with mutated constructs large aggregates in the 
soma and a reduction of Syt10-GFP signal in the branches were observed. 
For the most studied isoform of the Syt family, Syt1, it was suggested that the N-
terminus contains the targeting signal directing Syt1 to SVs (Han et al., 2004), even 
though the targeting mechanism has not been resolved unequivocally. It was 
reported that N- and O-glycosylation are both essential for sorting Syt1 to secretory 
vesicles (Atiya-Nasagi et al., 2005; Han et al., 2004; Kanno & Fukuda, 2008), 
although a recent publication suggested that glycosylation is dispensable for the 
targeting of Syt1 but that a combination of the Syt1 N-terminus and the C2 domains 
mediate Syt1 targeting (Kwon & Chapman, 2012). In line with this finding it may be 
hypothesized that there is more than one protein domain needed for the correct 
localization of the Syt10 protein. 
Besides the N-terminus, the linker region of all Syt isoforms is highly variable. 
Furthermore, this region comprises amino acids that are either palmitoylated or 
glycosylated by fatty acylation and thereby can play a role in oligomerization or in 
targeting of Syts (Flannery et al., 2010; Fukuda et al., 2001a; Han et al., 2004; 
Heindel et al., 2003; Veit et al., 1996). Considering the high variability and the fact 
that the linker region, together with the C-terminus, is essential for the Golgi 
localization of Syt4 (Fukuda et al., 2001a), it may be hypothesized that this region 
together with another Syt10 protein domain might determine the targeting of Syts 3, 
5, 6 or 10. Interestingly, Fukuda et al., 2001, suggest that not only the disulfide-
bonding contributes to oligomerization of Syt10 but also three cysteine residues 
between the transmembrane domain and the linker region do (Fukuda et al., 2001b). 
Correspondingly, two palmitoylation motifs were predicted for the linker region of 
Syt10. 
Recently, it was demonstrated that targeting of Syt7 to lysosomes is accomplished by 
the formation of a palmitoylation-dependent complex with a member of the 
transmembrane 4 superfamily, CD63. Co-expressed Syt7-YFP and CFP-CD63 
carrying a mutation in the lysosomal targeting motif were not trafficked to lysosomes 
but accumulated in the plasma membrane. Therefore, identification of binding 
partners of Syt10 or systematic mutation analyses of Syt protein domains would be 
required to define the regions responsible for Syt10 targeting or the potential role of 
palmitoylation. 
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Besides mediating the targeting of Syt10 by posttranslational modification, the 
exchange of N-terminal cysteines to alanines may impair the ability of Syt10 to 
homodimerize. This in turn could directly affect the stability of the protein as this 
could lead to a misfolded tertiary protein structure. As a consequence, misfolded 
Syt10 might not be properly processed in the Golgi Apparatus, leading to protein 
aggregates in this compartment. To examine whether Syt10 protein aggregates 
accumulate at the Golgi Apparatus, neurons transfected with the mutated constructs 
could be labeled with GM130. Moreover, analyzing movement of vesicles by live 
imaging (mentioned in chapter 6.1.1) of wildtype (WT) Syt10 and mutated Syt10 
might unravel whether the protein aggregates display an altered stability or turnover 
of Syt10 protein. 
 
6.4 Spatiotemporal and functional activation of Syt10 following SE 
Strong depolarization of primary hippocampal neurons elicited either by KCl or 
kainate resulted in a strong increase of endogenous Syt10, IGF1 and NPAS4. SE 
represents a particular strong stimulation in vivo. To relate the in vitro findings to an 
in vivo situation the spatiotemporal expression patterns of Syt10, IGF1 and NPAS4 
were studied in the mouse hippocampus after pilocarpine-induced SE. 
 
6.4.1 Syt10, IGF1 and NPAS4 exhibit distinct spatiotemporal expression 
patterns after SE 
In rats, Syt10 mRNA expression in the piriform cortex and hippocampus is rapidly 
and transiently induced three and six hours, respectively, following KA-induced SE 
(Babity et al., 1997). To date, the respective spatiotemporal expression profile in 
mice has not been examined yet. As a basis for functional studies in mice, C57/Bl6 
mice were injected with pilocarpine, sacrificed at different time points and the Syt10, 
IGF1 and NPAS4 mRNA expression was analyzed via quantitative real-time PCR. 
Different time points were chosen to reflect distinct stages of epileptogenesis: The 
acute phase (2 h, 6 h, 12 h), the latency stage (24 h, 36 h, 72 h) and the chronic 
epileptic phase (28 d). Surprisingly, Syt10 gene expression was different in mice as 
compared to rats (Babity et al., 1997). In the dentate gyrus Syt10 expression was 
either unchanged or lower, whereas in the CA3 and CA1 region, Syt10 was more 
abundant between 12 and 36 h after SE. The strongest induction, however, was 
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observed in CA1 36 h after SE (Figure 6.4), a 30 h delay compared to the peak 
induction in rats. In summary, in rats an augmentation in the acute phase (6 h after 
SE) was observed (Babity et al., 1997) whereas in mice the regions differ and the 
increase in CA1 and CA3 was shifted towards the latent phase compared to rats 
(present study). This altered spatiotemporal expression pattern after pilocarpine-
induced SE was more likely due to the different species than due to the diverse 
epilepsy model used, because in unpublished data from pilocarpine-induced SE, rats 
exhibited a comparable time course of Syt10 mRNA increase to Babity et al. 1997 
(Babity et al., 1997; personal communication T. Mittelstaedt).  
In OB neurons, IGF1 was suggested to be the cargo of Syt10 vesicles (Cao et al., 
2011). Moreover, IGF1 and Syt10 mRNA expression in the native brain exhibit a 
strikingly similar distribution mainly in the OB (Mittelstaedt et al., 2009; Rotwein et al., 
1988). It was therefore hypothesized that if Syt10 would be localized to IGF1 
containing vesicles also in the hippocampus, a parallel time course of IGF1 and 
Syt10 expression could be expected. IGF1 mRNA expression was elevated in all 
hippocampal subregions at nearly all time points. The expression patterns of IGF1 
and Syt10 in the CA3 and CA1 region did not show an exact parallelism, but peak 
induction of IGF1 seemed to be shifted 24 h later compared to Syt10 (Figure 6.4). 
Recent reports already showed an up-regulation of IGF1 in mice 2 d and in rats 3 
and 7 d after SE, as well as in the chronic phase of pilocarpine-induced SE (Choi et 
al., 2008; Okamoto et al., 2010). Taken together, the shifted peak induction of IGF1 
expression following SE compared to Syt10 could indicate that Syt10 vesicles 
contain a different cargo than IGF1. 
In contrast, NPAS4 mRNA expression was rapidly and strongly stimulated already 
2 h after SE (Figure 6.4). This is consistent with previous reports, which described an 
increase of NPAS4 mRNA 1 h following PTZ-induced seizures (Flood et al., 2004). 
Conceivably, augmented NPAS4 levels in response to SE mediate the up-regulation 
of Syt10 expression. The delayed peak of Syt10 gene expression argues in favor for 
this hypothesis. NPAS4 was reported to regulate activity-dependent inhibitory 
synapse development (Lin et al., 2008). To date, it remains unresolved, in which 
neuronal subpopulation Syt10 is expressed in the hippocampus. Given that the 
excitatory/inhibitory balance is disturbed in epilepsy, NPAS4 might contribute to this 
imbalance by increasing down-stream target gene expression only in a subpopulation 
thereby shifting the proportion towards for example more inhibitory synapses. 
Discussion 
 125 
In the native brain, IGF1, Per1 and Syt10 expression is mainly enriched in the SCN 
(Bohannon et al., 1988; Sun et al., 1997; Husse et al., 2011), in which circadian 
rhythms are controlled endogenously (Reppert and Weaver, 1997). Moreover, Per1 
has been reported to be expressed in an oscillatory manner in response to light 
exposure in the SCN (Albrecht et al., 1997; Hastings et al., 1999; Shearman et al., 
1997; Shieh et al., 2005; Tei et al., 1997) and in the hippocampus (Reick et al., 2001; 
Jilg et al., 2010; Gilhooley et al., 2011). Interestingly, the present study suggests that 
NPAS4 and Per1 can induce Syt10 expression synergistically and it was found that 
NPAS4, which was up-regulated following SE, caused an increase of endogenous 
Syt10 levels. 
An earlier study already reported an induction of Per1 mRNA and protein expression 
following seizures (Eun et al., 2011). Therefore, one possible consequence of the 
endogenous increase of Syt10, IGF1 and NPAS4 after SE may be a disruption in the 
circadian rhythm of vesicle depletion, and thereby an aggravation of seizures during 
a specific diurnal phase. Additionally, IGF1 mRNA expression was reported to be 
lowest during night (Kawai et al., 2010). Furthermore, parts of the synaptic vesicle 
cycle follow diurnal changes as well. At GABAergic synapses of the SCN, paired-
pulse depression is obtained only at day, whereas vGlut sorting to the plasma 
membrane takes place with a circadian rhythmicity (Gompf and Allen, 2004; Darna et 
al., 2009). 
Correspondingly, several different epilepsy models reported a diurnal tendency for 
the occurrence of seizures (Quigg 2000, Hellier & Dudek 1999, Tchekalarova 2010). 
Nevertheless, to clearly identify the role of Syt10 following SE and a putative 
alteration in seizure frequency or amplitude, a detailed analysis of seizure frequency 
and onset in the different phases of the day, was analyzed and compared between 
Syt10 WT and KO mice (personal communication J. Pitsch, data not shown). First 
analyses of EEG recordings from SE-experienced mice showed, different from WT 
mice, that the power of all frequency bands from KO mice were significantly 
increased ictally (during a seizure). This may well suggest that ablation of Syt10 
leads to an aggravation of seizures. Furthermore, throughout the night, KO mice 
generated most seizures out of sleep as compared to WT animals (personal 
communication J. Pitsch, data not shown). 
Taken together, one could hypothesize that under normal conditions, Per1 is 
expressed in the hippocampus with a circadian rhythm, which is not sufficient to drive 
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Syt10 oscillatory expression. Moreover, NPAS4 has not been reported to be 
expressed in an oscillatory manner. However, following SE, induction of Per1 could 
overrule the rhythmic expression and, together with NPAS4, activate Syt10. There is 
already evidence that the Per1 peak expression of kindled mice is shifted towards six 
hours earlier, which correlates with a shift in the sleep homeostasis (Yi et al., 2012). 
Earlier studies in a rat model of epilepsy reported that more seizures are generated 
out of an inactive state (Hellier & Dudek, 1999; Quigg et al., 1998), which would be 
contradictory to this hypothesis. However, there might be a difference in the 
occurrence of seizures and sleep rhythm between mice and rats and so far, a shift of 
the activity state following seizures was only examined in rats (Stewart and Leung, 
2003). To understand the role of sleep homeostasis after SE and the role of Syt10 in 
this regard, analysis of sleep and awake cycles of control and SE-experienced mice 
would be necessary. 
 
 
Figure 6.4 Time course of Syt10, IGF1 and NPAS4 expression following SE. Syt10 peak 
mRNA expression in the CA1 region was reached 36 h after SE (black line). Peak expression of IGF1 
mRNA was observed 72h after SE. NPAS4 mRNA expression was up-regulated immediately after SE 
and as NPAS4 and Per1 synergistically regulate the Syt10 promoter, Per1 might also be constantly 
increased in this heterodimer as well (red solid line). Time point of SE-induction is symbolized by a red 
flash. 
 
6.4.2 Role of Syt10 in progenitor cell proliferation in response to SE 
One hallmark of epilepsy is an aberrant network reorganization that is also mediated 
by increased neurogenesis (Parent et al., 1997; Parent et al., 2006; Parent et al., 
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2006). Adult neurogenesis occurs in the subgranular zone and in the subventricular 
zone (Curtis et al., 2012; Eriksson et al., 1998; Ming & Song, 2005). The factors 
contributing to increased neurogenesis are poorly understood. However, it was 
suggested that IGF1 promotes adult neurogenesis and mediates progenitor cell 
proliferation in the subgranular zone 2 d following SE (Choi et al., 2008). As 
mentioned above, IGF1 was reported to be the cargo of Syt10 vesicles in OB 
neurons (Cao et al., 2011). 
It was therefore hypothesized that if Syt10 would be localized to IGF1 containing 
vesicles in the hippocampus, a difference in cell proliferation should be obtained if 
Syt10 is knocked out. To probe this hypothesis Syt10 KO and WT animals were 
pilocarpine-injected. Two days afterwards mice were injected with BrdU and 
sacrificed two hours later. First as a control, newly proliferating cells were counted 
outside the subgranular zone, namely in the granule cell layer and in the hilus. In 
neither of the two regions a difference between WT and KO was found. As expected, 
SE-experienced mice exhibited more active cell proliferation in the subgranular zone. 
Intriguingly, this increase was less in Syt10 KO mice compared to WT mice. 
These results support a role for Syt10 in the regulation of IGF1 release after 
pilocarpine-induced SE. To further validate this finding, the release of IGF1 secretion 
could be analyzed in hippocampal Syt10 KO cells. The functional consequences of 
SE-induced subgranular zone neurogenesis vary between studies. One report states 
that newborn granule cells under epileptic conditions have decreased excitatory and 
increased inhibitory inputs (Jakubs et al., 2006). Thereby, neurogenesis would 
increase the threshold for seizure propagation. Other studies suggest that SE-
induced neurogenesis goes along with an increase in seizure frequency (McCloskey 
et al., 2006; Parent et al., 1997; Scharfman et al., 2003). 
Administration of intrahippocampal injection of KA causes substantial alterations 
such as astrogliosis, microgliosis and increased hippocampal neurogenesis. Previous 
studies described that this injury can be reversed by simultaneous injection of IGF1 
into mice and rats as assessed 13 d after KA treatment (Miltiadous et al., 2011; 
Miltiadous et al., 2010) indicating a neuroprotective function for IGF1. Furthermore, 
chronic treatment but not acute infusion of mice with IGF1 prevented KA-induced 
cognitive impairment (Bluthé et al., 2005). In contrast, Choi et al. (2008) reported that 
increased neuronal cell proliferation 2 d after SE was dependent on IGF1. Therefore, 
IGF1 may, in the acute phase following SE, mediate neurogenesis to compensate 
Discussion 
 128 
the extensive neuronal cell loss during SE. Later (in the latent or chronic phase), 
IGF1 might ameliorate hippocampal neurodegeneration (Miltiadous et al., 2011; 
Miltiadous et al., 2010) by preventing uncontrolled neurogenesis and thereby 
diminishing the progression of a hyperexcitable network. 
 
Epileptogenesis is accompanied by the occurrence of reactive astrocytes 
(astrogliosis) as well as microglia activation. Both phenomena are well documented 
to contribute to hyperexcitability (Binder & Steinhäuser, 2006; Heinemann et al., 
2000; de Lanerolle et al., 2010) and to epileptogenesis, respectively (Borges, 2003). 
Nevertheless, following induced dentate granule cell injury, IGF1 protein levels in 
astroglia and microglia and mRNA levels in the hippocampus become augmented 
(Wine et al., 2009). Different from WT mice, in IGF1 KO mice, this damage relates to 
a significantly increased CA1 neuronal cell death, suggesting a survival effect of this 
growth factor. 
However, interpreting the functional consequences of altered cell proliferation in 
Syt10 WT animals following SE is complicated, given that serum IGF1 is transported 
through the blood-brain-barrier to activated brain areas (Nishijima et al., 2010). 
Electrical, sensory and behavioral stimulation but not local synthesis increased the 
IGF1 input in these regions of the brain. 
Taken together, due to the multiple factors influencing IGF1 levels further studies will 
be required to identify the precise role of newly synthesized IGF1 in the 
hippocampus. 
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7 Outlook 
The results obtained in this study raise several questions that need to be addressed 
in further experiments. 
The next stage of this project would be to fully resolve the signaling cascades 
mediating Syt10 expression. In this regard, it will be first necessary to unravel if 
NPAS4 regulates the Syt10 promoter via direct or indirect binding. Next, it should be 
examined whether the Syt10 promoter is functional in vivo using viral gene transfer. If 
a differential regulation of the promoter is observed in response to SE it should be an 
intriguing tool to study consequences of epileptic seizures in a specific subset of 
cells. 
In addition, a detailed analysis of subcellular compartments will be required to 
determine to which vesicular structures Syt10 is localized in the hippocampus after 
SE and to identify, which proteins regulate the docking of Syt10 containing vesicular 
compartments. Therefore, the identification of Syt10 binding partners would be 
mandatory.  
Furthermore, it is important to understand the physiological relevance of Syt10 
following SE in more detail. It should be analyzed in vivo if the Syt10 protein is 
differentially regulated in a specific subset of cells in response to SE. Given that IGF1 
may be secreted by astrocytes as well as by microglia, analyzing differences in Syt10 
KO and WT mice with regard to astrogliosis and microgliosis after SE may provide 
important insights into the physiological role of Syt10 and IGF1 in the progression of 
epilepsy. 
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8 Summary 
During epileptogenesis multiple cellular and molecular changes occur in the brain 
resulting in the emergence of recurrent spontaneous seizures. Epileptogenesis 
encompasses acquired changes leading to neuropathological alterations of circuits 
and neuronal connections in the brain and to functional modifications of the cellular 
network. One member of the Synaptotagmin (Syt) gene family that is rapidly and 
transiently up-regulated in the rat hippocampus early after the experimental induction 
of SE but is barely detectable in the native brain is Syt10. However, the knowledge 
about the function of Syt10 in health and disease conditions, especially in the 
hippocampus, is very limited. 
In order to delineate the mechanisms regulating Syt10 gene expression in 
response to strong electrical stimulation, this study provided the first fundamental 
bioinformatic and functional characterization of the Syt10 promoter and genomic 
regulatory regions in different cell types. Conserved regions in the Syt10 gene 
mediated strong induction of Syt10 promoter activity, particularly in the hippocampal 
formation. The transcription factor NPAS4 was identified to positively regulate 
endogenous expression of Syt10 as well as, together with Per1, Syt10 promoter 
activity. Epilepsy-induced up-regulation of endogenous Syt10 expression was 
mimicked by induction of membrane depolarization and by application of the 
convulsant compound kainic acid. A key genomic region underlying depolarization-
mediated induction of the Syt10 promoter was clearly identified. 
As a way to obtain first insights into the putative function of Syt10, its subcellular 
distribution was examined in hippocampal neurons and was compared with the 
related Syt isoforms 3, 5 and 6. Syt10 was identified not to be a resident Golgi 
protein but partially co-localized with IGF1, which was suggested to be the cargo of 
Syt10 vesicles in OB neurons, and with NPY, a marker for secretory vesicles. A 
synaptic localization for Syt10, as analyzed by Syt1 and synapsin labelings, was not 
identified. These results support the hypothesis that Syt10 is localized to large 
vesicular structures but not to synaptic vesicles. Next, to identify targeting signals 
defining the subcellular localization of Syt10 two approaches were used. Mutation of 
Syt10 N-terminal cysteines known to mediate dimerization indicated the importance 
of cysteines rather for the stability than for the localization of Syt10. Syt10 chimera 
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with an exchanged N-terminus by the related Syts 3, 5 and 6 revealed that another 
domain besides the N-terminus might be important for the Syt10 targeting. 
Additionally, first steps have been accomplished regarding the identification of Syt10 
containing protein complexes or organelles forming the basis for an isolation of the 
respective complexes from the hippocampus following status epilepticus (SE). 
To date, the role of Syt10 in epileptogenesis remains enigmatic and the 
spatiotemporal expression profile was only analyzed in rats. Therefore, the time 
course of Syt10 expression following pilocarpine-induced SE was examined in mice. 
The strongest induction of Syt10 expression in mice was observed with a 30 hours 
delay compared to rats. The time course of IGF1 induction did not show an exact 
parallelism to Syt10 but, as reported for IGF1, Syt10 was observed to be important 
for SE-induced progenitor cell proliferation as well. These data may suggest that 
Syt10 plays a critical role in the attenuation of acquired changes during 
epileptogenesis. 
Taken together, the results of this thesis provide novel insights into the key 
mechanisms regulating Syt10 expression in the hippocampus in the normal and 
epileptic brain as well as into the subcellular distribution of Syt10 and form the basis 
for further studies into the precise understanding of the function of Syt10 during 
epileptogenesis. 
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9 Appendix 
Supplementary figure 1 Circular map of the pCRII TOPO vector. The vector contains an 
ampicillin and a kanamycin resistance gene, a lacZ gene, a multiple cloning site (MCS) and covalently 
bound topoisomerase I. Topoisomerase I leads to a ligation of the poly-A strand of the PCR product 
with the poly-T site of the vector. The MCS comprises sites for commonly used restriction enzymes 
and the arrows indicate the direction of transcription. 
Supplementary figure 2 Circular map of the pAAV-CMV-MCS vector. The vector comprises 
a cytomegalovirus (CMV) -promoter, with a ß-globin intron, a MCS and a polyadenylation site (poly A). 
These vector features are flanked by a left inverted terminal repeat (lITR) and a right inverted terminal 
repeat (rITR) which are needed for the synthesis of recombinant adeno-associated viruses (rAAV) 
genome. The most commonly used sites for restriction enzymes of the MCS are listed in the order of 
their appearance. The numbers in the circle are sequence reference points. 
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Supplementary figure 3 Circular map of the pSyn-MCS vector. The vector comprises a 
human synapsin I (Syn I) –promoter, a MCS and a polyadenylation site (poly A). The most commonly 
used sites for restriction enzymes of the MCS are listed in the order of their appearance. The numbers 
in the circle are sequence reference points. 
 
Supplementary figure 4 Circular map of the pAAV-Syn-MCS vector. The vector comprises 
a human synapsin I (SynI) –promoter, a MCS and a polyadenylation site (poly A). These vector 
features are flanked by a left inverted terminal repeat (lITR) and a right inverted terminal repeat (rITR) 
which are needed for the synthesis of recombinant adeno-associated viruses (rAAV) genome. The 
most commonly used sites for restriction enzymes of the MCS are listed in the order of their 
appearance. The numbers in the circle are sequence reference points. 
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Supplementary figure 5 Circular map of the pCMV-MCS vector. The vector comprises a 
cytomegalovirus (CMV)–promoter, with a ß-globin intron, a MCS and a polyadenylation site (poly A). 
The most commonly used sites for restriction enzymes of the MCS are listed in the order of their 
appearance. The numbers in the circle are sequence reference points. 
 
Supplementary figure 6 Circular map of the pGL3-basic vector. The vector comprises an 
ampicillin resistance (Ampr) gene, a MCS, and a firefly luciferase gene (luc+). The sites for the most 
commonly used restriction enzymes are listed in the order of their appearance and the numbers serve 
as sequence references. Note, that there are three restriction sites behind the luciferase gene (XbaI, 
BamHI, SalI). 
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Supplementary table 1: Overrepresented transcription factor binding sites in the Syt10 
promoter region of rat, mouse, human and dog 
 
 
 
TF 
Family 
number 
of 
matches  
Z-Score 
genome 
  TF 
Family 
number 
of 
matches 
Z-Score 
promoter 
         
Rat (5490 bp)        
         
1 V$ZF5F 11 8,22  1 V$BPTF 10 5,03 
2 V$ZF06 5 4,67  2 V$ZF06 5 4,19 
3 V$ZF02 22 4,23  3 V$MEF2 17 3,88 
4 V$BPTF 10 3,61  4 V$IRFF 23 3,11 
5 V$GLIF 14 3,22  5 V$CAAT 20 3,1 
6 V$MYBL 23 2,67  6 V$CHRF 9 2,65 
7 V$GRHL 10 2,59  7 V$PDX1 14 2,53 
8 V$RREB 8 2,59  8 V$GRHL 10 2,35 
9 V$MAZF 9 2,33  9 V$MYBL 23 2,19 
10 V$CAAT 20 2,3  10 V$BCL6 12 2,15 
         
Mouse (5413 bp)        
         
1 V$ZF5F 12 9,69  1 V$FKHD 48 5,04 
2 O$TF2B 2 5,88  2 V$CART 39 4,16 
3 V$NRF1 5 4,37  3 V$BPTF 9 3,98 
4 V$MYBL 27 4,09  4 V$LEFF 27 3,81 
5 V$E2FF 17 3,7  5 V$MYBL 27 3,51 
6 V$HDBP 2 2,82  6 V$MEF2 16 3,03 
7 V$BPTF 9 2,72  7 V$BCDF 16 2,71 
8 V$FKHD 48 2,45  8 V$IRFF 21 2,38 
9 V$OSRF 5 2,26  9 V$HBOX 31 2,37 
10 V$EGRF 15 2,17  10 V$SALL 4 2,22 
         
Human (3116 bp) 
         
1 V$ZF5F 12 12,1  1 V$NKX1 11 5,15 
2 V$NRF1 5 7,57  2 V$FKHD 31 5,02 
3 V$EGRF 17 7,17  3 V$PDX1 14 4,4 
4 V$E2FF 20 7  4 V$HBOX 26 3,78 
5 V$GABF 8 4,55  5 V$GRHL 8 3,52 
6 V$ZF07 6 4,06  6 V$GABF 8 3,41 
7 O$MTEN 4 3,98  7 V$DLXF 13 3,25 
8 V$GRHL 8 3,69  8 V$CART 24 3,21 
9 V$CTCF 7 3,5  9 V$LHXF 27 3,19 
10 V$WHNF 3 3,11  10 V$HOXF 29 3,16 
         
Dog (3250 bp)        
         
1 V$ZF5F 11 0,64  1 V$GABF 20 5,81 
2 V$NRF1 7 0,25  2 V$HBOX 29 4,6 
3 V$E2FF 15 0,41  3 V$HOXC 16 4,38 
4 V$GABF 20 5,81  4 V$HOXF 34 4,26 
5 V$ZFHX 9 2,46  5 V$CART 28 4,21 
6 V$HZIP 3 2,78  6 V$SALL 6 3,98 
7 V$RORA 10 3,02  7 V$BRN5 22 3,76 
8 V$HOXC 16 4,38  8 V$HOMF 40 3,7 
9 V$SALL 6 3,98  9 V$FKHD 27 3,52 
10 V$SF1F 5 1,65  10 V$SORY 30 3,4 
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Supplementary figure 7 Saturation curves of the transcription factors NPAS4 and Per1 
on the Syt10 promoter. Rat hippocampal neurons were transfected on DIV5 with the promoter 
fragment -4713 and with different concentrations of the transcription factor NPAS4 or Per1 (0 ng, 
50 ng, 120 ng, 200 ng, 250 ng, 350 ng and 500 ng). On DIV7, cells were lysed and luciferase activity 
was measured. (A) Concentration curve of NPAS4 reveals a saturation of the transcription factor at a 
concentration of 50 ng. (B) Per1 activation of the Syt10 promoter fragment -4713 is strongest at a 
concentration of 50 ng. All values were normalized to the basal condition (without transcription factor) 
and results are presented as mean +/- SEM. 
 
 
Supplementary figure 8 Single transfected PC12 cells. Upper row: Syt5-mCherry and Syt6-
mCherry, lower row: Syt10-mCherry and TfR-GFP. Scale bar: 5 µm. 
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Supplementary figure 9 Single transfected mouse primary neurons. Upper row: NPY-GFP 
and IGF1-mRFP, lower row: Syt10-mRFP and TfR-GFP. Scale bar: 20 µm. 
 
 
A 
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B 
Supplementary figure 10 Co-transfection of untagged Syt10 and IGF1-HA in mouse 
hippocampal neurons DIV14. (A) Staining with the monoclonal Syt10 antibody 1D3 and a specific 
HA antibody. Diffuse and weak co-expression of the two proteins in the soma and dendrites. No 
overlap in the dendrites is obtained. (B) Staining against Syt10 was accomplished by the polyclonal 
antibody 150 T3 and IGF1 was labeled by a HA-tag specific antibody. A similar distribution of the 
fluorescence signal was obtained compared with the other Syt10 antibodies. Numbers in the upper 
right image indicate the boxes with higher magnifications of the soma (1) and one branch (2). Scale 
bar: 20 µm, magnifications: 5 µm. 
 
 
Supplementary figure 11 Subcellular localization of Syt6-GFP in primary neurons 
DIV13-16. Inhibitory neurons were labeled by vGAT, dendrites by MAP2, presynapses by Synapsin 
and postsynapses by PSD95. Syt6 was distributed along the dendrites but no overlap with an 
inhibitory or pre- and postsynaptic marker was observed. Scale bar: 5 µm. 
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Supplementary figure 12 Immunoblot verifying the size of SF-TAP fusion proteins. 
HEK293T cells were either transfected with a SF-TAP-tagged Syt10 or Syt6 construct or with a GFP- 
tagged or untagged Syt10 plasmid as positive controls for the staining and the size of the protein 
bands. Protein samples were loaded as duplets (CMV Syt10 as triplets) and were stained with a FLAG 
antibody (red) and the polyclonal Syt10 antibody 150 T3 (green). Syt10 (62 kDa), Syt10-GFP (90 kDa) 
and Syt10-TAP (70 kDa) proteins are recognized by the polyclonal antibody 150 T3. The FLAG 
antibody also recognizes TAP-tagged Syt10. Note that there is less protein present in the sample 
under the control of the synapsin promoter compared to the CMV promoter due to its lesser activity in 
HEK293T cells. TAP-tagged Syt6 constructs are translated into proteins of a correct size and are 
recognized by the FLAG antibody. 
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10 Abbreviations 
Ac Histone acetylation 
AHS Ammon's horn sclerosis 
ANOVA Analysis of variance 
AP2 Clathrin assembly (adapter) protein 2 
Ara-C Arabinofuranosyl cytidine 
Arc/Arg3.1 Activity-regulated cytoskeletal protein  
B/K protein  Brain/kidney protein 
BDNF Brain-derived neurotrophic factor 
BES N,N-Bis-(2-hydroxyethyl)-2-amino-ethansulfonic acid 
BFA Brefeldin A 
bHLH Basic Helix-loop-helix 
bp Base pairs 
BrdU 5-bromo-2'-deoxyuridine 
CA1 Cornu Ammonis 1 
Ca2+ Calcium 
CA3 Cornu Ammonis 3 
CA4 Cornu Ammonis 4 
Cav3.2 T-type voltage-activated calcium channel 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CMV Cytomegalovirus 
CO2 carbon dioxide 
CRE cAMP response element  
CREB cAMP response element-binding protein 
Ctrl Control 
DAPI 4′,6-diamidino-2-phenylindole 
DDM n-Dodecyl-ß-maltoside 
DDM n-Dodecyl-ß-maltoside 
DG Dentate gyrus 
DMEM Dulbecco's modified eagle medium 
DMSO dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
DTT dithiothreitol 
E-Syts extended Syts  
EE early endosome 
EEG Electroencephalography 
e.g. exempli gratia 
Egr Early growth factor 
EGTA ethylene glycol tetraacetic acid 
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EPL external plexiform layer 
ER Endoplasmatic Reticulum 
ERGIC ER to Golgi Intermediate Compartment  
FCS fetal calf serum 
GABA Gamma-aminobutyric acid 
GCL Granule cell layer 
GFAP glial fibrillary acidic protein 
GFP Green fluorescent protein 
GM130 Golgi matrix protein 130 
h Hour 
HAT Histone acetyltransferase 
HAT sodium hypoxanthine, aminopterin, thymidine 
HBS HEPES buffered saline 
HBSS Hanks buffered salt solution 
HBSS Hank's Buffered Salt Solution  
HC Hippocampus 
HCl hydorchloride 
HEBS HEPES buffered saline 
HEK293T Human embryonic kidney cell line 293T 
Hi Hilus 
ICC Immunocytochemistry 
ICH Immunohistochemistry 
i.e. id est 
IGF1 Insulin-like growth factor 1 
IMDM Iscove's Modified Dulbecco's Medium 
INR Initiator 
KA kainic acid 
kb kilo base 
KCl Potassium chloride 
kDa Kilo Dalton 
KO Knockout 
l Liter 
LAR Luciferase  
LDCV Large dense core vesicle 
LE late endosome 
Lys lysosme 
MAP2 microtubule-associated protein 2 
MCL mitral cell layer 
MCS Multiple cloning site 
MEF2 Myocyte enhancer factor 2 
MEM Minimum essential medium 
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MgCl2 Magnesium chloride 
min Minute 
ml Milliliter 
mm Millimeter 
mM Millimolar 
MOB mouse olfactory bulb (neurons) 
mRNA Messenger RNA 
MTCPs Multiple C2-transmembrane proteins  
Munc13 Mammalian Unc-13 homolog  
n-Octyl-ß n-Octyl-ß-D-glucopyranoside 
n-octyl-ß n-octy-ß-D-glucopyranoside 
NaCl Sodium chloride 
NFkB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
ng Nanogram 
NG108-15 Neuroblastoma glioma cell line 108-15 
NGS Normal goat serum 
NPAS4 Neuronal PAS domain protein 4 
NPY neuropeptide Y 
NSF N-ethylmaleimide sensitive factor 
NTMCs N-terminal-TM-C2-domain genes 
OB Olfactory bulb 
Oligo Oligonucleotide 
P Phosphorylation 
PAS Period-Arnt-Sim 
PBS Phosphate buffered saline 
PC phosphatidlycholine 
PC12 Pheochromocytoma cell line 12 
PCR Polymerase chain reaction 
pen/strep penicillin/streptomycin  
Per1 Period1 
PFA Paraformaldehyde 
Pfu Pyrococcus furiosus 
PIP2 phosphatidylinositol 4,5-bisphosphate 
PM Plasma membrane 
PS phosphatidylserine 
PSD95 postsynaptic density protein 95 
rAAV recombinant adeno-associated virus 
RC rat cortical (neurons) 
RE recycling endosome 
REST repressor element 1-silencing transcription factor  
RFP red fluorescent protein 
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RH Rat hippocampal (neurons) 
RIM Rab3 interacting molecule 
RNA Ribonucleic acid 
RT-PCR Reverse transcription PCR 
SARE Synaptic activity response element  
s.c. subcutaneously 
SCN Suprachiasmatic nucleus 
SDS Sodium dodecyl sulfate 
SE Status epilepticus 
sec seconds 
SEM Standar error of mean 
SEM Standard error of mean 
SF-TAP  streptavidin/FLAG-tandem affinity purification  
Sim Single-minded 
SLMV synaptic-like microvesicle 
SLPs Syt-like proteins  
SNAP-25 Synaptosome-associated protein of 25 kDa 
SNARE 
N-ethylmaleimide sensitive factor (NSF) -attachment protein 
receptor  
SRE Serum response element  
SRF Serum response factor 
SV Synaptic vesicle 
Syn Synapsin 
Syp Synaptophysin 
Syt Synaptotagmin 
TCF Ternary complex factor  
TfR Transferrin receptor 
TLE Temporal lobe epilepsy 
TMD Transmembrane domain 
TSS Transcription start site 
TX-100 Triton X-100 
UCSC University of california, santa cruz 
USF Upstream regulatory factor 
vGAT vesicular GABA-transporter 
WB Western blot 
WT Wildtype 
ZRE Zeste-like response element 
ZW 3-14 Zwittergent 3-14 
µl Microliter 
µm Micrometer 
µM Micromolar 
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